Document:

Exhibit 10.30

 

* Information in this exhibit marked [***] has
been excluded pursuant to Regulation S-K, Item 601(b)(10). Such information is not material and is the type of information that the registrant
treats as private or confidential.

 

 

 

ASSET PURCHASE AGREEMENT

 

BY AND BETWEEN

 

DR. REDDY’S LABORATORIES S.A.,

 

AS SELLER

 

AND

 

CITIUS PHARMACEUTICALS, INC.,

 

AS PURCHASER

 

DATED AS OF

 

September 1, 2021

 

     

     

    

 

	TABLE OF CONTENTS
	 	 	 
	ARTICLE I DEFINITIONS AND INTERPRETATION	1
	 	 	 
	Section 1.01	Defined Terms.	1
	Section 1.02	Other Definitional and Interpretive Provisions.	1
	 	 	 
	ARTICLE II PURCHASE AND SALE; LICENSE GRANTS	2
	 	 	 
	Section 2.01	Purchase and Sale of Purchased Assets.	2
	Section 2.02	Further Expenses and Studies; Other Commitments.	4
	 	 	 
	ARTICLE III PURCHASE PRICE	4
	 	 	 
	Section 3.01	Purchase Price.	4
	Section 3.02	Payment Terms; Transfer Taxes.	8
	Section 3.03	Additional Covenants relating to the Milestone Payments and Quarterly Earn-Out Payments.	9
	Section 3.04	Additional Covenants relating to Milestone Events.	10
	 	 	 
	ARTICLE IV CLOSING	12
	 	 	 
	Section 4.01	Closing.	12
	Section 4.02	Closing Deliverables.	12
	 	 	 
	ARTICLE V REPRESENTATIONS AND WARRANTIES OF SELLER	14
	 	 	 
	Section 5.01	Organization and Authority of the Seller.	14
	Section 5.02	Authority, Non-Contravention, Required Filings.	14
	Section 5.03	Purchased Assets	15
	Section 5.04	Acquired Contracts.	15
	Section 5.05	Compliance with Law; Permits; Regulatory Matters.	15
	Section 5.06	Brokers	17
	Section 5.07	Litigation.	17
	Section 5.08	Intellectual Property.	18
	Section 5.09	No Other Assets. 	18
	Section 5.10	No Other Representations and Warranties	18
	 	 	 
	ARTICLE VI REPRESENTATIONS AND WARRANTIES OF PURCHASER	19
	 	 	 
	Section 6.01	Organization and Authority of the Purchaser	19
	Section 6.02	Authority; Non-Contravention, Required Filings.	19
	Section 6.03	Legal Proceedings	20
	Section 6.04	Sufficiency of Funds	20
	Section 6.05	Brokers	20
	Section 6.06	Financial Statements.	20
	Section 6.07	Solvency	21
	Section 6.08	Independent Investigation; No Other Warranties	21

 

    i

     

    

 

	ARTICLE VII COVENANTS	21
	 	 	 
	Section 7.01	Confidentiality	21
	Section 7.02	Preservation of Books and Records.	22
	Section 7.03	Public Announcements	23
	Section 7.04	Further Assurances	23
	Section 7.05	Certain Intellectual Property Matters.	24
	Section 7.06	License to Licensed Know-How.	24
	 	 	 
	ARTICLE VIII NON-COMPETE AND NON-SOLICITATION RESTRICTIONS	24
	 	 	 
	Section 8.01	Non-Compete.	24
	Section 8.02	Non-Solicitation.	24
	Section 8.03	Acknowledgements; Remedies.	24
	 	 	 
	ARTICLE IX INDEMNIFICATION	25
	 	 	 
	Section 9.01	Survival	25
	Section 9.02	Indemnification by Seller	25
	Section 9.03	Indemnification by Purchaser	26
	Section 9.04	Notice of Direct Claims.	26
	Section 9.05	Third Party Claims.	27
	Section 9.06	Limitations on Indemnification; Limitations on Liability.	28
	Section 9.07	Exclusion of Certain Damages	29
	Section 9.08	Purchaser’s Opportunity to Review.	29
	Section 9.09	Adjustment to Purchase Price	30
	Section 9.10	Reimbursement	30
	Section 9.11	Losses Net of Insurance	30
	Section 9.12	Subrogation	30
	Section 9.13	Sole Remedy/Waiver	30
	 	 	 
	ARTICLE X MISCELLANEOUS	31
	 	 	 
	Section 10.01	Expenses	31
	Section 10.02	Notices	31
	Section 10.03	Severability	31
	Section 10.04	Entire Agreement	31
	Section 10.05	Successors and Assigns	32
	Section 10.06	No Third Party Beneficiaries	32
	Section 10.07	Amendment and Waiver	32
	Section 10.08	Governing Law; Jurisdiction.	33
	Section 10.09	WAIVER OF JURY TRIAL	33
	Section 10.10	Specific Performance	34
	Section 10.11	No Other Duties	34
	Section 10.12	Reliance on Counsel and Other Advisors	34
	Section 10.13	Bulk Transfer Laws	34
	Section 10.14	Setoff Rights	34
	Section 10.15	Counterparts	34

 

    ii

     

    

 

List of Exhibits and Schedules

 

Seller Disclosure Schedules

 

	Exhibit A	Acquired Contracts
	 	 
	Exhibit B	Bill of Sale & Assignment and Assumption Agreement
	 	 
	Exhibit C	Assignment of Patents
	 	 
	Exhibit D	Knowledge of the Purchaser
	 	 
	Exhibit E	Knowledge of the Seller
	 	 
	Exhibit F	Purchased Patents
	 	 
	Exhibit G	Purchased Trademarks
	 	 
	Exhibit H	Transition Services Agreement
	 	 
	Exhibit I	Inventory Letter
	 	 
	Schedule 1.01	Definitions
	 	 
	Annex A	Proof of Concept Plan
	 	 
	Annex B	Compound
	 	 
	Schedule 2.01(e)	Certain Acquired Contracts
	 	 
	Schedule 2.01(g)	Proration Schedule 

 

    iii

     

    

 

ASSET PURCHASE AGREEMENT

 

This Asset Purchase Agreement (this “Agreement”)
dated as of September 1, 2021 (the “Effective Date”) by and between Dr. Reddy’s Laboratories S.A., a company
incorporated under the laws of Switzerland and having its principal place of business located at Elisabethenanlage 11, CH - 4051, Basel,
Switzerland (the “Seller”) and Citius Pharmaceuticals, Inc., a Nevada corporation having its principal place of business
located at 11 Commerce Drive, First Floor, Cranford, New Jersey 07016 (the “Purchaser”). The Seller and the Purchaser
may be collectively referred to herein as the “Parties” and each, individually, as a “Party”.

 

RECITALS

 

WHEREAS, the Seller
desires to sell, transfer and assign to the Purchaser, and the Purchaser desires to acquire from the Seller, all of the Purchased Assets
and Assumed Liabilities, all as more specifically, and subject to the terms and conditions, provided herein;

 

NOW, THEREFORE, in
consideration of the premises and the mutual covenants and agreements contained herein, the Parties, intending to be legally bound hereby,
do agree as follows:

 

ARTICLE I

DEFINITIONS AND INTERPRETATION

 

Section 1.01 Defined
Terms. Capitalized terms used in this Agreement have the meanings specified in Schedule 1.01, or as otherwise defined
within this Agreement.

 

Section 1.02 Other
Definitional and Interpretive Provisions.

 

(a) The
words “hereof”, “herein”, “hereto” and “hereunder” and words of similar import, when used
in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement.

 

(b) The
terms defined in the singular shall have a comparable meaning when used in the plural and vice versa.

 

(c) The
terms “dollars” and “$” shall mean United States of America dollars.

 

(d) The
term “including” (and with correlative meaning “include”) shall mean “including, without limitation.”

 

(e) Reference
to any Person includes such Person’s successors and assigns but, if applicable, only if such successors and assign are permitted
by this Agreement, and reference to a Person in a particular capacity excludes such Person in any other capacity.

 

(f) Reference
to any agreement (including this Agreement), document or instrument means such agreement, document or instrument as amended, modified
or supplemented and in effect from time to time in accordance with the terms thereof and, if applicable, the terms hereof.

 

     

     

    

 

(g) When
a reference is made in this Agreement to an Article, a Section, an Exhibit or a Schedule, such reference shall be to an Article of, a
Section of, an Exhibit to or a Schedule to, this Agreement unless otherwise indicated.

 

(h) The
Parties acknowledge that: (i) this Agreement is the result of negotiations between the Parties and shall not be deemed or construed as
having been drafted by any one Party; (ii) each Party and its counsel have reviewed and negotiated the terms and provisions of this Agreement
(including any exhibits, schedules, and disclosure schedules attached hereto) and have contributed to its revision; (iii) the rule of
construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of
this Agreement; and (iv) the terms and provisions of this Agreement shall be construed fairly as to all Parties and not in favor of or
against any Party, regardless of which Party was generally responsible for the preparation of this Agreement.

 

ARTICLE II

PURCHASE AND SALE; LICENSE GRANTS

 

Section 2.01 Purchase
and Sale of Purchased Assets.

 

(a) Purchased
Assets. Upon the terms and subject to the conditions set forth in this Agreement, at the Closing, the Seller shall (and shall cause
each of its Affiliates to) sell, convey, transfer and assign to the Purchaser, and the Purchaser shall purchase and acquire from the Seller
and its Affiliates, all of the Seller’s and its Affiliates’ right, title, and interest in the Purchased Assets, free from
any Encumbrances except for Permitted Encumbrances.

 

(b) Excluded
Assets. Other than the Purchased Assets, the Purchaser expressly understands and agrees that it is not purchasing or acquiring, and
the Seller is not selling, conveying, transferring, or assigning, any other assets or properties of the Seller (or any of the Seller’s
Affiliates), and all such other assets and properties shall be excluded from the Purchased Assets (the “Excluded Assets”).
For the avoidance of doubt, the Excluded Assets include all books and records of the Seller and its Affiliates (other than books and records
that constitute Regulatory Documentation or are otherwise specifically included in the definition of Purchased Assets); provided,
however, that Purchaser shall have the right to make copies of any portions of such retained books and records that expressly relate to
any of the Purchased Assets.

 

(c) Assumed
Liabilities. Upon the terms and subject to the conditions set forth in this Agreement, the Purchaser shall, effective upon the Closing,
assume (and shall pay, perform and discharge when due) all Assumed Liabilities.

 

(d) Excluded
Liabilities. Except for the Assumed Liabilities, the Purchaser will not acquire any interest in, or obligations in respect of, any
Liabilities of the Seller or any of the Seller’s Affiliates (the “Excluded Liabilities”). Notwithstanding anything
to the contrary, all Liabilities arising out of or relating to any breach of an Acquired Contract by Seller or any of its Affiliates prior
to the Closing, or any unauthorized use or disclosure of Eisai’s confidential information by Seller or any of its Affiliates, shall
be Excluded Liabilities and not Assumed Liabilities.

 

    2

     

    

 

(e) Consents.

 

(i) Notwithstanding
any other provision of this Agreement, this Agreement does not constitute an agreement to sell, convey, assign, assume, transfer or deliver
any interest in any Acquired Contract that would be a Purchased Asset (other than the Acquired Contracts listed on Schedule 2.01(e),
any required Consents with respect to which shall be obtained prior to Closing), or any claim or right of any benefit arising thereunder
or resulting therefrom, if an attempted direct or indirect assignment thereof, or agreement to sell, convey, assign, assume, transfer
or deliver any such Acquired Contract, without the Consent of any Third Party, (A) would violate applicable Laws or constitute a breach
or other contravention of the rights of such Third Party (including any Governmental Authority), or (B) would be ineffective with respect
to any party to such Acquired Contract (each such Acquired Contract, other than those listed on Schedule 2.01(e)), a “Non-Assignable
Contract”). If any direct or indirect transfer or assignment or agreement to do so by the Seller (and/or the Seller’s
Affiliates, as applicable) of, or any direct or indirect assumption by the Purchaser of, any interest in, or liability, obligation or
commitment under, any Non-Assignable Contract requires the Consent of a Third Party, then such transfer, assignment or assumption or agreement
to do so shall be made subject to such Consent being obtained.

 

(ii) The
Purchaser acknowledges that certain Consents to the transactions contemplated by this Agreement may be required from counterparties to
Non-Assignable Contracts and that such Consents may not be obtained prior to Closing. In the event that such required Consent is not obtained
with respect to a Non-Assignable Contract, notwithstanding any other provision to the contrary set forth in this Agreement, the Purchaser
agrees that the Seller shall not have any Liability whatsoever arising out of or relating to the failure to obtain such Consent that may
have been or may be required with respect to such Non-Assignable Contract in connection with the transactions contemplated by this Agreement,
provided that Seller complies with its obligations under in Section 2.01(e)(iii). The Purchaser further agrees that, provided that
Seller complies with its obligations under in Section 2.01(e)(iii), no representation, warranty or covenant of the Seller contained
herein shall be breached or deemed breached, and no condition to the Purchaser’s obligations to close the transactions contemplated
by this Agreement shall be deemed not satisfied, as a result of (i) the failure to obtain any such Consent with respect to a Non-Assignable
Contract; or (ii) any Legal Proceeding commenced or threatened by or on behalf of any Person arising out of or relating to the failure
to obtain any Consent with respect to a Non-Assignable Contract.

 

(iii) If
any Consent referred to in Section 2.01(e)(i) is not obtained prior to the Closing with respect to a Non-Assignable Contract, the
Closing shall nonetheless take place without any adjustment of the Purchase Price on account thereof, and thereafter each of the Seller
and the Purchaser shall use commercially reasonable efforts (A) to endeavor to obtain such Consent (provided that neither the Seller nor
the Purchaser shall be required to expend money, commence, defend or participate in any litigation or offer or grant any accommodation
(financial or otherwise) to any Third Party), and (B) to cooperate, upon written request of the Purchaser, in endeavoring to obtain for
the Purchaser, at no cost to the Seller, an arrangement to provide to the Purchaser, in compliance with Law, substantially comparable
benefits thereof. Upon obtaining the requisite Consent, such Non-Assignable Contract shall be transferred and assigned to the Purchaser
hereunder, for no additional consideration.

 

    3

     

    

 

(f) Transfer
of Purchased Assets. As soon as practicable following the Closing (and in no event later than [***] ([***]) Business Days after the
Closing), the Seller shall make available to the Purchaser electronically all Purchased Assets held electronically. Within [***] ([***])
Business Days after the Closing, the Seller shall make available to the Purchaser all tangible Purchased Assets for pick-up at the Seller’s
facilities, at the Purchaser’s sole cost, expense and risk; provided, that if the Seller finds, locates, discovers or otherwise
becomes aware that it possesses any Purchased Assets after the Closing, the Seller shall reasonably promptly notify the Purchaser in writing
and make such Purchased Assets available for pick-up at the Seller’s facilities, at the Purchaser’s sole cost, expense and
risk.

 

(g) Proration
Schedule. Schedule 2.01(g) (the “Proration Schedule”) sets forth certain deposits and other prepaid items, which
includes certain expenses that Seller or its respective Affiliates have paid or that are required to be paid by the Seller (or their applicable
Affiliates) by Law or contractual obligation, and which shall be prorated as of the Effective Date. At the Closing, the Purchaser shall
pay to the Seller an amount equal to the Purchaser’s Prorated Portion, which amount is set forth on the Proration Schedule. Any
amounts set forth in the Proration Schedule that are owed to a Third Party that have not been paid by the Seller prior to the Closing
Date will be paid by the Seller following the Closing Date and shall remain the Liability of the Seller.

 

Section 2.02 Further Expenses
and Studies; Other Commitments. After the Closing, the Purchaser shall be responsible for any and all of its further developmental
activities relating to Products and the Compound, including the Proof of Concept Plan and all expenses relating thereto.

 

ARTICLE III

PURCHASE PRICE

 

Section 3.01 Purchase
Price.

 

(a) Amount.
The aggregate consideration for the purchase of the Purchased Assets to be paid by the Purchaser (the “Purchase Price”)
shall be:

 

(i) A
non-refundable, non-creditable amount equal to Forty Million Dollars ($40,000,000.00) in respect of the Purchased Assets (the “Upfront
Payment”) and the assumption of the Assumed Liabilities;

 

(ii) the
Milestone Payments, as and to the extent provided in Section 3.01(b); and

 

(iii) the
Quarterly Earn-Out Payment(s), as and to the extent provided in Section 3.01(c) (including as adjusted pursuant to Section 3.01(c)(iv)(A));

 

(iv) any
Licensee Consideration Payments, as and to the extent provided in Section 3.01(c)(iv)(B); and

 

(v) the
Purchaser’s Prorated Portion.

 

    4

     

    

 

(b) Milestone
Payments. As consideration for the purchase of the Purchased Assets, in addition to the Cash Consideration, the assumption of the
Assumed Liabilities, the Quarterly Earn-Out Payments and the Licensee Consideration Payments, and subject to this Section 3.01(b),
the Purchaser shall pay to the Seller the following non-refundable, non-creditable amounts (each, a “Milestone Payment”)
upon the achievement by or on behalf of the Purchaser or its Affiliates, Licensees or Transferees, if any, of the following events (each,
a “Milestone Event”):

 

	 	 	 	Table 3.01(b)	 	 
	 	No.	 	Milestone Event	 	Milestone Payment
	 	1.	 	Upon Regulatory Approval of the first Product by the FDA in a CTCL Indication	 	$[***]
	 	2.	 	Upon a European Approval of the first Product in a CTCL Indication	 	$[***]
	 	3.	 	Upon Regulatory Approval of the first Product by the Health Canada in a CTCL Indication	 	$[***]
	 	4.	 	Upon Regulatory Approval of the first Product by the FDA in a PTCL Indication	 	$[***]
	 	5.	 	Upon a European Approval of the first Product in a PTCL Indication	 	$[***]
	 	6.	 	Upon Successful Proof of Concept	 	$[***]
	 	7.	 	Upon Regulatory Approval by the FDA of the first Product in an I/O Indication	 	$[***]
	 	8.	 	Upon the achievement of $[***] in cumulative Net Sales.	 	$[***]
	 	9.	 	Upon the achievement of $[***] in cumulative Net Sales.	 	$[***]

 

Each Milestone Payment
set forth in this Section 3.01(b) is payable only once (i.e., the first time the Milestone Event is achieved) and is non-refundable
once paid. Notwithstanding anything to the contrary, for the purposes of calculating Milestone No. 8 and Milestones No. 9 above, Licensee
Net Sales shall not be included in such calculation (other than in cases where Purchaser has granted a Licensee generating such Licensee
Net Sales a license to all rights with respect to the Purchased Assets and all Products throughout (A) [***] or (B) [***] (an “Entire
Rights License”)).

 

(c) Quarterly
Earn-Out Payments; Licensee Consideration Payments.

 

(i) As
consideration for the purchase of the Purchased Assets, in addition to the Cash Consideration, the assumption of the Assumed Liabilities,
the Milestone Payments and the Licensee Consideration Payments, and subject to this Section 3.01(c), commencing on the Effective
Date, each Quarter for the duration of the Earn-Out Term for a given Product in a given country of the Territory, Purchaser shall pay
to the Seller non-refundable, non-creditable amounts with respect to such Product in such country, based upon the cumulative Net Sales
of each Product in the applicable countries of the Territory in the applicable Calendar Year to which such Quarter relates (each payment
a “Quarterly Earn-Out Payment”). Such Quarterly Earn-Out Payment shall be calculated: (A) in the case of Licensee Net
Sales, in accordance with Section 3.01(c)(iv)(A) below; and (B) in the case of any Net Sales of Products other than Licensee Net
Sales, by multiplying the applicable rate set forth in Table 3.01(c) below (the “Quarterly Earn-Out Rate”) by the aggregate
Net Sales (other than Licensee Net Sales) of Product in the applicable countries of the Territory in an applicable Quarter; and, in each
case (for both of the preceding clauses (A) and (B)), applying any applicable reductions under Section 3.01(c)(v) below:

 

    5

     

    

 

	Table 3.01(c)
	 	No.	 	Aggregate Annual Net Sales (other than Licensee Net Sales)	 	Quarterly Earn-Out

 Rate	 
	 	1.	 	For that portion of Net Sales (other than Licensee Net Sales) of Products in a Calendar Year up to and including [***] Dollars ($[***])	 	[***] Percent ([***]%)	 
	 	2.	 	For that portion of Net Sales (other than Licensee Net Sales) of Products in a Calendar Year that is greater than [***] Dollars ($[***]) 	 	[***] Percent ([***]%)	 

 

(ii) Quarterly
Earn-Out Payments and Licensee Consideration Payments shall be paid pursuant to Section 3.01(c)(i) as from the Effective Date and
until the earlier to occur of (as determined on a Product-by-Product, country-by-country basis): (a) the fifteen (15) year anniversary
of the First Commercial Sale of the latest to be received Regulatory Approval of an Indication of such Product in the applicable country,
and (b) the date on which Biosimilar Entry with respect to a Product (for any Indication) occurs in such country (the “Earn-Out
Term”). For clarity, each time a Product is approved for a new Indication in a given country, the fifteen (15) year period described
in clause (a) of the definition of Earn-Out Term for such Product and country shall reset based on the date of the First Commercial
Sale of such Product in such country following the Regulatory Approval for such new Indication. For the avoidance of doubt, the Purchaser
shall be liable to make a Quarterly Earn-Out Payment pursuant to Section 3.01(c)(i), for the Quarter during which such event terminating
the obligation to make such Quarterly Earn-Out Payment occurs as long as the Product is sold in such Quarter. Notwithstanding anything
otherwise to the contrary, no amounts shall be counted more than once in the calculation of the Quarterly Earn-Out Payments or the Licensee
Consideration Payments.

 

(iii) Blended
Rate. The Parties acknowledge and agree that, the Quarterly Earn-Out Rates agreed upon by the Parties for the Product(s) have been
blended to take into consideration, the Purchased Know-How, the Quarterly Earn-Out Rate that could be applied to Products prior to the
expiration of any Valid Claims, the Quarterly Earn-Out Rate that could be applied after the expiration of any Valid Claims and the Quarterly
Earn-Out Rate that could be applied if no Valid Claims Cover the Product. The Parties recognize that the differing Quarterly Earn-Out
Rates that could apply to such periods could last for differing time periods. Therefore the Parties have determined to use the blended
Quarterly Earn-Out Rate in this Agreement for reasons of convenience, and the use of such blended Quarterly Earn-Out Rate is advantageous
to both Parties.

 

    6

     

    

 

(iv) Sales
of Product by Licensees; Licensee Net Sales; Licensee Consideration.

 

(A) Licensee
Sales. Notwithstanding anything to the contrary, the Quarterly Earn-Out Payment with respect to any sales of Product(s) by or on behalf
of a Licensee in an applicable Quarter during the Earn-Out Term for such Product in such country shall be an amount equal to the greater
of (1) [***] ([***]%) of all Licensee Sales-Based Royalties that are paid to Purchaser and/or its Affiliates with respect to such sales
of Product(s) by or on behalf of a Licensee and (2) [***] percent ([***]%) of such Licensee Net Sales. In the event that Purchaser or
its Affiliates enters into any agreement pursuant to which Licensee Net Sales may occur, Purchaser shall provide notice to Seller that
it has entered into such arrangement, and provide a copy of such agreement to the Seller (which agreement shall be deemed to be the Confidential
Information of Purchaser in accordance with Section 7.01).

 

(B) Licensee
Consideration Payments. As consideration for the purchase of the Purchased Assets, in addition to the Cash Consideration, the assumption
of the Assumed Liabilities, the Milestone Payments and the Quarterly Earn-Out Payments, Purchaser shall pay to the Seller [***] percent
([***]%) of any Licensee Consideration received with respect to a given Product in a given country of the Territory during the Earn-Out
Term for such Product in such country (such [***]% portion of such Licensee Consideration, the “Licensee Consideration Payments”).
Such Licensee Consideration Payments shall be paid to the Seller within [***] ([***]) days that such Licensee Consideration is received
by the Purchaser, and are non-creditable and non-refundable once paid. The Purchaser shall provide a notice to the Seller of the occurrence
of an event giving rise to a Licensee Consideration Payment prior to, or no later than on, the date of the payment of the corresponding
Licensee Consideration Payment.

 

(v) License
Stacking. If Purchaser or any of its Affiliates (A) determines it is required to obtain a license or other right to a Third Party’s
Intellectual Property (in the event such license or other right is not otherwise granted to Purchaser under the Eisai Agreement upon the
transfer of the Eisai Agreement to Purchaser at Closing) in order to Exploit a Product in the Territory and (B) enters into an agreement
with a Third Party in order to obtain a license or other right under such Third Party’s Intellectual Property in order to Exploit
a Product (a “Third Party License”), the Quarterly Earn-Out Payments with respect to such Product (on a Product-by-Product
Basis) shall be reduced by [***] percent ([***]%) of any amounts actually paid to such Third Party with respect to such Third Party License;
provided, however, that in no event will such reduction reduce a Quarterly Earn-Out Payment for a given Calendar Quarter
for such Product by more than [***] percent ([***]%). [***]. For the avoidance of doubt, Purchaser shall only be permitted to reduce the
amounts payable hereunder to the extent such payments to a Third Party for a Third Party License relate to a Product or any component
thereof, which are necessary for making, using, selling or otherwise Exploiting the Product in the Territory, and not to other components
or products that are not necessary for making, using, selling or otherwise Exploiting a Product in the Territory.

 

    7

     

    

 

Section 3.02 Payment
Terms; Transfer Taxes.

 

(a) Payment
of the Purchase Price.

 

(i) The
Purchaser shall pay the Cash Consideration to the Seller at Closing, by wire transfer of immediately available funds to an account designated
in writing by the Seller.

 

(ii) Each
Milestone Payment due and payable under Section 3.01(b) shall be paid by the Purchaser to the Seller within [***] ([***]) days
following the occurrence of the corresponding Milestone Event; provided, however, that [***]. The Purchaser shall provide
a notice to the Seller of the occurrence of the Milestone Event set forth in Section 3.01(b) prior to, or no later than on, the
date of the payment of the corresponding Milestone Payment.

 

(iii) Each
of the Quarterly Earn-Out Payments due and payable under Section 3.01(c) shall be paid by the Purchaser to the Seller promptly
(but no more than [***] ([***]) days) following the end of the Quarter to which they relate to; provided, that (x) notwithstanding
the foregoing, Quarterly Earn-Out Payments payable under Section 3.01(c)(iv)(A) with respect to sales of Product by or on behalf of Licensees)
shall be payable by Purchaser to Seller on [***] of (1) [***] and (2) the [***] ([***]) day following the end of the applicable Quarter
to such Quarterly Earn-Out Payment relates and (y) Purchaser shall [***]. The Purchaser shall provide a notice to the Seller prior to,
or no later than on, the date such of payment, which notice shall provide sufficient details to permit confirmation by the Seller of the
accuracy of the payments made.

 

(iv) Any
payments to be made to the Seller under this Agreement shall be made to the Seller without deduction, setoff or counterclaim by the Purchaser
for any taxes, fees, duties (except for any withholding required by applicable Tax Laws). Each Party shall use reasonable efforts to provide
the other Party with such reasonable assistance as the other Party may request from time to time to minimize any such taxes, fees or duties
arising at any time in connection with the Exploitation of the Products, Compound or Purchased Assets in the Territory. Upon written request,
Seller shall deliver to the Purchaser a properly completed W-8BEN-E Internal Revenue Service Form which may be required by Purchaser in
order for Purchaser not to withhold tax under the Double Tax Avoidance Treaty. The Parties agree that as of the Effective Date, no payments
under this Agreement are subject to deduction or withholding tax, including the Upfront Payment. Notwithstanding anything herein to the
contrary, if, in connection with an actual or proposed change in Tax Law applicable to the payment of any amounts from the Purchaser or
its Affiliates to the Seller hereunder, either Party reasonably believes that actual or proposed change in Tax Law may result in the Purchaser
withholding any amounts hereunder due to any Tax Law, at the time amounts become due under this Agreement, the Parties shall confer and
discuss in good faith any amendments of changes to this Agreement that might reduce the impact of such change in Tax Law.

 

    8

     

    

 

(b) Mode
of Payment. All payments to the Seller under this Agreement shall be made by way of direct wire transfer of immediately available
funds, in Dollars, in the requisite amount to such bank account as the Seller may from time to time designate by notice to the Purchaser.

 

(c) Transfer
Taxes. All transfer, documentary, sales, use, valued-added, gross receipts, stamp, registration or other similar transfer Taxes (collectively,
“Transfer Taxes”) incurred in connection with the transfer and sale of the Purchased Assets as contemplated by the
terms of this Agreement, including all recording or filing fees and other similar costs of the Closing, that may be imposed, payable,
collectible or incurred, shall be borne by the Purchaser. The Parties hereto agree to reasonably cooperate with each other to claim any
applicable exemption from, or reduction of, any applicable Transfer Taxes.

 

Section 3.03 Additional
Covenants relating to the Milestone Payments and Quarterly Earn-Out Payments.

 

(a) The
Purchaser shall, and shall cause its Affiliates, and any Licensees and Transferees of rights to Exploit any Product, to keep reasonable,
correct and complete books, records and documents (whether in hardcopy, electronic or other form) substantiating the achievement (or non-achievement)
of the Milestone Event set forth in Section 3.01(b) and the Net Sales amounts recognized in each Calendar Year for each Product
in each country of the Territory, as related to the Quarterly Earn-Out Payments (the “Milestone and Earn-Out Information”)
and shall maintain such Milestone and Earn-Out Information until the [***] ([***]) year following the end of the Calendar Year to which
such Milestone and Earn-Out Information relates.

 

(b) Commencing
with First Commercial Sale of the first Product, and until the first Calendar Year following the Calendar Year in which the Seller has
received all Milestone Payments and Quarterly Earn-Out Payments, the Purchaser shall provide the Seller, (i) on a quarterly basis, not
later than [***] ([***]) days after the end of each Quarter other than the Quarter ended December 31, the quarterly Sales Reports; and
(ii) on an annual basis, not later than [***] ([***]) days after the end of each Calendar Year, the annual Sales Report. “Sales
Reports” shall mean reasonably detailed quarterly and annual reports of the aggregate gross sales and Net Sales of the Product
in each applicable country of the Territory, for such Quarter or Calendar Year, as applicable. All Sales Reports shall also include separate
line items for the gross sales and the Net Sales of the Product, in each case per applicable country of the Territory.

 

    9

     

    

 

(c) From
the Closing until the Seller has received all Milestone Payments and Quarterly Earn-Out Payments, an independent, national or global third
party auditing firm that is reasonably acceptable to Purchaser (and who is subject to the obligations of confidentiality as set forth
herein) shall have reasonable access to, and shall be able to review and audit, once every [***] ([***]) months upon no less than [***]
([***]) days written notice and during normal business hours, the books, records, documents (whether in hardcopy, electronic or other
form), personnel, work papers and operations) of the Purchaser to the extent necessary to permit the auditor to verify compliance of Purchaser
with its obligations under Section 3.01(b), Section 3.01(c) and Section 3.03(a) and the Sales Reports. The Purchaser
agrees to reasonably assist such auditing firm in connection with the exercise of the audit rights granted by this Section 3.03(c).
All expenses and costs associated with the review and audit in this Section 3.03(c) shall be borne solely by the Seller; provided
that in the event that such review and audit results in a finding and determination that a Milestone Payment or Quarterly Earn-Out Payment
payable was not otherwise paid or that the amount paid was lower by more than [***] percent ([***]%) than the amount that should have
been paid, then the reasonable expenses and costs charged by such audit firm for such review and audit (including reasonable attorney’s
fees) shall be borne and paid by the Purchaser. The results of such audit will be binding on the Parties, absent manifest error. All amounts
due to the Seller as shown by the audit (that have not been previously paid by Purchaser to Seller) shall be paid within [***] ([***])
days following the receipt by Purchaser of a copy of the final audit report. Purchaser will include in all sublicenses granted with respect
to the Compound and/or Product, an audit provision substantially similar to the foregoing requiring such sublicensee to keep full and
accurate books and records relating to the Compound and/or Product and granting such independent third party auditing firm the right to
audit the accuracy of the information reported by any sublicensee in connection therewith in accordance with terms and conditions substantially
similar to those provided in this Section above.

 

(d) From
the Closing until the Seller has received all Milestone Payments and Quarterly Earn-Out Payments, the Purchaser and its Affiliates shall
not without the prior written consent of the Seller, sell, assign, or otherwise transfer (excluding, for clarity, grant of a license other
than an Entire Rights License) any of the Purchased Assets to any Person or grant an Entire Rights License to any Person; provided
that, no such consent shall be required for such sale, assignment, transfer or Entire Rights License to any Person who agrees in writing
to be bound by the terms of, and to assume all applicable obligations of Purchaser and its Affiliates under this Agreement and the other
Transaction Documents, including obligations under ARTICLE III of this Agreement. For the avoidance of doubt, “applicable
obligations” shall mean all obligations of Purchaser and its Affiliates under this Agreement and the other Transaction Documents
directly or indirectly relating to such Purchased Assets or Product(s) (or rights to such Purchased Assets or Product(s), as applicable)
that are the subject of such sale, assignment or transfer. Nothing contained herein shall release the Purchaser from its obligations under
this Agreement or any other Transaction Document after any sale, license, assignment or transfer of any Purchased Assets or Assumed Liabilities
and Purchaser hereby expressly agrees that it shall remain liable under this Agreement and the other Transaction Documents following any
assignment or license for the full and complete performance of all obligations arising hereunder or thereunder. The Parties will reasonably
cooperate to maximize efficiency with respect to payments to be made under this Agreement.

 

Section 3.04 Additional
Covenants relating to Milestone Events.

 

(a) From
the Closing and until the Seller has received all Milestone Payments and Quarterly Earn-Out Payments, the Purchaser and its Affiliates
or Licensees or Transferees, as applicable, shall use Commercially Reasonable Efforts in order to develop, launch, commercialize, sell
and market Products in the Territory in each of the CTCL Indication, the PTCL Indication and the I/O Indication. The Purchaser shall not
take any actions with the intent to avoid the achievement of any of the Milestone Events (except that the applicable efforts to achieve
the Milestone Events shall be subject to Section 3.04(c) and (d)) or Quarterly Earn-Out Payments or reduce the amount of any of
the Quarterly Earn-Out Payments, including, without limitation, intentionally delaying sales or incentivizing customers to delay placing
orders. Notwithstanding the foregoing, Purchaser shall launch each Product in a jurisdiction within the Territory on or before the six
(6) month anniversary of the date such Product receives Regulatory Approval for such jurisdiction.

 

    10

     

    

 

(b) With
respect to the CTCL Approval Milestones, the PTCL Approval Milestones, the I/O Approval Milestones (collectively, the “Approval
Milestones”) commencing on the Effective Date and continuing until such time as all Approval Milestones have been achieved,
Purchaser and its Affiliates or Licensees or Transferees, as applicable, shall use their Commercially Reasonable Efforts to achieve each
of the Approval Milestones (the “Approval Efforts”).

 

(c) Commencing
on the Effective Date, Purchaser and its Affiliates or Licensees or Transferees, as applicable, shall use their Commercially Reasonable
Efforts to achieve a Successful Proof of Concept (the “Proof of Concept Efforts”). The Purchaser and its Affiliates
or Licensees or Transferees, as applicable, shall complete the Proof of Concept Plan (unless the Proof of Concept Plan must be discontinued
or delayed for safety reasons or reasons outside Purchaser’s reasonable control (and not directly or indirectly caused by Purchaser,
its Affiliates (or their permitted transferees, licensees or sublicensees)), which shall include taking the actions set forth in Annex
A within the timetable set forth therein (provided that if Purchaser does not comply with such timetable due to delays outside of
Purchaser’s reasonable control, such timetable shall be automatically extended on a day-for-day basis for so long as such event
out of Purchaser’s reasonable control is existing and preventing the Purchaser to proceed on such applicable activities). Purchaser
shall not cease the Proof of Concept Plan prior to its completion without the prior written consent of the Seller (such consent not to
be unreasonably withheld, conditioned or delayed), unless the Proof of Concept Plan or Proof of Concept Efforts must be discontinued for
safety reasons or reasons outside of Purchaser’s reasonable control; provided, that Purchaser shall promptly provide notice
to the Seller (in accordance with Section 10.02) that Purchaser has discontinued the Proof of Concept Plan activities and the reasons
for such discontinuance. In the event that the Purchaser is required to delay the Proof of Concept Plan prior to its completion due to
delays outside of Purchaser’s reasonable control (which delays are not directly or indirectly caused by Purchaser, its Affiliates
or their permitted transferees, licensees or sublicensees, Purchaser shall provide notice (in accordance with Section 10.02) to Seller
of such delay and the events contributing to such delay. Purchaser and its Affiliates shall consult with Seller in connection with the
Proof of Concept Efforts and consider in good faith the suggestions of Seller with respect thereto.

 

(d) The
Parties acknowledge that Purchaser may suspend or discontinue development of the Product for a particular Indication and/or a particular
jurisdiction within the Territory, to the extent such suspension or discontinuation would be consistent with the exercise of Commercially
Reasonable Efforts. Without limiting the foregoing, Purchaser may suspend or discontinue development of the Product for the I/O Indication
if, based on the results of the Proof of Concept Plan, such suspension or discontinuation would be consistent with the exercise of Commercially
Reasonable Efforts. For the avoidance of doubt, in the event that the Purchaser, its Affiliates or Licensees or Transferees, as applicable,
suspends or abandons any of the Approval Efforts, but later continues or revives the program with respect to the Approval Milestones,
the Purchaser’s obligation to pay the applicable Milestone Payment with respect to each then applicable Approval Milestone shall
remain in the event such Milestone Payment had not been earlier paid hereunder to Seller and remains outstanding under Section 3.01(b).

 

    11

     

    

 

(e) Information
Rights.

 

(i) Subject
to 3.01(e)(iii), within [***] ([***]) calendar days of the end of each Calendar Year until all Approval Milestones have been achieved
(other than any Approval Milestones for which the applicable Approval Efforts have been properly discontinued in accordance with Section
3.04(c) and (d)), if requested by Seller, Purchaser shall meet and confer with Seller and update Seller on the status of the Approval
Milestones. [***] ([***]) calendar days prior to such meeting, Purchaser shall deliver to Seller a written report in reasonable detail
setting forth the preceding Calendar Year’s Approval Efforts and an update on the status of all Approval Milestones.

 

(ii) Subject
to 3.01(e)(iii), within [***] ([***]) calendar days of the end of each Quarter until the Proof of Concept Plan has been completed (or
the Proof of Concept Plan has been discontinued in accordance with Section 3.04(c) and (d)), if requested by Seller, Purchaser
shall meet and confer with Seller and update Seller on the status of the Proof of Concept Plan. [***] ([***]) calendar days prior to such
meeting, Purchaser shall deliver to Seller a written report in reasonable detail setting forth for the preceding Quarter’s Proof
of Concept Efforts and an update on the status of the Proof of Concept Plan.

 

(iii) Notwithstanding
anything to the contrary herein, Purchaser shall provide written notification (in accordance with Section 10.02) to the Seller (“Discontinuation
Notice”) upon its determination to discontinue of any of the Approval Efforts, which discontinuance shall be in accordance with
Section 3.04(c) and Section 3.04(d). Upon receipt of a Discontinuation Notice, Seller and Purchaser shall meet and confer over the discontinuation
of such Approval Efforts within forty-five (45) days. Thirty (30) calendar days prior to such meeting, Purchaser shall deliver to Seller
a written report in reasonable detail setting forth for the reasons for such discontinuance, and the efforts undertaken with respect to
such Approval Effort.

 

ARTICLE IV

CLOSING

 

Section 4.01 Closing.
The consummation of the transactions contemplated in this Agreement (the “Closing”) shall take place remotely,
via the exchange of electronic copies of the agreements, documents, certificates and other instruments set forth in Section
4.02. The Closing shall be deemed to be effective as of 12:00:01 a.m. eastern time on the Effective Date, and the date in which
the Closing occurs shall be deemed the “Closing Date”.

 

Section 4.02 Closing
Deliverables.

 

(a) At
the Closing, the Seller shall deliver or cause to be delivered to the Purchaser the following:

 

(i) the
Bill of Sale & Assignment and Assumption Agreement, duly executed by authorized officers of the Seller and any applicable Affiliate
of Seller;

 

    12

     

    

 

(ii) the
Eisai Assignment and Assumption Agreement, duly executed by an authorized officer of the Seller and an authorized officer of Eisai;

 

(iii) assignments
of Acquired Contracts not assigned pursuant to the Eisai Assignment or Bill of Sale & Assignment and Assumption Agreement, if any,
duly executed by an authorized officer of Seller and any applicable Affiliate of Seller;

 

(iv) the
Transition Services Agreement, duly executed by an authorized officer of the Seller;

 

(v) the
Assignment of Patents, duly executed by an authorized officer of the Seller and any applicable Affiliate of Seller;

 

(vi) such
other documents as the Purchaser may reasonably request to give effect to this Agreement.

 

(b) At
the Closing, the Purchaser shall deliver to the Seller the following:

 

(i) the
payment of the Cash Consideration in accordance with Section 3.02(b);

 

(ii) the
Bill of Sale & Assignment and Assumption Agreement, duly executed by an authorized officer of the Purchaser;

 

(iii) the
Eisai Assignment and Assumption Agreement, duly executed by an authorized officer of the Purchaser;

 

(iv) the
Transition Services Agreement, duly executed by an authorized officer of the Purchaser;

 

(v) the
Assignment of Patents, duly executed by an authorized officer of the Purchaser;

 

(vi) such
other documents as the Seller may reasonably request to give effect to this Agreement.

 

(c) Transition
Services Agreement. At Closing, the Purchaser and the Seller will enter into a Transition Services Agreement, in the form attached
hereto as Exhibit H (the “Transition Services Agreement”).

 

(d) Inventory
Letter. At the Closing, the Seller shall assign to the Purchaser all of the Seller’s rights and interest in the Inventory Letter
pursuant to the Eisai Assignment and Assumption Agreement.

 

    13

     

    

 

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF SELLER

 

Except as set forth in the disclosure
schedules attached hereto (the “Seller Disclosure Schedules”), but subject to the immediately following sentence, the
Seller represents and warrants to the Purchaser that the statements contained in this ARTICLE V are true and correct as of the
date hereof (unless in each case the particular statement speaks expressly as of a particular date, in which case it is true and correct
only as of such date). Notwithstanding the foregoing, it is expressly understood and acknowledged that any information disclosed in the
Seller Disclosure Schedule under any numbered or lettered schedule, section, or subsection shall be deemed to relate to and qualify such
schedule, section or subsection, as well as any other schedule, sections or subsections of the Seller Disclosure Schedule, but only where
the relevance of such disclosure to such other schedule, section or subsection is reasonably apparent from the text of such disclosure.

 

Section 5.01 Organization
and Authority of the Seller. The Seller is a company duly organized, validly existing and in good standing under the Laws
of Switzerland. The Seller has the requisite power and authority to own and operate the Purchased Assets that it owns or operates.
The Seller is duly qualified to do business and in good standing in each jurisdiction where the ownership of the Purchased Assets
requires such qualification, except where the failure to be so qualified or in such good standing will not prevent or delay the
ability of Seller to consummate the transactions contemplated by this Agreement and the other Transaction Documents.

 

Section 5.02 Authority,
Non-Contravention, Required Filings.

 

(a) The
Seller has the requisite power and authority to execute and deliver this Agreement and the other Transaction Documents to which the Seller
is a Party and to perform its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby
(including, but not limited to, the power and authority to cause each Affiliate of Seller who has any rights with respect to any Purchased
Asset to sell, convey, transfer and assign such Purchased Asset to Purchaser in accordance with this Agreement). The execution and delivery
of this Agreement and the other Transaction Documents and the performance by the Seller of its obligations hereunder and thereunder and
the consummation by the Seller of the transactions contemplated hereby and thereby, has been duly authorized by all necessary company
action on the part of the Seller and its Affiliates.

 

(b) This
Agreement and the other Transaction Documents to which the Seller is a Party have been duly executed and delivered by the Seller, and
constitutes a legal, valid and binding obligation of the Seller, enforceable against it in accordance with its respective terms, in each
case subject to: (i) the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws relating
to or affecting the enforcement of creditors’ rights generally; and (ii) general equitable principles (whether considered in a proceeding
in equity or at Law).

 

(c) The
execution and delivery by the Seller of this Agreement and the other Transaction Documents to which the Seller is a Party, the performance
by the Seller of its obligations hereunder and thereunder, and the consummation by the Seller of the transactions contemplated hereby
and thereby do not and will not (i) contravene any provision of the Organizational Documents of the Seller or any of its Affiliates, (ii)
constitute a material breach, materially violate the terms, conditions or provisions of, or result in a material default under, or give
to others any rights of termination, amendment, acceleration or cancellation of, or notice with regard to, any agreement to which the
Seller or an of its Affiliates is a party or is otherwise bound, (iii) result in the creation of any Encumbrance (except for Permitted
Encumbrances) upon the Purchased Assets or (iv) violate any provision of any Laws.

 

    14

     

    

 

(d) No
Permit, Consent, waiting period expiration or termination, approval or authorization of, or designation, declaration or filing with, any
Governmental Authority on the part of the Seller or any of its Affiliates is required in connection with the execution or delivery by
the Seller of this Agreement, or the consummation of the transactions contemplated hereby.

 

Section 5.03 Purchased
Assets. The Seller and/or its applicable Affiliate(s) are the sole and exclusive owners
of all right, title and interest in and to all of the Purchased Assets, free and clear of all Encumbrances other than Permitted Encumbrances;
and to the Knowledge of the Seller, no Person is infringing or otherwise violating any of the Purchased Assets. Upon Closing, good and
marketable title to the Purchased Assets will pass to Purchaser, free and clear of all Encumbrances other than Permitted Encumbrances.

 

Section 5.04 Acquired
Contracts.

 

(a) Each
Acquired Contract is a valid and binding obligation of the Seller or an Affiliate of Seller who is a party thereto (and, to the Knowledge
of the Seller, each other party thereto) and is enforceable against the Seller or the Affiliate of Seller who is a party thereto (and,
to the Knowledge of the Seller, each other party thereto) in accordance with its terms, and is in full force and effect, subject to (i) the
effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws relating to or affecting the
enforcement of creditors’ rights generally and (ii) general equitable principles (whether considered in a proceeding in equity
or at Law).

 

(b) Neither
Seller nor any Affiliate of Seller is in violation, breach or default in any material respect under any Acquired Contract to which it
is a party, and to the Knowledge of the Seller no event has occurred that will (with or without notice or lapse of time) result in a violation,
breach or default in any material respect by the Seller or any Affiliate of Seller under any Acquired Contract to which it is a party.
To the Knowledge of the Seller, there is no violation, breach, or default in any material respect under any Acquired Contract by any other
party to such Acquired Contracts. No party to any Acquired Contract has cancelled or withdrawn any such Acquired Contract, nor, to the
Knowledge of the Seller, has any party threatened in writing to do so.

 

(c) All
Consents required for the sale, conveyance, transfer and delivery of the Acquired Contracts to Purchaser pursuant to this Agreement have
been obtained.

 

Section
5.05 Compliance with Law; Permits; Regulatory Matters.

 

(a) The
Seller’s and its Affiliates’ use of the Purchased Assets has been and is being conducted in compliance in all material respects
with all applicable Laws.

 

    15

     

    

 

(b) To
the Knowledge of the Seller, the Existing Product is being and has been developed in material compliance with applicable Law, including
those requirements relating to good manufacturing practice, good laboratory practice and good clinical practice. Neither the Seller nor
any of its Affiliates have received (and, to the Knowledge of the Seller, neither Eisai nor any of its Affiliates has received) any (i)
written notice from the FDA or any other Governmental Authority, including the Office of Inspector General, any United States Attorney,
the Department of Justice or any attorney general of any jurisdiction, alleging that the Seller, Eisai or any of their respective Affiliates
has been or is in violation of any Applicable Healthcare Industry Laws or other applicable Laws, or commencing or indicating an intention
to conduct an investigation, audit, or review, in each case, in connection with the conduct of the Business or the Purchased Assets; (ii)
written notice of inspectional observation (including those recorded on form FDA 483), warning letter, penalty, fine, sanction, request
for recall or other remedial action in connection with the conduct of the Business or the Purchased Assets; or (iii) other written documents
issued by the FDA or any other Governmental Authority alleging lack of compliance with any Applicable Healthcare Industry Laws or other
applicable Laws by the Seller, Eisai or any of their respective Affiliates, or any Person engaged by the Seller, Eisai or any of their
respective Affiliates, to provide any service with respect to any Existing Product or otherwise in connection with the conduct of the
Business or the Purchased Assets.

 

(c) Seller
holds all Permits which are required by the Seller to conduct the Business as it currently being conducted, except where failure to hold
any Permit would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

(d) Neither
the Seller nor any of its Affiliates (nor, to the Knowledge of the Seller, Eisai or any Affiliate of Eisai) has made an untrue statement
or fraudulent statement of material fact to the FDA or any other Governmental Authority or to any physician or customer, failed to disclose
a material fact required to be disclosed to the FDA or any other Governmental Authority or to any physician or customer, or committed
any material act, made any material statement, or failed to make any material statement, that would reasonably be expected to provide
a basis for the FDA to invoke its policy respecting “Fraud, Untrue Statements of Material Fact, Bribery, and Illegal Gratuities”,
set forth in FDA’s Compliance Policy Guide Sec. 120.100 (CPG 7150.09) with respect to the Existing Product. Neither the Seller (nor
any of its Affiliates or its or their respective directors, officers or employees who has been involved in the development of the Existing
Product) nor, to the Knowledge of the Seller, Eisai or any Affiliate of Eisai (or any officers, employees, or agents of any of the foregoing)
or any agent of the Seller has (i) been convicted of any crime or engaged in any conduct that would reasonably be expected to result in,
or that has resulted in, debarment, disqualification or exclusion by any Governmental Authority or under applicable Law, including 21
U.S.C. §335a, or (ii) any knowledge of facts that would lead to a false claim, or debarment, and there are no proceedings pending
or threatened that would result in criminal liability or debarment or disqualification by any Governmental Authority.

 

    16

     

    

 

(e) Neither
the Seller, nor, to the Knowledge of the Seller, any Affiliate, director, manager, officer, equity holder or employee of the Seller has
(i) used any funds for contributions, gifts, entertainment or other expenses in violation in any material respect of applicable Law, (ii)
paid any bribe, kickback or other similar payment, directly or indirectly, to any foreign government official or employee in violation
of the Foreign Corrupt Practices Act of 1977 or other applicable Law, (iii) made any other payment of any kind in violation of any Law,
to secure any improper advantage for the Purchased Assets or the Seller or any of its Affiliates, or (iv) knowingly incorrectly recorded
any transactions in any of the foregoing categories on the books and records of the Seller or any of its Affiliates. No claims, actions
or proceedings or, to the Knowledge of the Seller, actual or threatened investigations that would be reasonably expected to result in
such a debarment, disqualification or exclusion are pending or to the Knowledge of the Seller, threatened, against the Seller or its Affiliates,
Eisai or its Affiliates or any of their respective officers, employees or agents.

 

(f) All
ongoing and completed preclinical studies and clinical trials conducted by the Seller or its Affiliates or, to the Knowledge of the Seller,
Eisai or any of its Affiliates, or by third-party vendors on behalf of any of them, with respect Products have been conducted in all material
respects in accordance with the applicable Good Clinical Practice regulations described in 21 CFR Parts 50, 54, 56 and 312, and applicable
Good Laboratory Practice regulations as described in 21 CFR Part 58 and comparable applicable Law solely to the extent the foregoing are
applicable to such studies and/or trials.

 

(g) Seller
has made available to Purchaser (or its agents) true, correct and complete copies of (i) the IND relating to the Existing Product and
(ii) any other material documents received from the FDA or equivalent non-US regulatory agency in the possession or control of Seller
or any of its Affiliates, including documents that indicate or suggest lack of compliance with the regulatory requirements of the FDA
or other regulatory agencies, in each case to the extent related to any Product (or the development or approval of any Product) or any
Purchased Asset. Seller has made available to Purchaser for review all material correspondence to or from the FDA, material minutes of
meetings, including material documents concerning communications to or from the FDA or other regulatory agencies, or prepared by the FDA
or other regulatory agency or which bear on the ability to obtain approval of the Existing Product or compliance with regulatory requirements
with respect to any of the foregoing, each of the foregoing, to the extent in the possession or control of Seller or any of its Affiliates.

 

(h) To
the Knowledge of the Seller and without making any due inquiry, the Seller is unaware of any material correspondence to or from the FDA
on the one hand, and Eisai or its Affiliates on the other hand, that indicate a lack of compliance with the regulatory requirements of
the FDA with respect to the Existing Product in the Territory, or which bear in any material respect on the ability to obtain approval
of the Existing Product in the Territory, which (i) are not part of the IND relating to the Existing Product that has been made available
to Purchaser, or (ii) has not otherwise been made available to Purchaser.

 

Section
5.06 Brokers. Neither the Seller nor any of its Affiliates has incurred, nor
will any of them incur, directly or indirectly, any Liability for brokers’ or finders’ fees or agents’ commissions
or any similar charges in connection with this Agreement or the consummation of the transactions contemplated hereby.

 

Section 5.07 Litigation.

 

(a) There
is no Legal Proceeding by any Person pending relating to or affecting the Business, Existing Product, the Purchased Assets or the Assumed
Liabilities. There is no Legal Proceeding pending or, to the Knowledge of the Seller, threatened that is reasonably likely to prohibit
or restrain the ability of the Seller to enter into this Agreement or consummate the transactions contemplated hereby.

 

    17

     

    

 

(b) There
is no written demand or other assertion by any Person pending nor, to the Knowledge of the Seller, threatened in writing, against or by
the Seller or its Affiliates (or, to the Knowledge of the Seller, against or by Eisai or any of its Affiliates) relating to or affecting
the Business, Existing Product, the Purchased Assets or the Assumed Liabilities (each, a “Business Claim”), which if determined
adversely to the Seller would result in a Material Adverse Effect (and, to the Knowledge of the Seller, there is no other Business Claim).

 

(c) Neither
the Seller nor any of its Affiliates is a party or subject to the provisions of any Governmental Order that is unsatisfied or that affects
the Business or Purchased Assets.

 

Section 5.08 Intellectual
Property.

 

(a) To
the Knowledge of the Seller, neither the Purchased Intellectual Property nor the Exploitation of the Product (as such Product exists as
of the date hereof or, if the Existing Product were being commercialized in the Territory as of the date hereof) infringes any intellectual
property rights or misappropriates any trade secrets owned by any Third Party in the Territory. No action, claim, demand, suit or other
assertion by any Person is pending, nor to the Knowledge of the Seller, has been threatened in writing as of or prior to the date hereof
against the Seller or any of its Affiliates (or, to the Knowledge of Seller, against Eisai or any of its Affiliates) by any Third Party
claiming that the (i) Purchased Intellectual Property, or (ii) the Exploitation of any Product (as such Products exist as of the Closing)
infringes the intellectual property rights or misappropriates any trade secrets of such Third Party. To the Knowledge of the Seller, no
Third Party is infringing any of the Purchased Intellectual Property in the Territory.

 

(b) Neither
the Seller nor any of its Affiliates has granted any Third Party any license, sublicense, option or other rights with respect to any of
the Purchased Assets (including, but not limited to, the Purchased Intellectual Property and any rights under any Acquired Contract),
nor is the Seller or any of its Affiliates obligated to pay any royalties or licensing fees to any Third Party in connection with any
of the Purchased Assets, Products or Compound (except for milestone payments expressly set forth in the Eisai Agreement).

 

Section 5.09 No
Other Assets. Except
for the Purchased Assets and the Licensed Know How, neither
Seller nor any of its Affiliates owns, licenses or otherwise has any rights with respect to any material asset (including, but not limited
to, any Intellectual Property, Contract, Regulatory Approval Application, Regulatory Approval and tangible material (other than materials
being assigned and transferred pursuant to the Inventory Letter)) that, as of the Closing Date, is used in, or otherwise necessary
for, the Exploitation of any Product (as such Products exist as of the Closing) or the Compound in the Territory.

 

Section
5.10 No Other Representations and Warranties. Except for the representations and warranties contained in this ARTICLE
VI, the Seller has not made any other express or implied representation or warranty, either written or oral, on behalf of the Seller,
including any representation or warranty as to the accuracy or completeness of any information regarding the Seller or the Purchased
Assets furnished or made available to the Purchaser or its representatives.

 

    18

     

    

 

ARTICLE VI

REPRESENTATIONS AND WARRANTIES OF PURCHASER

 

The Purchaser represents and
warrants to the Seller that the statements contained in this ARTICLE VI are true and correct as of the date hereof.

 

Section
6.01 Organization and Authority of the Purchaser. Purchaser is a corporation duly organized, validly existing and in
good standing under the Laws of the State of Nevada and has the requisite power and authority to own and operate its business as presently
conducted. Purchaser is duly qualified to do business and in good standing in each jurisdiction where the operations of its business
requires such qualification, except where the failure to be so qualified or in such good standing will not prevent or delay the ability
of Purchaser to consummate the transactions contemplated by this Agreement and the other Transaction Documents.

 

Section 6.02 Authority;
Non-Contravention, Required Filings.

 

(a) The
Purchaser has the requisite corporate power and authority to execute and deliver this Agreement and the other Transaction Documents to
which it is a party and to perform its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and
thereby. The execution and delivery by the Purchaser of this Agreement and the other Transaction Documents to which the Purchaser is a
party, and the performance by the Purchaser of its obligations hereunder and thereunder, and the consummation by the Purchaser of the
transactions contemplated hereby and thereby, has been duly authorized by all necessary corporate action on the part of the Purchaser.

 

(b) This
Agreement and the other Transaction Documents to which the Purchaser is a party have been duly executed and delivered by the Purchaser
and each constitutes a valid and binding obligation of the Purchaser, enforceable against it in accordance with its terms, in each case
subject to: (i) the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws relating
to or affecting the enforcement of creditors’ rights generally; and (ii) general equitable principles (whether considered in a proceeding
in equity or at Law).

 

(c) The
execution and delivery by the Purchaser of this Agreement and the other Transaction Documents to which the Purchaser is a party, the performance
by the Purchaser of its obligations hereunder or thereunder, and the consummation by the Purchaser of the transactions contemplated hereby
and thereby do not and will not (i) contravene any provision of the Organizational Documents of Purchaser, (ii) constitute a breach, violate
the terms, conditions or provisions of, or result in a default under, or give to others any rights of termination, amendment, acceleration
or cancellation of any contract or agreement to which the Purchaser is a party or is otherwise bound, or (iii) violate any provision of
any Laws to which the Purchaser is subject.

 

    19

     

    

 

(d) No
Permit, Consent, waiting period expiration or termination, approval or authorization of, or designation, declaration or filing with, any
Governmental Authority on the part of the Purchaser is required in connection with the execution or delivery by the Purchaser of this
Agreement or the consummation of the transactions contemplated hereby.

 

Section
6.03 Legal Proceedings. There are no Legal Proceedings pending or, to the Knowledge of the Purchaser, threatened against
or by Purchaser or any Affiliate of Purchaser, that are reasonably likely to prohibit or restrain the ability of the Purchaser to enter
into this Agreement or consummate the transactions contemplated hereby.

 

Section
6.04 Sufficiency of Funds. The Purchaser has sufficient cash, available lines of credit or other sources of immediately
available funds to enable it to timely make payment of the Upfront Payment and consummate the transactions contemplated by this Agreement.

 

Section
6.05 Brokers. No broker, finder or investment banker is entitled to any brokerage,
finder’s or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements
made by or on behalf of the Purchaser. 

 

Section
6.06 Financial Statements. Complete copies of the Purchaser’s audited financial
statements consisting of the balance sheet of the Purchaser as at September 30, 2020 and as at September 30, 2019 and the related statements
of income and retained earnings, stockholders’ equity and cash flow for the 12 month periods then ended (the “Audited Financial
Statements”), and unaudited financial statements consisting of the balance sheet of the Purchaser as at June 30, 2021 and the
related statements of income and retained earnings and cash flow for the three-month period then ended (the “Interim Financial
Statements” and together with the Audited Financial Statements, the “Financial Statements”) have been filed
with the SEC and are publicly available. The Audited Financial Statements have been prepared in accordance with GAAP and the Interim Financial
Statements have been prepared in accordance with GAAP, both as applied on a consistent basis throughout the period involved, subject,
in the case of the Interim Financial Statements, to normal and recurring year-end adjustments (the effect of which will not be materially
adverse) and the absence of notes (that, if presented, would not differ materially from those presented in the Audited Financial Statements).
The Financial Statements are based on the books and records of the Purchaser, and fairly present the financial condition of the Purchaser
as of the respective dates they were prepared and the results of the operations of the Purchaser for the periods indicated. The Purchaser
maintains a standard system of accounting established and administered in accordance with GAAP, as the case may be. The Purchaser acknowledges
that, in making their decision to enter into this Agreement and the Transaction Documents and to consummate the transactions contemplated
hereby and thereby, the Seller is expressly relying on the Purchasers’ representations and warranties in this Section 6.06 and that,
without such representations and warranties, the Seller would not have entered into this Agreement and the other Transaction Documents
or consented to the transactions contemplated hereby and thereby.

 

    20

     

    

 

Section
6.07 Solvency. Immediately after the Closing, and after giving effect to the transactions
contemplated by this Agreement, the Purchaser will be Solvent.

 

Section
6.08 Independent Investigation; No Other Warranties. The Purchaser acknowledges that (a) they have conducted their
own independent investigation, review and analysis of the materials and information provided by Seller to Purchaser prior to Closing
and publicly-available information related to the Purchased Assets and have formed an independent judgment concerning the Purchased Assets,
the Assumed Liabilities and the other rights or obligations to be transferred under this Agreement, and (b) they have been provided reasonable
access to the personnel, properties, assets, premises, books and records, and other documents and information of the Seller and relating
to the Purchased Assets. The Purchaser further acknowledges and agrees that: (i) the only representations, warranties, and covenants
made by the Seller are the representations, warranties, and covenants expressly set forth in this Agreement, the other Transaction Documents
and the certificates and documents delivered hereunder and thereunder; (ii) in making its decision to enter into this Agreement
and to consummate the transactions contemplated hereby, the Purchaser has relied solely upon its own investigation and the express representations
and warranties of the Seller set forth in this Agreement and the other Transaction Documents; and (iii) the Purchaser has not relied
upon any other representations or other information made or supplied by or on behalf of the Seller (including any information provided
by the Seller’s advisors or in management presentations) and the Purchaser will not have any right or remedy arising out of any
such other representations or information. The Purchaser acknowledges and agrees that, except as expressly provided in ARTICLE V,
the sale of the Purchased Assets is “as is” and “where is,” and the Purchaser is acquiring the Purchased Assets
without any other representation or warranty, written or oral, statutory, express or implied, including any implied warranty of merchantability,
fitness of any asset for a particular purpose, title, or non-infringement.

 

ARTICLE VII

COVENANTS

 

Section
7.01 Confidentiality. From and after the Closing:

 

(a) The
Confidentiality Agreement will terminate without further action by the Parties thereto.

 

(b) The
Seller shall treat as confidential and shall safeguard any and all Confidential Information of the Purchaser (which shall include information,
knowledge, and data regarding the Products, the Purchased Assets, and the Assumed Liabilities and the terms and conditions of this Agreement)
by using the same degree of care, but no less than a reasonable standard of care, to prevent the unauthorized use, dissemination, or disclosure
of such Confidential Information as the Seller or its Affiliates used with respect thereto prior to the execution of this Agreement. The
Seller shall not use the Confidential Information of the Purchaser for any purpose except for the benefit of the Purchaser, unless expressly
permitted by this Agreement.

 

    21

     

    

 

(c) The
Purchaser shall treat as confidential and shall safeguard any and all Confidential Information of the Seller relating to the businesses
of the Seller, other than any information specifically related to the Products, the Purchased Assets, or the Assumed Liabilities, and
except as otherwise agreed to by the Seller in writing; provided, however, that nothing in this Section 7.01(c) shall prevent
the disclosure of any such Confidential Information to any directors, officers, employees, or professional advisors of the Purchaser to
whom such disclosure is necessary in the conduct of the Purchaser’s business if such Persons are informed by the Purchaser of the
confidential nature of such information and are directed by the Purchaser to comply with the provisions of this Section 7.01(c).

 

(d) The
Purchaser and the Seller acknowledge that the confidentiality obligations set forth herein shall not extend to information, knowledge
and data that is publicly available or becomes publicly available through no act or omission of the Party owing a duty of confidentiality,
or becomes available on a non-confidential basis from a source other than the Party owing a duty of confidentiality so long as such source
is not known by such Party to be bound by a confidentiality agreement with or other obligations of secrecy to the other Party.

 

(e) In
the event of a breach of the obligations hereunder by the Purchaser or the Seller, the non-breaching Party(ies), in addition to all other
available remedies, will be entitled to injunctive relief to enforce the provisions of this Section 7.01 in any court of competent
jurisdiction, without the necessity of posting a bond and the burden of proving actual damages.

 

Section 7.02 Preservation
of Books and Records.

 

(a) The
Seller shall have the right to retain copies of all books and records relating to the Purchased Assets relating to periods ending on or
prior to the Closing Date, provided that such books and records are kept confidential in accordance with the Seller’s normal confidentiality
procedures and the provisions of Section 7.01.

 

(b) Without
prejudice to the provisions of Section 3.03, the Purchaser shall preserve and keep, or cause to be preserved and kept, the books
and records included in the Purchased Assets in the possession of the Purchaser or its Affiliates for the longer of: (i) any applicable
statute of limitations; and (ii) a period of [***] ([***]) years from the Closing.

 

(c) Without
prejudice to the provisions of Section 3.03, during such retention period:

 

(i) the
Seller, its Affiliates and their respective representatives shall, upon reasonable notice and for any reasonable business purpose, have
access during normal business hours to examine, inspect and copy such books and records; and

 

(ii) the
Purchaser shall provide, or cause to be provided to, the Seller, its Affiliates and their respective representatives, access to such books
and records relating to the Purchased Assets as they shall reasonably request in connection with any Legal Proceeding to which any of
them are parties or in connection with the requirements of any Law applicable to them.

 

    22

     

    

 

(d) No
Party shall be obligated to provide the other Party with access to any books or records pursuant to this Section 7.02 where such
access would violate any Law.

 

Section
7.03 Public Announcements. Neither the Seller, the Purchaser nor any of their respective Affiliates shall issue any
press release or make any public announcement with respect to this Agreement and the transactions contemplated hereby without obtaining
the prior written consent of the other Party, except as may be required by Law, including any federal, state or local securities law
(or stock exchange rules and regulations), upon the advice of counsel and only if the disclosing Party (x) provides the non-disclosing
Party with an opportunity to first review the release or other public announcement, (y) consults with the non-disclosing Party (whether
such Party is named in such publicity, news release or public announcement or not) at a reasonable time prior to its release to allow
the non-disclosing Party to comment thereon (provided that the foregoing shall not prevent the disclosing Party from proceeding with
such release or other public announcement by any applicable deadline required under applicable Law or stock exchange rules or regulations
if the non-disclosing Party fails to timely respond to such requests) and (z) after its release, shall provide the non-disclosing
Party with a copy thereof. If a Party, based on the advice of its counsel, determines that this Agreement or exhibits thereto must be
filed with the United States Securities and Exchange Commission (“SEC”) or similar Governmental Authority, then such
Party, prior to making any such filing, shall provide the other Party and its counsel with a redacted version of this Agreement which
it intends to file and any draft correspondence with the SEC (or similar Governmental Authority) requesting the confidential treatment
by the SEC (or similar Governmental Authority) of those redacted sections of the Agreement, and will give due consideration to any comments
provided by such other Party or its counsel and use good faith efforts to obtain confidential treatment by the SEC of those sections
specified by such other Party or its counsel; provided, however, that the Party filing this Agreement or its exhibits will not be required
to seek confidential treatment of any information that it determines it is required to publicly disclose based on advice of counsel.
Following the Closing, the Purchaser shall be entitled to make such public announcements as it deems appropriate related to the Compound
or Products; provided however that except as otherwise provided above, without the Seller’s prior written consent, no such announcement
shall contain any reference to the Agreement or the terms set forth therein or the Seller, its Affiliates or actions taken with respect
to the Compound or Products prior to the Effective Date other than references consistent with those previously approved by the Seller.

 

Section
7.04 Further Assurances. Except as otherwise set forth herein, subject to the terms and conditions set forth herein
and to applicable legal requirements, each of the Parties hereto shall, and shall cause its respective Affiliates to, cooperate and use
their respective commercially reasonable efforts to take, or cause to be taken, all appropriate action, and do, or cause to be done,
and assist and cooperate with the other Party in doing, all things necessary, proper or advisable to consummate and make effective, in
the most expeditious manner practicable, the transactions contemplated in this Agreement.

 

    23

     

    

 

Section 7.05 Certain Intellectual
Property Matters. Any recovery realized because of litigation of the Purchased Patents or Purchased Intellectual Property (whether
by way of settlement or otherwise) shall be first allocated to reimburse Purchaser for their direct and out of pocket costs and expenses
in making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses). Any remainder
after such reimbursement is made shall be retained by Purchaser provided, however, that to the extent that any award or settlement (whether
by judgment or otherwise) with respect to Purchased Intellectual Property is attributable to loss of sales or profits with respect to
the Product, that has impacted a Milestone Payment based on Net Sales or other Quarterly Earn-Out Payments to Seller, the Parties shall
negotiate in good faith an appropriate allocation of such remainder to reflect the economic interests as a whole of the Parties under
this Agreement with respect to the Product, including the adjustment of Net Sales.

 

Section 7.06 License to
Licensed Know-How. Effective as of the Closing, Seller (on behalf of itself and its Affiliates) hereby grants to Purchaser a perpetual,
irrevocable, paid-up, royalty-free, transferable, sub-licensable, worldwide, exclusive (even as to Seller and its Affiliates) license
under the Licensed Know-How solely in order to Exploit the Compound and any Product (including any companion diagnostic related to a Product).
For the avoidance of doubt, the Licensed Know-How shall not be used for products of the Purchaser, its Affiliates, Licensees or Transferees,
other than Products.

 

ARTICLE VIII

NON-COMPETE AND NON-SOLICITATION RESTRICTIONS

 

Section 8.01 Non-Compete.
For a period of [***] ([***]) years commencing on the Closing Date (the “Restricted Period”),
Seller shall not, and shall ensure that its Affiliates do not, directly or indirectly engage in, or assist anyone other than Purchaser
in engaging in, the Exploitation in the Territory of any Restricted Product.

 

Section 8.02 Non-Solicitation.
For a period of [**] ([***]) years commencing on the Closing Date, neither Party shall directly or indirectly contact or solicit any person
while such person is employed or engaged as an independent contractor by the other Party hereto (or any of its Affiliates) for the purposes
of hiring or engaging such person, or encourage any such employee or independent contractor to leave such employment or engagement, without
the prior written consent of such other Party. The foregoing restriction shall not apply to employees or independent contractors who respond
to general solicitations which are not directed specifically to any such employees or independent contractors.

 

Section 8.03 Acknowledgements;
Remedies. Seller acknowledges that the restrictions contained in Section 8.01 are reasonable
and necessary to protect the legitimate interests of Purchaser and constitute a material inducement to Purchaser to enter into this Agreement
and consummate the transactions contemplated by this Agreement. Seller further acknowledges that a breach or threatened breach of Section
8.01 may give rise to irreparable harm to Purchaser, for which monetary damages would not be an adequate remedy, and hereby agrees
that in the event of a breach or a threatened breach by Seller of any such obligations, Purchaser shall, in addition to any and all other
rights and remedies that may be available to it in respect of such breach, be entitled to seek equitable relief, including a temporary
restraining order, an injunction, specific performance and any other relief that may be available from a court of competent jurisdiction.
In the event that any covenant contained in Section 8.01 should ever be adjudicated to exceed the time, geographic, product or
service or other limitations permitted by applicable Law in any jurisdiction, then any court is expressly empowered to reform such covenant,
and such covenant shall be deemed reformed, in such jurisdiction to the maximum time, geographic, product or service or other limitations
permitted by applicable Law.

 

    24

     

    

 

ARTICLE IX

INDEMNIFICATION

 

Section 9.01 Survival.
Except for the representations and warranties contained in Section [***] and Section [***] (collectively, the “Fundamental
Representations”) (which shall survive and remain in full force and effect for a period of [***] ([***]) years following the
Closing Date), the representations and warranties contained in ARTICLE V and ARTICLE VI of this Agreement shall survive
the Closing until the close of business on the [***] ([***]) month anniversary of the Closing Date. All covenants and agreements contained
in this Agreement, whether of the Purchaser or the Seller, shall survive the Effective Date until the applicable statute of limitations
has expired or until the expiration date for such covenant or agreement specified in this Agreement, if sooner. Any claims for Losses
arising out of or caused by or relating to fraud shall survive indefinitely. The representations and warranties of the Seller are bargained
for assurances. All claims by any Indemnified Party pursuant to this ARTICLE IX must be made on or before the applicable survival
date, it being understood that so long as the Indemnified Party gives written notice of a claim on or prior to the applicable survival
date, such representations and warranties and covenants shall continue to survive solely with respect to such claim until such claim
is fully and finally resolved in accordance with the terms of this Agreement.

 

Section 9.02 Indemnification
by Seller. Subject to the terms and conditions of this ARTICLE IX, from and after the Closing, the Seller shall indemnify
and defend the Purchaser, its Affiliates, and each of their respective employees, directors, officers, stockholders, agents, and representatives
(collectively, the “Purchaser Group”), against, and shall hold each of them harmless from, any and all Losses incurred
or sustained by the Purchaser Group based upon or arising out of:

 

(a) any
inaccuracy in or breach of any of the representations or warranties of the Seller contained in this Agreement, as of the date such representation
or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties
that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);

 

(b) any
breach or non-fulfillment of any covenant, agreement, or obligation to be performed by the Seller pursuant to this Agreement or any other
Transaction Document (which shall not include the Transition Services Agreement); or

 

(c) any
Excluded Asset or Excluded Liability.

 

    25

     

    

 

The foregoing indemnity obligations
will not apply to (i) the extent that such Losses arise out of or result from the fraud, gross negligence, and/or willful misconduct of
Purchaser or its Affiliates, and/or any related breach by Purchaser of its representations, warranties, and/or covenants hereunder, or
(ii) Losses for which Purchaser has an obligation to indemnify the Seller Group pursuant to Section 9.03, as to which Losses
each Party shall indemnify the other to the extent of its respective liability for such Losses.

 

Section 9.03 Indemnification
by Purchaser. Subject to the terms and conditions of this ARTICLE IX, from and after the Closing, the Purchaser shall indemnify
and defend the Seller, its Affiliates, and each of their respective employees, directors, officers, stockholders, agents, and representatives
(collectively, the “Seller Group”), against, and shall hold each of them harmless from, any and all Losses incurred
or sustained by the Seller Group based upon or arising out of:

 

(a) any
inaccuracy in or breach of any of the representations or warranties of the Purchaser contained in this Agreement or in any certificate
or instrument delivered by or on behalf of the Purchaser pursuant to this Agreement, as of the date such representation or warranty was
made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly
relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);

 

(b) any
breach or non-fulfillment of any covenant, agreement, or obligation to be performed by the Purchaser pursuant to this Agreement or any
other Transaction Document (which shall not include the Transition Services Agreement);

 

(c) any
Assumed Liability; or

 

(d) the
Exploitation, development, manufacture, supply, marketing or distribution of the Compound or any Product following the Closing.

 

The foregoing indemnity obligations
will not apply to (i) the extent that such Losses arise out of or result from the fraud, gross negligence, and/or willful misconduct of
Seller or its Affiliates, and/or any related breach by Seller of its representations, warranties, and/or covenants hereunder, or (ii)
Losses for which Seller has an obligation to indemnify the Purchaser Group pursuant to Section 9.02, as to which Losses each
Party shall indemnify the other to the extent of its respective liability for such Losses.

 

Section 9.04 Notice of
Direct Claims.

 

(a) If
any of the Persons to be indemnified under this ARTICLE IX (the “Indemnified Party”) has suffered or incurred
any Loss subject to indemnification under this ARTICLE IX that does not involve a Third Party Claim, the Indemnified Party shall
so notify the Party responsible for providing indemnification therefor under this Agreement (the “Indemnifying Party”)
promptly in a writing describing such Loss, the basis for indemnification hereunder, the amount or estimated amount of such Loss, if known
or reasonably capable of estimation, and the method of computation of such Loss, all with reasonable particularity and containing a reference
to the provisions of this Agreement in respect of which such Loss shall have occurred. A failure by the Indemnified Party to give notice
in a timely manner pursuant to this Section 9.04(a) (so long as a notice pursuant to this Section 9.04(a) is given before
the expiration of the applicable period set forth in Section 9.01) shall not limit the obligation of the Indemnifying Party under
this ARTICLE IX, except to the extent such Indemnifying Party is prejudiced by failure to give such notice in a timely manner.

 

    26

     

    

 

(b) Except
when a notice, report or other filing must be filed immediately pursuant to applicable Law, the Purchaser shall provide notice and an
opportunity to comment to the Seller before the Purchaser files any report, notification or filing with any Governmental Authority or
Third Party in connection with an event that would be reasonably likely to result in a Loss subject to the indemnification provisions
of Section 9.02. In the event the Purchaser is required to file such a report, notification or filing immediately, the Purchaser
shall provide notice to the Seller promptly after it submits such report, notification or filing to the applicable Governmental Authority.

 

Section 9.05 Third Party
Claims.

 

(a) If
any Legal Proceeding is instituted by or against a Third Party with respect to which the Indemnified Party intends to seek indemnity under
this ARTICLE IX (a “Third Party Claim”), the Indemnified Party shall promptly notify the Indemnifying Party
of such Third Party Claim (such notice describing, to the extent practicable, such matter in reasonable detail and such being accompanied
by a copy of any written notice of the Third Party claimant to the Indemnified Party asserting the Third Party Claim) and tender to the
Indemnifying Party the conduct or defense of such Third Party Claim. A failure by the Indemnified Party to give notice in a timely manner
pursuant to this Section 9.05(a) (so long as a notice pursuant to this Section 9.05(a) that includes any written notice
of the Third Party claimant is given before the expiration of the applicable period set forth in Section 9.01) and to tender the
conduct or defense of the Third Party Claim in a timely manner pursuant to this Section 9.05(a) shall not limit the obligation
of the Indemnifying Party under this ARTICLE IX, except (i) to the extent such Indemnifying Party is materially prejudiced thereby,
and (ii) to the extent expenses are incurred during the period in which notice was not provided.

 

(b) The
Indemnifying Party shall have the right to defend the Indemnified Party against such Third Party Claim. If the Indemnifying Party notifies
the Indemnified Party that the Indemnifying Party elects to assume the defense of the Third Party Claim (such election to be without prejudice
to the right of the Indemnifying Party to dispute whether such claim is an indemnifiable Loss under this ARTICLE IX), then the
Indemnifying Party shall have the right to defend such Third Party Claim with counsel selected by the Indemnifying Party, in all appropriate
proceedings, to a final conclusion or settlement at the discretion of the Indemnifying Party in accordance with this Section 9.05(b).
The Indemnifying Party shall have full control of such defense and proceedings, including any compromise or settlement thereof; provided,
however, that the Indemnifying Party shall not enter into any settlement agreement without the written consent of the Indemnified Party
(which consent shall not be unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing, such consent shall not be required
if (i) the settlement agreement contains a complete and unconditional general release by the Third Party asserting the Third Party
Claim to all Indemnified Parties affected by the claim and (ii) the settlement agreement does not impose any obligation on, or contain
any sanction or restriction upon the conduct or operation of any business by, the Indemnified Party or its Affiliates. The Indemnified
Party may participate in, but not control, any defense or settlement of any Third Party Claim controlled by the Indemnifying Party pursuant
to this Section 9.05(b), and the Indemnified Party shall bear its own costs and expenses with respect to such participation.

 

    27

     

    

 

(c) If
the Indemnifying Party does not notify the Indemnified Party that the Indemnifying Party elects to defend the Indemnified Party pursuant
to Section 9.05(b) within thirty (30) days after receipt of any Claim Notice, then the Indemnified Party shall defend, and be reimbursed
for its reasonable cost and expense (but only if the Indemnified Party is actually entitled to indemnification hereunder) in regard to
the Third Party Claim with counsel selected by the Indemnified Party, in all appropriate proceedings, which proceedings shall be prosecuted
diligently by the Indemnified Party. In such circumstances, the Indemnified Party shall defend any such Third Party Claim in good faith
and have full control of such defense and proceedings; provided, however, that the Indemnified Party may not enter into any compromise
or settlement of such Third Party Claim if indemnification is to be sought hereunder, without the Indemnifying Party’s consent (which
consent shall not be unreasonably withheld, conditioned or delayed). The Indemnifying Party may participate in, but not control, any defense
or settlement controlled by the Indemnified Party pursuant to this Section 9.05(c), and the Indemnifying Party shall bear its own
costs and expenses with respect to such participation; provided, however, if at any time the Indemnifying Party acknowledges in
writing that such Third Party Claim is an indemnifiable Loss under this ARTICLE IX, the Indemnifying Party shall be entitled to
assume the defense of such Third Party Claim in accordance with Section 9.05(b).

 

(d) If
requested by the Indemnifying Party, the Indemnified Party agrees, at the sole cost and expense of the Indemnifying Party (but only if
the Indemnified Party is actually entitled to indemnification hereunder), to cooperate with the Indemnifying Party and its counsel in
contesting any Third Party Claim which the Indemnifying Party elects to contest, including providing access to documents, records and
information. In addition, the Indemnified Party will make its personnel available to the Indemnifying Party, at the Indemnifying Party’s
expense, for conferences, discovery, proceedings, hearings, trials or appeals as may be reasonably required by the Indemnifying Party.
The Indemnified Party also agrees to cooperate with the Indemnifying Party and its counsel in the making of any related counterclaim against
the Person asserting the Third Party Claim or any cross complaint against any Person and executing powers of attorney to the extent necessary.

 

Section 9.06 Limitations
on Indemnification; Limitations on Liability.

 

(a) Thresholds.
Notwithstanding the other provisions of this ARTICLE IX, other than claims for Losses arising out of, or caused by or relating
to fraud or for any breach of a Fundamental Representation, the Seller shall not be liable to provide indemnification for any Losses arising
from or in connection with matters described under Section 9.02 suffered by any Indemnified Party unless and until the aggregate
amount of all such Losses suffered by the Indemnified Parties exceeds, on a cumulative basis, an amount equal to $[***] ([***] Dollars)
(the “Indemnity Threshold”), and then the Seller shall only be liable to provide indemnification to the extent exceeding
the Indemnity Threshold. No Losses shall be included in determining whether the Indemnity Threshold has been reached unless a notice seeking
indemnification for such Losses has been given by the Purchaser Group to the Seller in accordance with Section 9.04(a) or Section
9.05(a), as applicable.

 

    28

     

    

 

(b) Caps.
Other than claims for Losses arising out of, or caused by or relating to fraud, in no event shall the Seller be liable to provide indemnification
pursuant to ARTICLE IX for Losses arising from or in connection with matters described under Section 9.02(a) in the aggregate
in excess of an amount equal to $[***] ([***] Dollars (the “Cap”). Notwithstanding anything to the contrary herein,
with respect to breaches of Fundamental Representations, the Cap shall be an amount equal to [***].

 

Section 9.07 Exclusion of Certain
Damages. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, EXCEPT FOR (I) LIABILITY FOR ANY PARTY’S FRAUD AND (II)
THE OBLIGATIONS OF ANY PARTY TO INDEMNIFY AN INDEMNIFIED PARTY UNDER ARTICLE IX FROM AND AGAINST THIRD PARTY CLAIMS PURSUANT TO
WHICH A THIRD PARTY HAS BEEN AWARDED SUCH DAMAGES, NO INDEMNIFIED PARTY SHALL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, TREBLE, REMOTE,
SPECIAL, EXEMPLARY, OPPORTUNITY COST, CONSEQUENTIAL OR PUNITIVE DAMAGES OR DAMAGES FOR, MEASURED BY OR BASED ON LOST PROFITS, LOSS OF
REVENUE OR INCOME, DIMINUTION IN VALUE, MULTIPLE OF EARNINGS, PROFITS OR CASH FLOWS, OR OTHER SIMILAR MEASURES OR FOR ANY LOSS OF BUSINESS
REPUTATION OR OPPORTUNITY THAT ARISES OUT OF OR RELATES TO THIS AGREEMENT OR THE PERFORMANCE OR BREACH HEREOF OF ANY LIABILITY RETAINED
OR ASSUMED HEREUNDER.

 

Section 9.08 Purchaser’s
Opportunity to Review. The Purchaser acknowledges that it and its representatives have received or been afforded the opportunity to
review prior to the date of this Agreement all written materials furnished or made available, as the case may be, to the Purchaser on
or prior to the date of this Agreement in connection with the transactions contemplated by this Agreement. The Purchaser acknowledges
that it and its Affiliates and representatives have been permitted full and complete access to the books and records, and other assets
related to the Purchased Assets that it and its representatives have desired or requested to see or review and that it and its representatives
have had a full opportunity to meet with the officers and employees of the Seller to discuss the Purchased Assets and the Assumed Liabilities.
The Purchaser further acknowledges and agrees that (i) other than the representations and warranties of the Seller specifically contained
in ARTICLE V of this Agreement, neither the Seller nor any other Person has made any representation or warranty either expressed
or implied (A) with respect to the Purchased Assets, the Assumed Liabilities or the transactions contemplated hereby or (B) as to the
accuracy or completeness of any information regarding the Purchased Assets, the Assumed Liabilities or the transactions contemplated hereby
or by any other agreements related hereto furnished or made available to the Purchaser and its representatives, (ii) the Purchaser has
not relied on any representation or warranty from the Seller or any other Person in determining to enter into this Agreement, except as
expressly set forth in ARTICLE V of this Agreement and (iii) no Person who is part of the Purchaser Group shall have any claim
or right to indemnification pursuant to this ARTICLE IX and neither the Seller nor any other Person shall have or be subject to
any Liability to the Purchaser Group (or any Person who is part of such group) or any other Person with respect to any information, documents
or materials furnished by the Seller or any of their representatives or agents to the Purchaser (it being understood that this clause
(iii) does not supersede or otherwise affect the representations and warranties of the Seller specifically contained in ARTICLE V
of this Agreement). Without limiting the generality of the foregoing, the Purchaser acknowledges and agrees that, except as otherwise
expressly set forth in Article 5, (i) the Seller does not make any representations or warranties relating to the maintenance, repair,
condition, design, performance or marketability of any Purchased Asset, including merchantability or fitness for a particular purpose,
(ii) Purchaser shall obtain rights in the Purchased Asset in their present condition and state of repair, “as is” and “where
is”.

 

    29

     

    

 

Section 9.09 Adjustment
to Purchase Price. The Seller and the Purchaser agree to treat all payments made either to or for the benefit of the other Party
under this Agreement as adjustments to the Purchase Price for tax purposes to the extent permitted under applicable tax Law.

 

Section 9.10 Reimbursement.
If an Indemnified Party recovers an amount from a Third Party in respect of a Loss that is the subject of indemnification hereunder
after all or a portion of such Loss has been paid by an Indemnifying Party pursuant to this ARTICLE IX, the Indemnified Party
shall promptly remit to the Indemnifying Party the amount received from the Third Party in respect thereof.

 

Section 9.11 Losses Net
of Insurance. In determining the amount of Losses in respect of a claim under this ARTICLE IX, there shall be deducted an
amount equal to the amount of any Third Party insurance proceeds actually received (net of direct collection expenses) by an Indemnified
Party making such claim with respect to such Losses, provided that the foregoing shall not (i) require an Indemnified Party to proceed
or seek action or recovery from any such Third Party as a requirement hereunder or as a condition to seeking or recovering indemnification
from any Indemnifying Party hereunder (but the Indemnified Party shall use its good faith efforts to
recover under insurance policies or indemnity, contribution or other similar agreements for any Losses and promptly notify in
reasonable detail any such recovery to the Indemnifying Party and reimburse it in accordance with the provisions of Section 9.09
hereof, if applicable), or (ii) be construed or interpreted as a guaranty of any level or amount of insurance recovery with the provisions
of Section 9.09 hereof, if applicable with respect to any Losses hereunder or as a requirement to maintain any insurance or to
make any claim for insurance as a condition to any indemnification hereunder.

 

Section 9.12 Subrogation.
To the extent that the Indemnifying Party makes or is required to make any indemnification payment to the Indemnified Party, the
Indemnifying Party shall be entitled to exercise, and shall be subrogated to, any rights and remedies (including rights of indemnity,
rights of contribution and other rights of recovery) that the Indemnified Party or any of its Affiliates may have against any other Person
with respect to any Losses to which such indemnification payment is directly related.

 

Section 9.13 Sole Remedy/Waiver.
Should the Closing occur, the remedies provided for in this ARTICLE IX shall be the sole and exclusive remedies of any Indemnified
Party in respect of this Agreement, the Purchased Assets, the Product, the Excluded Assets, the Assumed Liabilities, the Excluded Liabilities
or the transactions contemplated hereby, other than (i) for actions for specific performance or other equitable remedies, (ii) for
claims arising out or related to ARTICLE III, or (iii) for claims against a Party directly arising out of the knowing and intentional
fraud of such Party in respect of a provision of this Agreement. In furtherance of the foregoing, each Party hereby waives (on behalf
of itself and the relevant Indemnified Parties) any provision of applicable Law to the extent that it would limit or restrict the agreement
contained in this Section 9.13.

 

    30

     

    

 

ARTICLE X

MISCELLANEOUS

 

Section
10.01 Expenses. Except as otherwise provided in this Agreement, the Seller, on the one hand, and the Purchaser, on
the other hand, shall bear their own expenses incurred in connection with the negotiation and execution of this Agreement, each other
agreement, document and instrument contemplated by this Agreement, and the consummation of the transactions contemplated hereby and thereby.

 

Section
10.02 Notices. All notices, requests, consents, claims, demands, waivers, and other communications hereunder shall
be in writing and shall be deemed to have been given: (i) when delivered, if delivered personally to the intended recipient; (ii) when
received by the addressee, if sent by an internationally recognized overnight courier service; (iii) on the date sent by facsimile (with
verification of transmission) or email (with confirmation of receipt of the email and any attachments); or (iv) on the fifth (5th)
day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent
to the respective Parties at the following addresses (or at such other address for a Party as shall be specified in a notice given in
accordance with this Section 10.02):

 

		(a)	if to the Seller:

 

	 	 	Dr. Reddy’s Laboratories SA
	 	 	Elisabethenanlage 11
	 	 	CH – 4051, Basel
	 	 	Switzerland
	 	 	Attention: [***]
	 	 	 
	 	 	With a copy (which shall not constitute notice) to:
	 	 	 
	 	 	Dr. Reddy’s Laboratories Limited
	 	 	8-2-337, Road No. 3
	 	 	Banjara Hills, Hyderabad – 500 034, Telangana, India
	 	 	Attention: [***]
	 	 	 
	 	 	And
	 	 	 
	 	 	Dr. Reddy’s Laboratories, Inc.
	 	 	107 College Road East
	 	 	Princeton, New Jersey 08540
	 	 	Email: [***]
	 	 	Fax: [***]
	 	 	Attention: Legal Affairs

 

	 	(b)	 if to the Purchaser:
	 	 	 
	 	 	Citius Pharmaceuticals, Inc.
	 	 	11 Commerce Drive, First Floor
	 	 	Cranford, New Jersey 07016
	 	 	Facsimile: (908) 967-6683
	 	 	Email: [***]
	 	 	Attention: Chief Financial Officer
	 	 	 
	 	 	With a copy (which shall not constitute notice) to:
	 	 	 
	 	 	Lowenstein Sandler LLP
	 	 	One Lowenstein Drive
	 	 	Roseland, New Jersey 07068
	 	 	Attn: Michael J. Lerner, Esq.

 

Section
10.03 Severability. If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction,
such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Agreement in such jurisdiction
or invalidate or render unenforceable such term or provision in any other jurisdiction.

 

Section
10.04 Entire Agreement. This Agreement, together with the Exhibits, Annexes and Schedules hereto, the Seller Disclosure
Schedule, the other Transaction Documents, Transition Services Agreement, constitute the entire agreement, and supersedes all prior agreements
and understandings (both written and oral), among the Parties regarding the subject matter hereof.

 

    31

     

    

 

Section 10.05 Successors
and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the Parties
hereto and their respective successors and permitted assigns. Seller may assign their rights or obligations hereunder without the prior
written consent of the Purchaser. Purchaser may not assign any of its rights or obligations hereunder without the prior written consent
of the Seller (such consent not to be unreasonably withheld, denied or conditioned); provided, that following the payment in full of the
Milestone Payment for the US CTCL Approval Milestone, the Purchaser may make an assignment or transfer of any of its rights or obligations
hereunder without Seller’s consent to its Affiliates or to a Third Party successor that acquires all or substantially all of the
assets of the business of Purchaser to which this Agreement relates or rights with respect to any Product. As a condition to any assignment
hereunder, (i) the assignee hereunder shall agree in writing to assume all applicable obligations (as defined in Section 3.03(d), in the
case of an assignment by Purchaser) of the assignor under this Agreement, the Transition Services Agreement (as applicable) and other
Transaction Documents as a condition to such assignment and (ii) the assignor shall provide notice to remaining party containing the name
and contact information of the assignee. Further, as a condition to any assignment by the Purchaser hereunder, Purchaser shall pay any
amounts owed to Seller as of the date of such assignment. No assignment hereunder will relieve any Party of responsibility for the performance
of any accrued obligation of such Party prior to the date of such assignment under this Agreement. Any assignment in breach of the provisions
of this Section 10.05 shall be null and void ab initio. Notwithstanding the foregoing, Seller hereby acknowledges and agrees that
for so long as New Subsidiary (defined below) remains a wholly owned subsidiary of the Purchaser, Purchaser shall have the right to assign
its rights and obligations in whole or in part under this Agreement to Citius Acquisition Corp., a wholly owned subsidiary of Purchaser
(“New Subsidiary”), without any requirement to obtain Seller’s prior consent; provided, that (a) Purchaser hereby guarantees
and remains jointly and severally liable for all of such subsidiary’s obligations under this Agreement and (b) for the purposes
of the definition of Commercially Reasonable Efforts: (i) [***] and (ii) with respect to the Purchaser, all references to a “Party”
shall refer to Purchaser, Citius Pharmaceuticals, Inc. and New Subsidiary, taken as a whole. Further, upon assignment to New Subsidiary,
until [***], Purchaser shall not permit a Subsidiary Change of Control to occur without the prior written consent of the Seller (such
consent not to be unreasonably withheld, denied or conditioned). As a condition to its assignment of its rights and obligations hereunder
to New Subsidiary, Purchaser shall deliver to the Seller written confirmation that New Subsidiary has assumed, in writing, all obligations
of the Purchaser under this Agreement. “Subsidiary Change of Control” means, with respect to New Subsidiary, (i) the sale,
transfer or other disposition of (in one transaction or a series of related transactions) all or substantially all of the assets of such
Person, (ii) any event, transaction or upon any occurrence under which Citius Pharmaceuticals, Inc. ceases to own greater than [***]%
of the capital stock or voting power of New Subsidiary.

 

Section
10.06 No Third Party Beneficiaries. This Agreement is for the sole benefit of the Parties hereto and their respective successors
and permitted assigns. Nothing in this Agreement, express or implied, is intended to or shall confer on any other Person any legal or
equitable right, benefit, or remedy of any nature whatsoever.

 

Section
10.07 Amendment and Waiver. This Agreement may only be amended, modified or supplemented by an agreement in writing signed
by each Party hereto. No waiver by any Party of any of the provisions hereof shall be effective unless explicitly set forth in writing
and signed by the Party so waiving. No waiver by any Party shall operate or be construed as a waiver in respect of any failure, breach
or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before
or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement
shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege
hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

 

    32

     

    

 

Section 10.08 Governing
Law; Jurisdiction.

 

(a) This
Agreement and its negotiation, execution, performance or non-performance, interpretation, termination, construction and all claims or
causes of action (whether in contract, in tort, at Law or otherwise) that may be based upon, arise out of, or relate to this Agreement,
or the transactions contemplated hereby (including any claim or cause of action based upon, arising out of or related to any representation
or warranty made in connection with this Agreement or as an inducement to enter this Agreement), shall be exclusively governed by, and
construed in accordance with, the Laws of the State of Delaware regardless of Laws that might otherwise govern under any applicable conflict
of laws principles.

 

(b) Any
Legal Proceeding based upon, arising out of, or related to this Agreement and its negotiation, execution, performance, non-performance,
interpretation, termination, construction or the transactions contemplated hereby shall be heard and determined in the Court of Chancery
in the City of Wilmington, New Castle County, Delaware or, in the event such court lacks subject matter jurisdiction, the United States
District Court sitting in Wilmington, Delaware or, in the event such federal district court lacks subject matter jurisdiction, then in
the Superior Court in the City of Wilmington, New Castle County, Delaware. The Parties hereto hereby irrevocably submit to the exclusive
jurisdiction and venue of such courts in any such Legal Proceeding and irrevocably and unconditionally waive the defense of an inconvenient
forum, or lack of jurisdiction to the maintenance of any such Legal Proceeding. The consents to jurisdiction and venue set forth herein
shall not constitute general consents to service of process in the State of Delaware and shall have no effect for any purpose except as
provided in this Section 10.08 and shall not be deemed to confer rights on any Person other than the Parties hereto. Each Party
hereto agrees that the service of process upon such Party in any Legal Proceeding arising out of or relating to this Agreement shall be
effective if notice is given by overnight courier at the address set forth in Section 10.02. Each of the Parties also agrees that
any final, non-appealable judgment against a Party in connection with any Legal Proceeding arising out of or relating to this Agreement
shall be conclusive and binding on such Party and that such award or judgment may be enforced in any court of competent jurisdiction,
either within or outside of the United States. A certified or exemplified copy of such award or judgment shall be conclusive evidence
of the fact and amount of such award or judgment.

 

Section 10.09 WAIVER OF JURY
TRIAL. TO THE FULLEST EXTENT PERMITTED BY LAW, THE PARTIES HERETO HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY LEGAL
PROCEEDING (WHETHER IN CONTRACT, IN TORT, AT LAW OR OTHERWISE) BASED UPON, ARISING OUT OF, OR RELATED TO THIS AGREEMENT OR ANY OF THE
TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT
MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, CONTRACT CLAIMS, TORT
CLAIMS, BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THE PARTIES HERETO ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL
INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THAT
EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS. THE PARTIES HERETO FURTHER WARRANT AND REPRESENT THAT EACH
HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION
WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THIS WAIVER SHALL
APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR TO ANY OTHER DOCUMENTS OR AGREEMENTS
RELATING TO THE TRANSACTIONS CONTEMPLATED HEREBY. IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL
BY THE COURT.

 

    33

     

    

 

Section
10.10 Specific Performance. The Seller, on the one hand, and the Purchaser, on the other hand, acknowledge and agree
that the breach of this Agreement or other failure to perform any provision of this Agreement would cause irreparable damage to the other
and such other Party will not have an adequate remedy at law. Therefore, the Parties shall be entitled to specific performance of the
terms of this Agreement in addition to any other remedy to which they are entitled at law or in equity.

 

Section 10.11 No Other Duties.
The only duties and obligations of the Parties under this Agreement are as specifically set forth in this Agreement, and no other
duties or obligations shall be implied in fact, Law or equity, or under any principle of fiduciary obligation.

 

Section 10.12 Reliance on
Counsel and Other Advisors. Each Party has consulted such legal, financial, technical or other expert as it deems necessary or desirable
before entering into this Agreement. Each Party represents and warrants that it has read, knows, understands and agrees with the terms
and conditions of this Agreement.

 

Section
10.13 Bulk Transfer Laws. The Purchaser hereby waives compliance by the Seller and its Affiliates with any applicable
provisions of any so-called “bulk transfer law” of any jurisdiction in connection with the transactions contemplated under
this Agreement.

 

Section 10.14 Setoff Rights.
Neither Party shall have any right of setoff of any amounts due and payable, or any Liabilities arising, under against any amounts
due and payable under this Agreement against any other amounts due and payable under this Agreement or any amounts due and payable, or
any Liabilities arising, under the Transition Services Agreement or any other Transaction Document.

 

Section
10.15 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but
all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, email,
or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this
Agreement.

 

[signature page follows]

 

    34

     

    

 

IN WITNESS WHEREOF, the Parties have caused this
Agreement to be executed as of the date first written above by their respective duly authorized officers.

 

Seller:

 

	DR. REDDY’S LABORATORIES S.A.	 
	 	 
	By:	/s/ Patrick Aghanian	 
	Name:	Patrick Aghanian	 
	Title	Head of PPG	 
	 	 	 
	By:	/s/ Sameer Natu	 
	Name:	Sameer Natu	 
	Title	Finance Head	 
	 	 	 
	Purchaser	 
	 	 
	CITIUS PHARMACEUTICALS, INC.	 
	 	 	 
	By:	/s/ Myron Holubiak	 
	Name:	Myron Holubiak	 
	Title	CEO and President	 

 

[Signature Page of Asset Purchase Agreement]

 

    35

     

    

 

Schedule 1.01

 

DEFINITIONS

 

“Acquired
Contracts” shall mean those Contracts listed on Exhibit A.

 

“Affiliate” of a Person or
Party shall mean any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under
common control with, such Person or Party. The term “control” (including the terms “controlled by”
and “under common control with”) shall mean the possession, directly or indirectly, of the power to direct or cause
the direction of the management and policies of a Person or Party, whether through the ownership of voting securities, by contract or
otherwise.

 

“Agreement” shall have the
meaning set forth in the Preamble.

 

“Approval Efforts” shall have
the meaning set forth in Section 3.04(b).

 

“Applicable Healthcare Industry Laws”
means any international, federal, state, local municipal, foreign or other statute, law, ordinance, order, ruling, judgment, rule, regulation
or other requirement issued by a Governmental Authority, including, but not limited to: (i) the Federal Food, Drug, and Cosmetic Act,
the False Claims Act, the Anti-Kickback Statute, and HIPAA/HITECH, and any equivalent or similar Law enacted in any state in the United
States, (ii) the EU Drug Directives, and related national legislation of individual EU Member States implementing the provisions of the
EU Drug Directives into their national laws, the relevant guidelines published by the European Commission, the EU Member States and the
NBOG, and national laws of individual EU Member States governing bribery and corruption, related industry codes and physicians’
codes of professional conduct and (iii) all equivalent or similar Laws relating to the development, regulatory approval, provision, administration,
management or payment for health care or healthcare-related products, services or professionals.

 

“Approval Milestones” shall
have the meaning set forth in Section 3.04(b).

 

“Assignment of Patents” shall
mean the certain Assignment of Patents Agreement to be entered into on the Closing Date by and between the Purchaser and the Seller in
the form attached hereto as Exhibit C.

 

“Assumed Liabilities” shall
mean the following Liabilities, but in each case solely to the extent such Liability arises after the Closing (and subject to the last
sentence of Section 2.01(d)):

 

		a)	Liabilities arising under or relating to the Regulatory Approvals, Regulatory Approval Applications, Regulatory
Documentation, including any and all costs and expenses relating thereto;

 

		b)	Liabilities arising under or relating to the Proof of Concept Plan including any and all costs and expenses
relating thereto;

 

    36

     

    

 

		c)	all Liabilities arising out of or relating to the ownership or operation
of the Business and the Purchased Assets after the Closing, including the development of the Compound
and Products;

 

		d)	all Liabilities arising out of or relating to any product liability, breach of warranty or similar claim
for injury or other harm to person or property, which result from the use or misuse of a Product or otherwise related to a Product (including
all Legal Proceedings relating to any such liabilities) sold by or on behalf of the Purchaser and its Affiliates after the Closing;

 

		e)	all Liabilities, obligations and commitments arising out of or relating to any Product recall in the Territory;

 

		f)	any Liabilities, obligations or commitments arising out of or relating to any Acquired Contract to the
extent incurred after the Closing;

 

		g)	all Liabilities, obligations and commitments arising out of or relating to the return of, or warranty
claims relating to any Product sold after the Closing;

 

		h)	any liability or amount payable to Eisai, after the Closing;

 

		i)	any Liabilities, obligations or commitments arising out of or relating to any Legal Proceeding relating
to the Purchased Assets or the Compound for which the cause of action arises after the Closing;

 

		j)	all other Liabilities, obligations and commitments of whatever kind and nature, primary or secondary,
direct or indirect, absolute or contingent, known or unknown, whether or not accrued, arising out of or relating to, directly or indirectly,
the Compound, a Product, the Purchased Assets, the Business or the ownership, sale or lease of any of the Purchased Assets in the Territory
to the extent arising after the Closing.

 

“Bill of Sale & Assignment and Assumption
Agreement” shall mean the certain Bill of Sale and Assignment and Assumption Agreement, to be entered into on the Closing Date
by and between the Purchaser and the Seller in the form attached hereto as Exhibit B.

 

“Biosimilar Entry” means with
respect to a Product in a country within the Territory, the first Business Day following the occurrence of both of the following: (i)
the date that the first sale of a Biosimilar of the Product is sold in such country within the Territory, and (ii) the reduction in Net
Sales of the Product in such country [***] from the average Net Sales of such Product in such country in [***] immediately prior to the
first commercial sale of a Biosimilar in such country.

 

    37

     

    

 

“Biosimilar” means, with respect
to a particular Product in a particular country in the Territory, any pharmaceutical product that: (a) is claimed to be biosimilar to
or interchangeable with such Product or otherwise references or relies on such Product to support a Drug Approval Application or an application
submitted under Section 351(k) of the PHSA or any corresponding foreign application in the Territory, including, with respect to the European
Union, a Marketing Authorization Application filed with the EMA or with respect to the United Kingdom, a Marketing Authorization Application
filed with MHRA pursuant to the centralized approval procedure; (b) is approved for sale for at least one (1) Indication that is the same
as an Indication for which such Product is approved for sale in such country; and (c) is sold in such country by a Third Party that (i)
is not a direct or indirect Licensee or Transferee of the Purchaser or its Affiliates, (ii) did not purchase such product in a chain of
distribution that included any of the Purchaser or its Affiliates, Licensees or Transferees, as applicable, and/or (iii) did not otherwise
acquire any rights from the Purchaser or its Affiliates, Licensees or Transferees, as applicable, including any Purchased Patents, Eisai
Patents (as defined in the Eisai Agreement) Purchased Know-how or Eisai Know-how (as defined in the Eisai Agreement), directly or indirectly,
from the Purchaser or its Affiliates, Licensees or Transferees, as applicable.

 

“BLA” means a Biologics License
Application submitted to the FDA under subsection (a) of Section 351 of the PHSA.

 

“Business Day” shall mean any
day other than a Saturday, Sunday, or other day on which commercial banks located in New York, New York or Mumbai, India are authorized
or required by Law to be closed for business.

 

“Business” shall mean the development
of the Compound.

 

“Calendar Year” shall mean
each respective period of twelve (12) consecutive months ending on December 31.

 

“Cash Consideration” shall
mean the Upfront Payment, plus the Purchaser’s Prorated Portion.

 

“Commercially Reasonable Efforts”
means with respect to any objective hereunder, including, relating to the development or commercialization of a Product or the Compound
by a Party, the application by such Party, consistent with the exercise of its prudent scientific and business judgment, of diligent efforts
and resources to fulfill the obligation in issue, consistent with the level of efforts as [***] would devote to a product at a similar
stage in its product life and having similar profit potential and strategic value, taking into account, without limitation, commercial,
legal and regulatory factors, target product profiles, product labeling, past performance, the regulatory environment and competitive
market conditions in the therapeutic area, safety and efficacy and such other factors as such Party may reasonably consider, all based
on conditions then prevailing.

 

“Compound” means the recombinant
DNA-derived cytotoxic protein as described on Annex B.

 

“Confidential Information”
shall mean, with respect to a Party, all Information, data, documents, agreements, files, and other materials, whether disclosed orally
or disclosed or stored in written, electronic, or other form or media, which is obtained from or disclosed by a Party or its representatives,
whether obtained before or on or after the date hereof, relating to such Party, its business, any of its Affiliates or any of their respective
businesses, or the Purchased Assets, together with the terms and conditions or other facts relating to the transactions contemplated hereby,
including, without limitation, all notes, analyses, compilations, reports, forecasts, studies, samples, and other documents prepared by
or for the other Party which contain or otherwise reflect or are derived or based in whole or in part on such information, data, documents,
agreements, files, or other materials. The terms and conditions of this Agreement shall be deemed the Confidential Information of both
Parties. The term Confidential Information as used herein does not include information that: (a) at the time of disclosure or thereafter
is generally available to and known by the public, other than as a result of disclosure by the receiving Party or any of its representatives
in violation of this Agreement; or (b) is or becomes available to the receiving Party on a non-confidential basis from a source other
than the disclosing Party provided that such source, to the receiving Party’s knowledge after reasonable inquiry, is not and was
not bound by a confidentiality agreement with respect to such information or otherwise prohibited from transmitting such information by
a contractual, legal, or fiduciary obligation; or (c) has been independently acquired or developed by the receiving Party without reference
to the Confidential Information.

 

    38

     

    

 

“Confidentiality Agreement”
shall mean the confidentiality agreement between the Parties dated as of March 23, 2021.

 

“Consent” shall mean any and
all notices to, consents, approvals, clearances, ratifications, permissions, authorizations or waivers from Third Parties, including from
any Governmental Authority.

 

“Contract” shall mean all contracts,
leases, deeds, mortgages, licenses, purchase orders, statements of work, instruments, notes, commitments, undertakings, indentures, joint
ventures and all other agreements, commitments and legally binding arrangements, whether written or oral.

 

“Cover” means, as used in relation
to a Patent and a product or invention, and in connection with a duty, obligation or performance of a Party, that such Patent would be
infringed by the manufacture, use, offer for sale, sale or import of, or other Exploitation of, such product or invention by such Party,
but for this Agreement, including infringement of patent claims claiming compositions of matter as well as methods of manufacture or use.

 

“CTCL Indication” means Cutaneous
T-Cell Lymphoma.

 

“CTCL Milestones” means Milestones
No. 1, 2 and 3 set forth in Table 3.01(b).

 

“Cure Period” shall have the
meaning set forth in Section 3.04(c).

 

“Discontinued Product” means
all dosage forms, formulations, strengths, package sizes and types of pharmaceutical products containing the Compound, previously sold
in the United States under the Trademark ONTAK® and described in BLA #103767.

 

“Earn-Out Term” shall have
the meaning set forth in Section 3.01(c)(iii).

 

“Eisai Agreement” means, collectively,
that Amended and Restated License, Development and Commercialization Agreement made and entered into as of February 26, 2018 by and between
Eisai and the Seller, as amended by that (i) Amendment to Amended and Restated License, Development and Commercialization Agreement made
as of August 9, 2018 by and between Eisai and the Seller, (ii) the Inventory Letter and (iii) that Amendment No. 2 to Amended and Restated
License, Development and Commercialization Agreement made as of August 31, 2021 by and between Eisai and the Seller.

 

“Eisai Assignment and Assumption Agreement”
means that certain Consent to Assignment and Assumption Agreement with Novation by and among the Seller, Eisai and the Purchaser, dated
as of August 31, 2021.

 

    39

     

    

 

“Eisai Territory” means Japan,
China, Korea, Taiwan, Hong Kong, Macau, Indonesia, Thailand, Malaysia, Brunei, Singapore, India, Pakistan, Sri Lanka, Philippines, Vietnam,
Myanmar, Cambodia, Laos, Afghanistan, Bangladesh, Bhutan, Nepal, Mongolia and Papua New Guinea.

 

“Eisai” means EISAI Co. Ltd.

 

“EMA” means the European Medicines
Agency and any successor agency thereto.

 

“Encumbrances” shall mean any
charge, claim, community property interest, pledge, condition, equitable interest, lien (statutory or other), option, security interest,
mortgage, easement, encroachment, right of way, right of first refusal, or restriction of any kind, including any restriction on use,
voting, transfer, receipt of income or exercise of any other attribute of ownership.

 

“Europe” means all of countries
in continental Europe, including the European Union, the United Kingdom, Ireland, Switzerland, Turkey and Eastern Europe, including the
Czech Republic, Serbia, Russia and Central Independent States of the former USSR.

 

“European Approval” means Regulatory
Approval of a Product in any country in Europe, including any approval from the EMA or MHRA.

 

“European Union” means, at
any particular time, all countries that are then officially recognized as member states of the European Union or members of the European
Economic Area. For clarity, any event that first occurs in a county of the European Union that later ceases to be a member of the European
Union will still be treated as an event that occurred in the European Union.

 

“Excluded Assets” shall have
the meaning set forth in Section 2.01(b).

 

“Excluded Liabilities” shall
have the meaning set forth in Section 2.01(d).

 

“Existing Product” means the
pharmaceutical product known as E7777, containing the Compound as an active ingredient and described in IND #110489. For the avoidance
of doubt, the definition of “Existing Product” does not include the Discontinued Product.

 

“Exploit” means to make, have
made, import, use, sell, or offer for sale, including to research, develop, commercialize, register, modify, enhance, improve, manufacture,
have manufactured, hold or keep (whether for disposal or otherwise), formulate, optimize, have used, export, transport, distribute, promote,
market, have sold or otherwise dispose of, and otherwise exploit.

 

“FDA” shall mean the United
States Food and Drug Administration and any successor agency thereto.

 

“First Commercial Sale” means
the first sale of a Product by Purchaser or its Affiliate, Licensee or Transferee, as applicable, for monetary value to a Third Party
in the Territory. For clarity, sales prior to receipt of Regulatory Approval for a Product, if any, such as so-called “treatment
IND sales,” “named patient sales,” and “compassionate use sales,” shall not be construed as a First Commercial
Sale with respect to a Product.

 

    40

     

    

 

“GAAP” shall mean generally
accepted accounting principles in the United States, consistently applied.

 

“Governmental Authority” shall
mean any federal, state, local or foreign government, or political subdivision thereof, any regulatory or administrative authority, any
agency or instrumentality of any such government or political subdivision, or any self-regulated organization or other non-governmental
regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority
have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction.

 

“Governmental Order” shall
mean any order, writ, judgment, injunction, decree, stipulation, determination, or award entered by or with any Governmental Authority.

 

“Health Canada” means the Canadian
federal Department of Health and any successor thereof.

 

“I/O Indication” means the
targeting of a cell, cell surface or the like, whose engagement has the effect of modulating, inducing, enhancing, or suppressing an immune
response for the purpose of preventing or treating any cancer. Solely for the purposes of determining whether the I/O Milestone is achieved,
and therefore payable, the I/O Indication shall not include any CTCL Indication or any PTCL Indication.

 

“I/O Milestone” means Milestone
No. 7 set forth in Table 3.01(b).

 

“IND” means: (a) an investigational
new drug application filed with the FDA for authorization to commence clinical studies and its equivalent in other countries or regulatory
jurisdictions; and (b) all supplements and amendments that may be filed with respect to the foregoing.

 

“Indemnified Party” shall have
the meaning set forth in Section 9.04(a).

 

“Indemnifying Party” shall
have the meaning set forth in Section 9.04(a).

 

“Indemnity Threshold” shall
have the meaning set forth in Section 9.06(a).

 

“Indication” means a disorder
or medical condition for which a product is approved by a Regulatory Authority to diagnose, treat, prevent, cure, and/or mitigate in the
indication section of the product labeling for such product.

 

“Information” means any technical,
scientific and other data, in written, electronic or other form, including results, approvals, technology, trade secrets, practices, techniques,
methods, processes, inventions, ideas, drawings, study designs, protocols, assays and biological methodology, developments, specifications,
formulations, formulae, materials or compositions of matter of any type or kind (whether or not patentable), software, algorithms, marketing
reports, expertise, technology, test data (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical, analytical
test data and data resulting from pre-clinical and clinical studies), manufacturing and quality control data, and safety data.

 

    41

     

    

 

“Intellectual Property” shall
mean any and all intellectual property and proprietary rights of any kind or nature, whether protected, created or arising under any Law,
including all: (i) Patents, (ii) Know-How, (iii) trademarks, (iv) domain names and URLs, (v) copyrights, mask works, and works of
authorship, (vi) registered designs, (vii) rights in databases, compilations of data and data, including all personally identifiable information
and clinical trial data, and all aggregated data, (viii) moral rights, rights of publicity and other rights to use or exploit the name,
image and likeness of any individual, (ix) rights under applicable Laws in customer lists, supplier lists, pricing and cost information,
and business and marketing plans, in any form whether or not specifically listed herein, all rights to limit the use or disclosure of
any of the foregoing, and all embodiments of, and all documentation relating to, any of the foregoing, (x) rights under applicable Laws
in software (including both object codes and source codes) and application programming interfaces, (xi) rights under applicable Laws to
bring an action for infringement, dilution, misappropriation or other impairment or violation of rights and to receive damages, proceeds
or any other legal or equitable protections and remedies with respect to any of the foregoing, and (xii) similar or equivalent rights
to any of the foregoing recognized by any Governmental Authority anywhere in the world.

 

“Inventory Letter” shall mean
that certain Letter dated 12 August 2021 from Eisai to the Seller entitled “Available Inventory of E7777 Injection Vials”
which is attached hereto as Exhibit I.

 

“Know-How” shall mean all technical,
scientific and other know-how and information, trade secrets, knowledge, technology, methods, processes, formulae, designs, drawings,
assembly procedures, specifications, data, results and other material, including: biological, chemical, pharmacological, toxicological,
pharmaceutical, physical and analytical, pre-clinical, clinical, safety, manufacturing and quality control data and information, including
study designs and protocols, assays and biological methodology, in each case (whether or not confidential, proprietary, patented or patentable)
in written or electronic form.

 

“Knowledge of the Purchaser”
shall mean the actual knowledge after due inquiry of any of the individuals listed on Exhibit D (Knowledge of the Purchaser).

 

“Knowledge of the Seller” shall
mean the actual knowledge after due inquiry of any of the individuals listed on Exhibit E (Knowledge of the Seller).

 

“Law” shall mean any statute,
law, ordinance, regulation, rule, code, Order, constitution, treaty, common law, judgment, decree, other requirement or rule of law of
any Governmental Authority.

 

“Legal Proceeding” shall mean
any judicial, administrative or arbitral action, suit, proceeding (public or private), litigation, investigation, hearing, or any other
claim or proceeding by or before a Governmental Authority.

 

“Liability” shall mean, with
respect to any Person, any indebtedness, liabilities, obligation, commitment, expense, claim, complaint, deficiency, guaranty or endorsement
of or by such Person of any type, whether or not accrued, absolute, contingent, matured, unmatured, liquidated, unliquidated, determined
or determinable, known or unknown.

 

    42

     

    

 

“Licensed Know-How” means all
Know-How owned by the Seller or any of its Affiliates (other than Purchased Know-How) within the Territory that (a) is related to a Product
or the Compound and (b) has been developed or is used by Seller or its Affiliates or Eisai or its Affiliates in the Territory prior to
or as of the Closing in connection with the Exploitation of any Product or Compound. Without limiting the foregoing, Licensed Know-How
includes any such Know-How (as of the Closing) relating to (i) any companion diagnostics relating to any Product or (ii) the manufacture
of any Product or Compound.

 

“Licensee Consideration” means
any consideration (other than Licensee Sales-Based Royalties) received by the Purchaser and/or its Affiliates from a Licensee in consideration
of a license to exploit a Product, the Compound or any Purchased Asset, including, but not limited to, lump-sum payments, up-front payments,
milestones (of all kind) and other deferred payments. For clarity, Licensee Consideration does not include any bona fide payments from
Third Parties for (a) research, development, manufacturing or other services, (b) supply of Compounds or Products or other items to customers,
(c) amounts received for the acquisition of equity interests (including stock, options or preferred shares) in Purchaser or any of its
Affiliates or (d) amounts received in the form of a loan (but, with respect to (c) and (d), that is not in consideration of the grant
of a license to exploit a Product, the Compound or any Purchased Asset).

 

“Licensee Net Sales” means
Net Sales of Product(s) by or on behalf of a Licensee (other than any licensee or sublicensee that is an Affiliate of Purchaser).

 

“Licensee Sales-Based Royalties”
means any amounts (whether characterized as royalties, earn-out payments, revenue payments, revenue share payments, license fees, profit
share payments, or otherwise) that are received by Purchaser or its Affiliates from any Licensee (or a sublicensee of a Licensee (as applicable),
in each case only to the extent the calculation of such amounts payable to Purchaser or its Affiliates is based on sales of Product(s)
by or on behalf of a Licensee. Notwithstanding the foregoing, any milestone payments or other comparable one-time lump sum payments received
by the Purchaser and/or its Affiliates from a Licensee that are based on achievement of an aggregate level of sales are Licensee Consideration
and are not Licensee Sales-Based Royalties.

 

“Licensee” means any Person
(other than an Affiliate of Purchaser) to which a license or sublicense is granted by the Purchaser or its Affiliates with respect to
the Purchased Assets, Product(s) or Compounds enabling such Person to promote, market, offer for sale, sell, distribute or otherwise commercialize
a Product or Compound. For clarity, Purchaser and its Affiliates’ customers (which shall include distributors, wholesalers, and/or
resellers of a Product) shall not be considered Licensees, provided that the sale of Products to such Persons are considered Net Sales
by the Purchaser or its Affiliates.

 

“Loss” or “Losses”
shall mean actual out-of-pocket losses, damages, liabilities, costs or expenses, including reasonable attorneys’ fees.

 

    43

     

    

 

“Material Adverse Effect” means
any event, occurrence, fact, condition, change or effect that is materially adverse (individually or in the aggregate) to the Purchased
Assets, Exploitation of the Compound or the Product, the Business, the results of operations of the Seller or the financial condition
of the Seller; provided, however, that none of the following shall be deemed, either alone or in combination, to constitute a Material
Adverse Effect, or be taken into account in determining whether there has or will be a Material Adverse Effect: (a) changes or effects
that are generally applicable in the economies (including changes in interest or exchange rates) of any country in which Purchased Assets
are located or in which any of the Parties to this Agreement operate, or in the securities, syndicated loan, credit or financial markets
of any such country; (b) changes in general legal, tax, regulatory, political or economic conditions affecting the exploitation of the
Compound or the Product in general or within the relevant jurisdiction; (c) changes in GAAP; (d) changes or effects that arise out of
or are attributable to (i) the acts or omissions of, or circumstances affecting, the Purchaser and/or its Affiliates, or (ii) the transactions
contemplated by this Agreement or changes or effects that arise out of or are attributable to the negotiation, execution, public announcement
or performance of this Agreement; (e) changes or effects that generally affect the markets in which the Compound or the Product are exploited;
(f) changes or effects that arise out of or are attributable to the commencement, occurrence, continuation or intensification or reduction
or cessation of any war (whether or not declared), sabotage, armed hostilities or acts of terrorism, (g) changes or effects that arise
out of or are attributable to earthquakes, hurricanes or other natural disasters, epidemics or other outbreaks of disease; (h) any matter
disclosed in the Seller Disclosure Schedules to this Agreement, including in each case, any adverse effect that occurs after the date
of this Agreement but that arises out of or results from any such matter or (i) any existing event or occurrence or circumstance of which
the Purchaser has Knowledge as of the date hereof.

 

“MHRA” means the Medicines
and Healthcare Products Regulatory Agency, and any successor thereof.

 

“Milestone and Earn-Out Information”
shall have the meaning set forth in Section 3.03(a).

 

“Milestone Event” shall have
the meaning set forth in Section 3.01(b).

 

“Milestone Payment” shall have
the meaning set forth in Section 3.01(b).

 

“Net Sales” shall mean the
aggregate gross amounts invoiced or otherwise received for all of the Purchaser’s, its Affiliates’, Licensees’ or Transferees
(as applicable) sales or other commercial distribution of a Product (including any Biosimilar version of a Product), for any Indication,
during the applicable period in the considered territory less the sum of the following, to the extent related to the sale or commercial
distribution of a Product and otherwise included in such gross amounts: (1) trade, quantity and cash discounts in amounts reasonable
or customary in the trade and to extent accrued or actually taken; (2) credits, refunds, allowances, chargebacks, volumes rebates, direct
and indirect rebates, distribution fees, reimbursements, or similar payments granted or given to wholesalers and other distributors, managed
care and pharmacy benefit management companies, but only to the extent not previously deducted from gross sales; (3)  rejected goods,
damaged goods, product recall and sales returns; (4) patient co-pay assistance benefits, rebates and coupon or voucher redemptions
provided specifically to the concerned Product; (5) reasonable rebates paid or other price reductions provided in connection with
sale of the concerned Product to any government or regulatory authority in respect of any state or federal Medicare, Medicaid, or similar
programs available under or required by applicable Law; (6) freight, postage, shipping and insurance charges, (7) taxes, duties or other
governmental charges levied on, absorbed or otherwise imposed on sale of such Product, including value-added taxes, or other governmental
charges otherwise measured by the billing amount (including a reasonable allocation of any fees paid pursuant to Section 9008 of the Patient
Protection and Affordable Care Act), and (8) any other deductions taken by Purchaser or any of its Affiliates, licensees or sub-licensees
in calculating net sales in the ordinary course of its business, consistent with GAAP (or the applicable accounting standard of such Purchaser
or any of its Affiliates, licensees or sub-licensees if the sale occurs in a jurisdiction outside of the United States). In the event
the Purchaser (and/or any its Affiliates, licensees or sublicensees) sells the concerned Product as part of a bundle or group sale with
other products, (i) the Net Sales shall be adjusted to be proportional to the ratio of the individual selling price of the concerned
Product to the aggregate of the individual selling prices of each other product included as part of such bundle or group sale, and (ii) to
the extent the Purchaser (and/or any its Affiliates, licensees or sublicensees) provides discounts, allowance or rebate to the purchaser
of the concerned Product based on the invoiced price for the products sold as a bundle or group sale, such discount must be allocated
pro rata based on the selling prices of such products sold individually before taking into account the discount, allowance or rebate on
product provided as part of such bundle. The foregoing deductions from gross sales shall be deducted only once and only to the extent
not otherwise deducted from the gross sales. “Net Sales” cannot be negative. For clarity, Net Sales does not include
any Licensee Consideration or Licensee Sales-Based Royalties.

 

    44

     

    

 

“Orders” shall mean all judgments,
orders, writs, injunctions, decisions, rulings, decrees and awards of any Governmental Authority.

 

“Organizational Documents”
shall mean with respect to a Person (other than an individual), the documents by which such Person was organized (such as a certificate
of incorporation, certificate of limited partnership or articles of organization, and including, without limitation, any certificates
of designation for preferred stock or other forms of preferred equity) and which relate to the internal governance of such Person (such
as bylaws, a partnership agreement or an operating, limited liability or members agreement), all, as amended.

 

“Party” or “Parties”
shall have the meaning set forth in the introductory paragraph hereto.

 

“Patents” means any and all
(a) patent applications and issued patents, including, all national, regional, and international patents and patent applications; provisionals;
continuations; divisionals; continuations-in-part; continued prosecution applications; reissues, renewals, substitutions, reexaminations,
and revivals thereof; (b) patents that have issued or in the future issue from the foregoing patent applications, including utility models,
petty patents and design patents and certificates of invention; and (c) extensions (including pediatric exclusivity, patent term extension
and supplementary patent certificate) or restorations of the patents described above by existing or future extension or restoration mechanisms.

 

“Permits” shall mean all certifications
(including those of standards-setting organizations), licenses, permits, franchises, approvals, authorizations, exemptions, notices to,
consents or orders of, or filings with, any trade association, any standards-setting organization, or any Governmental Authority.

 

“Permitted Encumbrances” shall
mean: (a) liens for Taxes not yet due and payable or being contested in good faith by appropriate procedures; (b) mechanics’, carriers’,
workmen’s, repairmen’s or other like liens arising or incurred in the ordinary course of business; (c) liens arising under
original purchase price conditional sales contracts and equipment leases with Third Parties entered into in the ordinary course of business;
and (d) other immaterial imperfections of title or immaterial Encumbrances, if any.

 

“Person” shall mean an individual,
a limited liability company, joint venture, a corporation, a partnership, an association, a trust, a division or operating group of any
of the foregoing or any other entity or organization.

 

“PHSA” means the Public Health
Service Act as set forth at 42 U.S.C. Chapter 6A, as may be amended from time to time, together with any rules, regulations and requirements
promulgated thereunder (including all additions, supplements, extensions and modifications thereto).

 

    45

     

    

 

“Product” means any product
that is comprised of or contains the Compound as an active ingredient, including: (a) any combination product which contains the Compound
as an active ingredient; (b) the Existing Product; and (c) all formulations, dosages and forms of release for any of the foregoing products.

 

“Proof of Concept Efforts”
has the meaning set forth in Section 3.04(c).

 

“Proof of Concept Plan” means
the Proof of Concept Plan which is set forth in Annex A hereto. The Proof of Concept Plan includes the Proof of Concept Studies.

 

“Proof of Concept Studies”
has the meaning set forth in Annex A hereto.

 

“Proration Schedule” shall
have the meaning set forth in Section 2.01(g).

 

“PTCL Indication” means Peripheral
T-Cell Lymphoma.

 

“PTCL Milestones” means Milestones
No. 4 and 5 set forth in Table 3.01(b).

 

“Purchase Price” shall have
the meaning set forth in Section 3.01(a).

 

“Purchased
Assets” shall mean each of the following: (a) the Purchased Intellectual
Property, (b) the Regulatory Documentation, (c) the Acquired Contracts (including all rights and claims of Seller and its Affiliates
to any amounts prepaid under any Acquired Contracts), and (d) a copy of all books, records, files and papers of the Seller and/or its
Affiliates to the extent exclusively relating to the Business and/or the Compound.

 

“Purchased Intellectual Property”
shall mean collectively all Purchased Patents, Purchased Trademarks and Purchased Know-How.

 

“Purchased Know-How” means
all Know-How owned by the Seller or any of its Affiliates that (a) is exclusively related to any Product, and (b) has been used in connection
with the Exploitation of, or is otherwise necessary or useful to Exploit, any Product.

 

“Purchased Patent(s)” means
the Patents set forth in Exhibit F.

 

“Purchased Trademarks” shall
mean, as owned by the Seller or its Affiliates, and to the extent exclusively related to the Product, the trademarks, service marks, logos,
slogans and trade names (whether or not registered), including all variations, derivations, combinations, registrations applications for
registration or renewals of the foregoing and all goodwill associated therewith, listed on Exhibit G.

    46

     

    

 

“Purchaser Group” shall have
the meaning set forth Section 9.02.

 

“Purchaser’s Prorated Portion”
means the amount equal to the Purchaser’s portion of the prorated expenses and other items, which the Purchaser shall pay to the
Seller at Closing and is set forth on the Proration Schedule.

 

“Purchaser” shall have the
meaning set forth in the preamble.

 

“Quarter” shall mean each respective
period of three (3) consecutive months ending on March 31, June 30, September 30, and December 31.

 

“Quarterly Earn-Out Payments”
shall have the meaning set forth in Section 3.01(c)(i).

 

“Quarterly Earn-Out Rate” has
the meaning set forth in Section 3.01(c)(i).

 

“Regulatory Approval Application”
means an application to the applicable Regulatory Authority for approval to commercialize a product in a particular country or other jurisdiction.

 

“Regulatory Approval” means
any and all approvals (including supplements, amendments, pre- and post-approvals), licenses, registrations or authorizations of any Regulatory
Authority, national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental
entity, that are necessary for the manufacture, distribution, use or sale of a product in a regulatory jurisdiction.

 

“Regulatory Authority(ies)”
means any applicable supra-national, federal, national, regional, state, provincial or local regulatory agencies, departments, bureaus,
commissions, councils or other government entities regulating or otherwise exercising authority with respect to the exploitation of any
Product in the Territory, including the FDA, EMA, MHRA and Health Canada.

 

“Regulatory Documentation”
shall mean the following, to the extent owned by the Seller or any of its Affiliates and related to the Compound or any Product: (a) any
applications (including all investigational new drug (INDs) and Regulatory Approvals), registrations, licenses, authorizations and approvals;
(b) correspondence and reports submitted to or received from Regulatory Authorities and all supporting documents with respect thereto,
including all adverse event files and complaint files; (c) chemistry, manufacturing and controls data
and documentation (including, but not limited to, batch records, master batch production records, standard operating procedures that specifically
pertain to any Product, testing logs, sample logs, laboratory logs, and stability logs), preclinical
and clinical studies and tests, (d) records maintained under record keeping or reporting requirements of the FDA or any Governmental Authority;
and (e) clinical and other data contained or relied upon in any of the foregoing.

 

“Restricted Products” shall
mean any product that contains (a) [***] or (b) [***]; in each case whether formulated alone or in combination with any other compound
or product.

 

“Sales Reports” shall have
the meaning set forth in Section 3.03(b).

 

“SEC” shall have the meaning
set forth in Section 7.03.

 

“Seller Disclosure Schedules”
shall have the meaning set forth in the introductory sentence to ARTICLE V.

 

“Seller” shall have the meaning
set forth in the preamble.

 

    47

     

    

 

“Solvent” shall mean used with
respect to any Person, shall mean that, as of any date of determination, (a) the amount of the “fair saleable value”
of the assets of such Person on a going concern basis will, as of such date, exceed (i) the value of all “liabilities of such Person,
including contingent and other liabilities” as of such date, as such quoted terms are generally determined in accordance with applicable
United States federal Laws governing determinations of the insolvency of debtors and (ii) the amount that will be required to pay the
probable liabilities of such Person on its existing debts (including contingent liabilities) as such debts become absolute and matured,
(b) such Person will not have, as of such date, an unreasonably small amount of capital for the operation of the businesses in which it
is engaged or proposed to be engaged following such date and (c) such Person will be able to pay its liabilities, including contingent
and other liabilities, as they mature. For purposes of this definition, each of the phrases “not have an unreasonably small amount
of capital for the operation of the businesses in which it is engaged or proposed to be engaged” and “able to pay its liabilities,
including contingent and other liabilities, as they mature” means that such Person will be able to generate enough cash from operations,
asset dispositions or refinancing, or a combination thereof, to meet its obligations as they become due.

 

“Successful Proof of Concept”
has the meaning set forth in Annex A hereto.

 

“Taxes” shall mean all federal,
state, local, foreign and other income, gross receipts, sales, use, production, ad valorem, transfer, franchise, registration, profits,
license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, severance, environmental, stamp,
occupation, premium, property (real or personal), real property gains, windfall profits, customs, duties or other taxes, fees, assessments
or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest in respect
of such additions or penalties.

 

“Territory” means all countries
in the world, excluding those countries in the Eisai Territory.

 

“Third Party Claim” shall have
the meaning set forth in Section 9.05(a).

 

“Third Party” shall mean any
Person other than the Parties.

 

“Transaction Documents” shall
mean this Agreement, the Bill of Sale & Assignment and Assumption Agreement, the Eisai Assignment and Assumption Agreement and the
Assignment of Patents.

 

“Transfer Taxes” shall have
the meaning set forth in Section 3.02(c).

 

“Transferee” means any Third
Party (other than an Affiliate of Purchaser or an Affiliate of Seller) to which any rights in or to the Compound, a Product or the Purchased
Assets that are granted or transferred to Purchaser under this Agreement are subsequently assigned or transferred in turn by Purchaser
following the Closing.

 

“Transition Services Agreement”
shall have the meaning set forth in Section 4.02(c).

 

“United States” shall mean
the United States of America and its territories and possessions.

 

“Upfront Payment” shall have
the meaning set forth in Section 3.01(a)(i).

 

“US CTCL Approval Milestone”
means Milestone No. 1 set forth in Table 3.01(b).

 

“Valid Claim” shall mean (i)
any claim of a Patent or any other patent covering the considered Product (including if filed after the
date hereof and including all reissues, reexaminations, divisionals, continuations, continuations-in-part, provisional and continued examinations,
extensions, restorations or renewals of such patents to the extent they relate to the Product)
that has been granted by a patent granting authority, that is in force, and that has not been surrendered, abandoned, revoked or held
invalid or unenforceable by a decision taken by an administrative or civil court in a jurisdiction, or (ii) a pending claim in an application
for a Patent or any other patent set forth under (i).

 

 

48Exhibit
10.31

 

*Information
in this exhibit marked [***] has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such information is not material and is the
type of information that the registrant treats as private or confidential.

 

 

AMENDED
AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

 

between

 

EISAI
CO., LTD.

 

and

 

DR.
REDDY’S LABORATORIES S.A.

Dated
as of February 26, 2018

 

     

    

    

 

TABLE OF CONTENTS

  

	 	 	Page
	 	 	 
	ARTICLE 1	DEFINITIONS	1
	 	 	 
	ARTICLE 2	GRANT OF RIGHTS	17
	2.1.	Grants to Licensee	17
	2.2.	Grants to Eisai	18
	2.3.	Sublicenses	19
	2.4.	Reservation of Rights	20
	2.5.	Covenant Not to Sue	20
	2.6.	Exclusivity and Territorial Restrictions	21
	2.7.	India Option	21
	2.8.	India Restriction	21
	2.9.	Technical Document and Know-How Transfer	22
	2.10.	Distribution Agreements	22
	 	 	 
	ARTICLE 3	DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES	23
	3.1.	Development	23
	3.2.	Regulatory Activities	26
	3.3.	Commercialization	31
	3.4.	Compliance with Applicable Law	32
	3.5.	Supply of Licensed Compound and Licensed Products	32
	3.6.	Subcontracting	34
	3.7.	Assumption of Activities upon a Change of Control of Eisai	34
	 	 	 
	ARTICLE 4	GOVERNANCE	35
	4.1.	Joint Steering Committee	35
	4.2.	Joint Subcommittees	36

 

    i

    

    

 

	4.3.	General Provisions Applicable to Committees	39
	4.4.	JSC and Joint Subcommittee Dispute Resolution	39
	4.5.	Discontinuation; Disbandment; Annual Reports	42
	4.6.	Working Teams	42
	4.7.	Alliance Managers	42
	 	 	 
	ARTICLE 5	PAYMENTS AND RECORDS	43
	5.1.	Milestones	43
	5.2.	Reports and Reconciliation	43
	5.3.	Mode of Payment; Offsets	44
	5.4.	Taxes	44
	5.5.	Interest on Late Payments	44
	5.6.	Financial Records	45
	5.7.	Audit	45
	5.8.	Audit Dispute	45
	 	 	 
	ARTICLE 6	INTELLECTUAL PROPERTY	46
	6.1.	Ownership of Intellectual Property	46
	6.2.	Maintenance and Prosecution of Patents	47
	6.3.	Enforcement of Patents	50
	6.4.	Infringement Claims by Third Parties	51
	6.5.	Invalidity or Unenforceability Defenses or Actions	52
	6.6.	Third Party Patent Rights	53
	6.7.	Eisai Trademarks	53
	6.8.	Eisai Territory Product Trademarks	56
	6.9.	Licensee Trademarks	57
	6.10.	Corporate Names	58

 

    ii

    

    

 

	ARTICLE 7	CONFIDENTIALITY AND NON-DISCLOSURE	58
	7.1.	Confidentiality Obligations	58
	7.2.	Permitted Disclosures	59
	7.3.	Use of Name	60
	7.4.	Public Announcements	61
	7.5.	Publications	61
	7.6.	Return of Confidential Information	62
	7.7.	Privileged Communications	62
	7.8.	Obligations of the Licensee with Respect to Eisai Trade Secrets	62
	 	 	 
	ARTICLE 8	REPRESENTATIONS AND WARRANTIES	63
	8.1.	Mutual Representations and Warranties	63
	8.2.	Additional Representations and Warranties of Eisai	64
	8.3.	Disclaimer Of Warranties	65
	8.4.	Anti-Bribery and Anti-Corruption Compliance	65
	 	 	 
	ARTICLE 9	INDEMNITY	66
	9.1.	Indemnification of Eisai	66
	9.2.	Indemnification of the Licensee	66
	9.3.	Indemnification Procedures	66
	9.4.	Special, Indirect and Other Losses	68
	 	 	 
	ARTICLE 10	TERM AND TERMINATION	68
	10.1.	Term and Expiration	68
	10.2.	Termination	68
	10.3.	Rights in Bankruptcy	69
	10.4.	Consequences of Termination of this Agreement in its Entirety	69
	10.5.	Consequences of Termination of this Agreement for a Terminated Territory	71

 

    iii

    

    

 

	10.6.	Additional Consequences for Change of Control Termination.	72
	10.7.	Remedies	73
	10.8.	Accrued Rights; Surviving Obligations	73
	 	 	
	ARTICLE 11	MISCELLANEOUS	73
	11.1.	Force Majeure	73
	11.2.	Export Control	73
	11.3.	Assignment	73
	11.4.	Severability	74
	11.5.	Dispute Resolution	74
	11.6.	Governing Law, Jurisdiction and Service	76
	11.7.	Notices	77
	11.8.	Entire Agreement; Amendments	78
	11.9.	English Language	78
	11.10.	Equitable Relief	78
	11.11.	Change of Control	78
	11.12.	Waiver and Non-Exclusion of Remedies	78
	11.13.	No Benefit to Third Parties	79
	11.14.	Further Assurance	79
	11.15.	Relationship of the Parties	79
	11.16.	References	79
	11.17.	Construction	79
	11.18.	Counterparts	79

 

    iv

    

    

 

	Schedules
	 
	Schedule 1.3 – ‘302 Development Plan
	Schedule 1.25 – CMC Development Plan
	Schedule 1.34(a) – Eisai Corporate Names
	Schedule 1.66 – Eisai Trade Secrets
	Schedule 1.67 – Eisai Trademarks
	Schedule 1.114 – Licensed Compound
	Schedule 2.9 – Technical Document and Know-How Transfer
	Schedule 7.4 – Press Release
	Schedule 8.2.13 – Eisai’s Response to India Antitrust Questions

 

    v

    

    

 

AMENDED
AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

 

This
Amended and Restated License, Development and Commercialization Agreement (this “Agreement”) is made and entered into
as of February 26, 2018 (the “Execution Date”) by and between Eisai Co., Ltd., a Japanese corporation (“Eisai”)
and Dr. Reddy’s Laboratories S.A., a Swiss company (the “Licensee”). Each of Eisai and the Licensee are sometimes
referred to herein individually as a “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS,
Eisai owns or controls certain intellectual property rights with respect to the Licensed Compound (as defined herein) and Licensed Products
(as defined herein);

 

WHEREAS,
Eisai wishes to grant to the Licensee, and the Licensee wishes to receive, a license (or sublicense) under such intellectual property
rights to develop and commercialize Licensed Products in the Field (as defined herein) in the Licensee Territory (as defined herein),
in each case in accordance with the terms and conditions set forth below;

 

WHEREAS,
the Parties previously executed a License, Development and Commercialization Agreement on March 30, 2016 (the “Original
Agreement”) and a binding term sheet (the “Binding Term Sheet”) dated as of the September 29, 2017 (the
“Effective Date”); and

 

WHEREAS,
the Parties desire to incorporate the terms of the Binding Term Sheet into this agreement and to amend and restate the Binding Term Sheet
on the terms and subject to the conditions set forth in this Agreement.

 

NOW,
THEREFORE, in consideration of the premises and the mutual promises and conditions set forth herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:

 

ARTICLE
1

DEFINITIONS

 

Unless
otherwise specifically provided herein, the following terms shall have the following meanings:

 

1.1.
“‘302 Development Activities” means the activities necessary to generate the deliverables set forth in the
‘302 Development Plan.

 

1.2.
“‘302 Development Costs” means the FTE Costs incurred and the direct out-of-pocket costs recorded as an
expense, in accordance with GAAP, by or on behalf of Eisai or any of its Affiliates related to the ‘302 Development Activities.

 

1.3.
“‘302 Development Plan” means the development plan, including a detailed budget, setting forth the deliverables
(including the Final ‘302 Development Report) to be provided by Eisai with respect to a pivotal Phase 2 clinical trial for the
Existing Licensed Product for the CTCL Indication, attached hereto as Schedule 1.3, as the same may be amended from time to time by the
Parties in accordance with Section 3.1.2(a).

 

     

    

    

 

1.4.
“Affiliate” means, with respect to a Person, any Person that, directly or indirectly, through one (1) or more
intermediaries, controls, is controlled by or is under common control with such first Person at any time for so long as such Person controls,
is controlled by or is under common control with such first Person. For purposes of this definition, “control” and, with
correlative meanings, the terms “controlled by” and “under common control with” mean: (a) the possession, directly
or indirectly, of the power to direct the management or policies of a business entity, whether through the ownership of voting securities,
by contract relating to voting rights or corporate governance or otherwise; or (b) the ownership, directly or indirectly, of more than
fifty percent (50%) of the voting securities or other ownership interests of a business entity (or, with respect to a limited partnership
or other similar entity, its general partner or controlling entity).

 

1.5.
“Agreement” has the meaning set forth in the preamble hereto.

 

1.6.
“[***] Agreement” means that certain Distributorship Agreement, dated December 24, 1999, as amended, between [***]
and [***], collectively (as predecessor in interest to Eisai) and [***] (as predecessor in interest to [***]) with respect to Italy,
the Vatican State and the Republic of San Marino.

 

1.7.
“Alliance Manager” has the meaning set forth in Section 4.7.

 

1.8.
“Anti-Corruption Laws” means, as applicable, the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery
Act 2010, as amended, sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or any sanctions
or measures imposed by the United Nations Security Council, the European Union or Her Majesty’s Treasury, and any other applicable
anti-corruption laws and laws for the prevention of bribery, fraud, racketeering, money laundering or terrorism.

 

1.9.
“Applicable Law” means applicable laws, rules and regulations, including any rules, regulations, guidelines or
other requirements of the Regulatory Authorities, that may be in effect from time to time, including the FFDCA, the PHSA and the Anti-Corruption
Laws.

 

1.10.
“Arbitral Tribunal” has the meaning set forth in Section 11.5.2(a).

 

1.11.
“Arbitration Rules” has the meaning set forth in Section 11.5.2(a).

 

1.12.
“Auditor” has the meaning set forth in Section 5.9.

 

1.13.
“Binding Term Sheet” has the meaning set forth in the recitals hereto.

 

1.14.
“Biosimilar Product” means, with respect to a particular Licensed Product in a particular country in the Eisai
Territory or Licensee Territory, any pharmaceutical product that: (a) is claimed to be biosimilar to or interchangeable with such Licensed
Product or otherwise references or relies on such Licensed Product to support a Drug Approval Application or an application submitted
under Section 351(k) of the PHSA or any corresponding foreign application in the Eisai Territory or Licensee Territory, including, with
respect to the European Union, a Marketing Authorization Application filed with the EMA pursuant to the centralized approval procedure;
(b) is approved for sale for at least one (1) Indication that is the same as an Indication for which such Licensed Product is approved
for sale in such country; and (c) is sold in such country by a Third Party that is not a direct or indirect sublicensee of the Licensee
or its Affiliates, did not purchase such product in a chain of distribution that included any of the Licensee or its Affiliates or sublicensees,
and did not otherwise acquire any Eisai Patents or Eisai Know-how, directly or indirectly, from the Licensee.

 

    2

    

    

 

1.15.
“BLA” has the meaning set forth in the definition of Drug Approval Application.

 

1.16.
“BPCI Act” means the Biologics Price Competition and Innovation Act of 2009, as set forth at 42 U.S.C. §262
and as may be amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all
additions, supplements, extensions and modifications thereto).

 

1.17.
“Breaching Party” has the meaning set forth in Section 10.2.1.

 

1.18.
“Business Day” means a day other than a Saturday or Sunday or a day on which banking institutions in New York,
New York, Tokyo, Japan or Basel, Switzerland are permitted or required to be closed.

 

1.19.
“Calendar Quarter” means each successive period of three (3) calendar months commencing on April 1, July 1, October
1 and January 1, except that the first Calendar Quarter of the Term shall commence on the Original Effective Date and end on the day
immediately prior to the first to occur of April 1, July 1, October 1 or January 1 after the Original Effective Date and the last Calendar
Quarter shall end on the last day of the Term.

 

1.20.
“Challenge” means, with respect to any Eisai Patents or Licensee Patents, to contest the validity or enforceability
of any such Patents, in whole or in part, in any court, arbitration proceeding or other tribunal, including the United States Patent
and Trademark Office and the United States International Trade Commission. As used in this Section 1.20, the term “contest”
includes (a) filing an action under 28 U.S.C. §§ 2201-2202 seeking a declaration of invalidity or unenforceability of any such
Patents; (b) filing, or joining in, a petition under 35 U.S.C. § 311 to institute inter partes review of any such Patents or any
portion thereof; (c) filing, or joining in, a petition under 35 U.S.C. § 321 to institute post-grant review of any such Patents
or any portion thereof; (d) any foreign equivalent of clauses (a), (b) or (c) in any country outside of the United States; or (e) filing
or commencing any opposition, nullity or similar proceedings challenging the validity of any such Patents in any country outside the
United States; but excludes (i) becoming a party to a Third Party interference for the purpose of defending the validity of any such
Patents, (ii) filing a request under 35 U.S.C. § 302 for re-examination of any such Patents, (iii) filing a request under 35 U.S.C.
§ 251 for a reissue of any such Patents or (iv) any foreign equivalents of clause (i) to (iii) applicable outside of the United
States.

 

    3

    

    

 

1.21.
 “Change of Control” means, with respect to a Party: (a) a merger, reorganization or consolidation involving such
Party, or any parent company of such Party and a Third Party in which the voting securities of such Party or its parent company, as applicable,
outstanding immediately prior thereto cease to represent fifty percent (50%) or more of the combined voting power of the surviving entity
immediately after such merger, reorganization or consolidation or (b) a Person, or group of Persons (acting in concert), directly or
indirectly, become the beneficial owner (as defined in Rule 13d-3 under the U.S. Securities Exchange Act of 1934, as amended) of fifty
percent (50%) or more of the voting equity securities or management control of such Party or any parent company of such Party.

 

1.22.
“Clinical Quality Agreement” has the meaning set forth in Section 3.5.3.

 

1.23.
“Clinical Supply Agreement” has the meaning set forth in Section 3.5.3.

 

1.24.
“CMC Development Activities” means the activities necessary to generate the deliverables set forth in the CMC
Development Plan.

 

1.25.
“CMC Development Plan” means the development plan, including a detailed budget, setting forth the deliverables
(including the Final CMC Development Report) to be provided by Eisai with respect to chemistry, manufacturing and controls for the Existing
Licensed Product, attached hereto as Schedule 1.25, as will be finalized by the Parties in accordance with Section 3.1.3(a), and as may
be amended from time to time by the Parties in accordance with Section 3.1.3(b).

 

1.26.
“Commercialization” means, in respect of a biologic product, any and all activities directed to the preparation
for sale of, offering for sale of or sale of such product, including activities related to using, holding or keeping (whether for disposal
or otherwise), marketing, promoting, co-promoting, distributing, transporting, exporting, importing and disposing of such product and
interacting with Regulatory Authorities regarding any of the foregoing. When used as a verb, “to Commercialize” or “Commercializing”
means to engage in Commercialization and “Commercialized” has a corresponding meaning.

 

1.27.
“Commercially Reasonable Efforts” means, with respect to the performance of any particular Exploitation activities
with respect to the Licensed Compound or a Licensed Product by a Party, the carrying out of such activities in a sustained and diligent
manner and using efforts and resources comparable to the efforts and resources commonly used in the [***] for compounds or products of
similar market potential at a similar stage in development or product life. “Commercially Reasonable Efforts” shall be determined
on a country-by-country (or region-by-region, where applicable) and Indication-by-Indication basis.

 

1.28.
“Committee” has the meaning set forth in Section 4.3.1.

 

1.29.
“Confidential Information” has the meaning set forth in Section 7.1.

 

1.30.
“Contract Year” means each successive period of twelve (12) calendar months commencing on April 1 and ending on
March 31, except that the first Contract Year of the Term shall commence on the Original Effective Date and end on the first March 31
to occur after the Original Effective Date and the last Contract Year of the Term shall commence on April 1 of the year in which the
Term ends and end on the last day of the Term.

 

    4

    

    

 

1.31.
“Control” means, with respect to any Intellectual Property Rights or Regulatory Documentation, and subject to
Section 11.3.2, possession of the right, whether directly or indirectly and whether by ownership, license or otherwise (other than by
operation of the license and other grants in Section 2.1 or Section 2.2), to grant a license, sublicense or other right (including the
right to reference Regulatory Documentation or a covenant not to sue, as applicable) to or under such Intellectual Property Rights or
Regulatory Documentation as provided for herein without violating the terms of any agreement with any Third Party.

 

1.32.
“Controlling Party” has the meaning set forth in Section 6.5.

 

1.33.
“Copyrights” means any works of authorship, copyrights (including copyright in software), database rights, rights
in designs and mask work rights, in each case whether registered or unregistered and including applications for registration of any of
the foregoing.

 

1.34.
“Corporate Names” means: (a) with respect to Eisai, the Trademarks, names and logos identified in Schedule 1.34(a)
and such other Trademarks, names and logos as Eisai may designate in writing from time to time; and (b) with respect to the Licensee,
the name Dr. Reddy’s, Dr. Reddy’s Laboratories or any similar name and such other Trademarks, names and logos as Licensee
may designate in writing from time to time.

 

1.35.
“Corruption” has the meaning set forth in Section 8.4.1.

 

1.36.
“Cost of Goods” means, with respect to any Licensed Product, the Licensee’s cost of goods for such Licensed
Product, excluding corporate, general and administrative overheads and overheads not attributable to any facility or activities relating
to the Manufacture of such Licensed Product, determined in accordance with the Licensee’s cost accounting policies that are in
accordance with GAAP and consistently applied across the Licensee’s manufacturing network to other products that the Licensee or
any of its Affiliates manufactures and shall not include inter-company profits among the Licensee and its Affiliates.

 

1.37.
“CTCL Indication” means cutaneous T-cell lymphoma.

 

1.38.
“Defending Party” has the meaning set forth in Section 6.4.2.

 

1.39.
“Development” means, in respect of a biologic product, all activities related to research, pre-clinical and other
non-clinical testing, clinical testing and clinical test method development, including the performance of trials relating to the safety,
dosing and efficacy, stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and validation,
quality assurance/quality control, including Manufacturing in support thereof, statistical analysis and report writing and, to the extent
necessary to conduct any of the foregoing, the preparation and submission of Drug Approval Applications, regulatory affairs and all other
activities necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of
obtaining or maintaining a Regulatory Approval for any of the foregoing activities. When used as a verb, “Develop” means
to engage in Development.

 

    5

    

    

 

1.40.
“Development Plans” means the CMC Development Plan and the ‘302 Development Plan.

 

 

1.41.
“Discontinued Licensed Product” means all dosage forms, formulations, strengths, package sizes and types of pharmaceutical
products containing the Licensed Compound, previously sold in the United States under the Trademark ONTAK® and described in BLA #103767.

 

1.42.
“Dispute” has the meaning set forth in Section 11.5.1.

 

1.43.
“Distribution Agreements” means the [***] Agreement and the [***] Agreements.

 

1.44.
“Distribution Products” means, with respect to a Distribution Agreement, Products that contain denileukin diftitox,
as defined in such Distribution Agreement.

 

1.45.
“Dollars” or “$” means United States Dollars.

 

1.46.
“Drug Approval Application” means (a) a Biologics License Application submitted to the FDA under subsection (a)
of Section 351 of the PHSA (“BLA”) or any corresponding foreign application, including, with respect to the European
Union, a Marketing Authorization Application filed with the EMA pursuant to the centralized approval procedure, and (b) all supplements
and amendments that may be filed with respect to the foregoing.

 

1.47.
“Effective Date” has the meaning set forth in the recitals hereto.

 

1.48.
“Eisai” has the meaning set forth in the preamble hereto.

 

1.49.
“Eisai Covenant Patent” means any Patent that (a) Eisai or any of its Affiliates Controls that is not part of
the Eisai Technology and (b) would be infringed by the exercise by the Licensee of any of the rights granted to the Licensee under Section
2.1.1.

 

1.50.
“Eisai Developed Know-how” means all rights in Know-how comprised within the Eisai Developed Technology.

 

1.51.
“Eisai Developed Technology” means all Intellectual Property Rights (including any Intellectual Property Rights
subsisting in any Improvements) owned by Eisai pursuant to Section 6.1.2.

 

1.52.
“Eisai Existing Know-how” means all rights in Know-how Controlled by Eisai or any of its Affiliates as of the
Original Effective Date that is necessary or reasonably useful for the Exploitation of the Licensed Compound or the Existing Licensed
Product.

 

    6

    

    

 

1.53.
 “Eisai Existing Regulatory Documentation” means all Regulatory Documentation, Controlled by Eisai or any of its
Affiliates as of the Original Effective Date which relates to the Licensed Compound, Existing Licensed Product or Discontinued Licensed
Product.

 

1.54.
“Eisai Indemnitees” has the meaning set forth in Section 9.1.

 

1.55.
“Eisai Know-how” means: (a) the Eisai Existing Know-how and (b) the Eisai Developed Know-how, but excluding in
each of clauses (a) and (b) above any rights in Know-how to the extent covered or claimed by any published Eisai Patents.

 

1.56.
“Eisai Patents” means all Patents owned by Eisai or any of its Affiliates that are filed after the Original Effective
Date and that contain, disclose or claim any Eisai Developed Know-how.

 

1.57.
“Eisai Proprietary Product” means any pharmaceutical product that is owned, licensed or otherwise controlled by
Eisai or any of its Affiliates.

 

1.58.
“Eisai Regulatory Documentation” means the Eisai Existing Regulatory Documentation and all Regulatory Documentation
Controlled by Eisai or any of its Affiliates created after the Original Effective Date which relates to the Licensed Compound or Licensed
Products.

 

1.59.
“Eisai Technology” means: (a) all Intellectual Property Rights Controlled by Eisai or any of its Affiliates as
of the Original Effective Date that are necessary or reasonably useful for the Exploitation of the Licensed Compound or a Licensed Product;
and (b) all Eisai Developed Technology.

 

1.60.
“Eisai Territory” means (a) the following countries: Japan, China, Korea, Taiwan, Hong Kong, Macau, Indonesia,
Thailand, Malaysia, Brunei, Singapore, India, Pakistan, Sri Lanka, Philippines, Vietnam, Myanmar, Cambodia, Laos, Afghanistan, Bangladesh,
Bhutan, Nepal, Mongolia and Papua New Guinea, provided that following any exercise of the India Option by the Licensee in accordance
with Section 2.7 the “Eisai Territory” shall exclude India and (b) any Terminated Territory.

 

1.61.
“Eisai Territory Commercial Quality Agreement” has the meaning set forth in Section 3.5.4.

 

1.62.
“Eisai Territory Commercial Supply Agreement” has the meaning set forth in Section 3.5.4.

 

1.63.
“Eisai Territory Commercialization Plan” has the meaning set forth in Section 3.3.3(b).

 

1.64.
“Eisai Territory Development Plan” has the meaning set forth in Section 3.1.5.

 

    7

    

    

 

1.65.
 “Eisai Territory Product Trademarks” means any Trademark other than an Eisai Trademark or any Corporate Name
used by or on behalf of Eisai or any of its Affiliates on or in connection with the Exploitation of any Licensed Product in the Eisai
Territory, but excluding, for clarity, any trade dress.

 

1.66.
“Eisai Trade Secrets” means the information described on Schedule 1.66.

 

1.67.
“Eisai Trademarks” means (a) the Trademarks set forth on Schedule 1.67 and (b) any variation or derivation thereof
used by or on behalf of the Licensee or any of its Affiliates on or in connection with the Exploitation of any Licensed Product in the
Licensee Territory.

 

1.68.
“EMA” means the European Medicines Agency and any successor agency thereto.

 

1.69.
“Enforcing Party” has the meaning set forth in Section 6.3.2.

 

1.70.
“European Union” means the economic, scientific and political organization of member states as it may be constituted
from time to time, which as of the Original Effective Date consists of Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark,
Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal,
Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom of Great Britain and Northern Ireland and that certain portion of Cyprus
included in such organization.

 

1.71.
“Exclusion Lists” has the meaning set forth in Section 8.1.5.

 

1.72.
“Execution Date” has the meaning set forth in the preamble hereto.

 

1.73.
“Existing Licensed Product” means the pharmaceutical product known as E7777, containing the Licensed Compound
as an active ingredient and described in IND #110489.

 

1.74.
“Expedited Matters” has the meaning set forth in Section 3.2.2(d).

 

1.75.
“Expedited Procedures” has the meaning set forth in Section 3.2.2(d).

 

1.76.
“Expert” has the meaning set forth in Section 10.6.5.

 

1.77.
“Expert List” has the meaning set forth in Section 10.6.6.

 

1.78.
“Exploit” means, in respect of a biologic product, to Develop, obtain or maintain Regulatory Approvals for, Manufacture,
have Manufactured or Commercialize such product, including to make, have made, import, use, sell or offer for sale such product. “Exploitation”
means the act of Exploiting a product.

 

1.79.
“Extension Term” has the meaning set forth in Section 10.1.

 

    8

    

    

 

1.80.
 “FDA” means the United States Food and Drug Administration and any successor agency thereto.

 

1.81.
“[***] Agreements]” means that certain Distributorship Agreement, dated March 26, 1999, as amended, between [***]
and [***], collectively (as predecessor in interest to Eisai) and [***] with respect to Spain, Portugal and Greece, and that certain
Distributorship Agreement, dated March 26, 1999, as amended, between [***] and [***], collectively (as predecessor in interest to Eisai)
and [***] with respect to Argentina, Chile, Uruguay, Paraguay, Bolivia, Brazil, Peru, Ecuador, Colombia, Venezuela, Guyana, Surinam,
French Guyana, Panama, Costa Rica, Nicaragua, Honduras, El Salvador, Guatemala, Belize and Dominican Republic.

 

1.82.
“FFDCA” means the United States Food, Drug, and Cosmetic Act, as amended from time to time, together with any
rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto).

 

1.83.
“Field” means the diagnostic, prophylactic or therapeutic use of a product in humans or animals.

 

1.84.
“Final ‘302 Development Report” means a clinical study report in a format that is in accordance with Eisai’s
standard operating procedures and customary practices with respect to its other proprietary oncology products that (a) has been signed
by the applicable investigator and applicable Eisai personnel, (b) except for publication (which will occur in connection with the filing
of the BLA for the Existing Licensed Product for the CTCL Indication in the United States), is in a format that is ready for submission
to FDA, and (c) has been fully reviewed by all appropriate quality control personnel at Eisai.

 

1.85.
“Final ‘302 Development Report Dispute” has the meaning set forth in Section 3.1.2(b).

 

 

1.86.
“Final CMC Development Report” means a written report in a format that is in accordance with Eisai’s standard
operating procedures and customary practices with respect to its other proprietary oncology products that (a) has been signed by the
applicable Eisai personnel, (b) except for publication (which will occur in connection with the filing of the BLA for the Existing Licensed
Product for the CTCL Indication in the United States), is in a format that is ready for submission to FDA, and (c) has been fully reviewed
by all appropriate quality control personnel at Eisai.

 

1.87.
“Final CMC Development Report Dispute” has the meaning set forth in Section 3.1.3(b).

 

1.88.
“FTE” means the equivalent of the work of one (1) employee full time for one (1) Contract Year (consisting of
at least a total of [***] ([***]) hours per Contract Year) of work directly related to the applicable FTE Activities. No additional payment
shall be made with respect to any employee who works more than [***] ([***]) hours per Contract Year related to the applicable FTE Activities,
and any employee who devotes less than [***] ([***]) hours per Contract Year to the applicable FTE Activities shall be treated as an
FTE on a pro rata basis based upon the actual number of hours worked divided by [***] ([***]).

 

    9

    

    

 

1.89.
“FTE Activity” means any activity for which Eisai is reimbursed for its FTEs Costs and direct out-of-pocket costs
with respect to such activity.

 

1.90.
“FTE Costs” means, with respect to any activity for any period, the applicable FTE Rate multiplied by the applicable
number of FTEs of the applicable Party or any of its Affiliates performing such activity during such period, including on a pro rata
basis.

 

1.91.
“FTE Rate” means, as of the Original Effective Date, [***] Dollars ($[***]). The FTE Rate shall be adjusted annually,
with each annual adjustment effective as of April 1 of each Contract Year, with the first such annual adjustment to be made as of April
1, 2017, to correspond with the total percentage change in the Consumer Price Index for All Urban Consumers (CPI-U) for the U.S. City
Average, 1982-84 = 100, calculated by the Bureau of Labor Statistics over the twelve (12)-month period preceding each such April 1.

 

1.92.
“GAAP” means, with respect to a Party or its Affiliates or, with respect to the Licensee, its or their Sublicensees,
United States generally accepted accounting principles, International Financial Reporting Standards or such other similar national standards
as such Party, Affiliates or, with respect to the Licensee, its or their Sublicensee adopts, in each case, consistently applied.

 

1.93.
“Governmental Authority” means any federal, state, national, provincial or local government, or political subdivision
thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive,
judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division
thereof, or any governmental arbitrator or arbitral body).

 

1.94.
“ICC” has the meaning set forth in Section 11.5.2(a).

 

1.95.
“Improvements” means any invention, discovery, development or modification with respect to the Licensed Compound
or a Licensed Product or relating to the Exploitation thereof, whether or not patented or patentable, including any enhancement in the
efficiency, operation, Manufacture, ingredients, preparation, presentation, formulation, means of delivery or dosage of such Licensed
Compound or Licensed Product, any discovery or development of any new or expanded Indications for such Licensed Compound or Licensed
Product, any diagnostic devices relating to such Licensed Compound or Licensed Product, or any discovery or development that improves
the stability, safety or efficacy of such Licensed Compound or Licensed Product, in each case, arising directly from any Development
activities under or in connection with this Agreement.

 

1.96.
“IND” means: (a) an investigational new drug application filed with the FDA for authorization to commence clinical
studies and its equivalent in other countries or regulatory jurisdictions; and (b) all supplements and amendments that may be filed with
respect to the foregoing.

 

    10

    

    

 

1.97.
 “Indemnification Claim Notice” has the meaning set forth in Section 9.3.1.

 

1.98.
“Indemnified Party” has the meaning set forth in Section 9.3.1.

 

1.99.
“India Option” has the meaning set forth in Section 2.7.

 

1.100.
“India Option Period” has the meaning set forth in Section 2.7.

 

1.101.
“Indication” means any human and animal diagnostic, prophylactic and therapeutic indications.

 

1.102.
“Infringement” has the meaning set forth in Section 6.3.1.

 

1.103.
“Initial Term” has the meaning set forth in Section 10.1.

 

1.104.
“Intellectual Property Rights” means all: (a) rights in Patents; (b) rights in Know-how; (c) rights in Copyrights;
and (d) rights or forms of protection, anywhere in the world, having equivalent or similar effect to the rights referred to in paragraphs
(a) to (c) above, in each case, whether registered or unregistered and including applications for registration of any of the foregoing,
but excluding Trademarks and internet domain names.

 

1.105.
“IP Strategy” has the meaning set forth in Section 4.2.4.

 

1.106.
“Joint Commercialization Committee” or “JCC” has the meaning set forth in Section 4.2.

 

1.107.
“Joint Development Committee” or “JDC” has the meaning set forth in Section 4.2.

 

1.108.
“Joint IP Committee” or “JIPC” has the meaning set forth in Section 4.2.4.

 

1.109.
“Joint Manufacturing Committee” or “JMC” has the meaning set forth in Section 4.2.

 

1.110.
“Joint Steering Committee” or “JSC” has the meaning set forth in Section 4.1.

 

1.111.
“Joint Subcommittees” has the meaning set forth in Section 4.2.

 

1.112.
“Know-how” means all technical, scientific and other know-how and information, trade secrets, knowledge, technology,
means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance,
designs, drawings, assembly procedures, apparatuses, specifications, data, results and other material, including biological, chemical,
pharmacological, toxicological, pharmaceutical, physical and analytical, pre-clinical, clinical, safety, manufacturing and quality control
data and information, including study designs and protocols, assays and biological methodology, in each case (whether or not confidential,
proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed.

 

    11

    

    

 

1.113.
“Knowledge” means the actual knowledge after reasonable internal inquiry of, (a) with respect to Eisai, Associate
Director, Global Business Development Unit, Asia and Executive Director, Program & Alliance Management, Oncology PCU of Eisai and
(b) with respect to the Licensee, Head of Corporate Ethics & Compliance in North America and Senior Director of Finance of the Licensee.

 

1.114.
“Licensed Compound” means the recombinant DNA-derived cytotoxic protein as described on Schedule 1.114.

 

1.115.
“Licensed Product” means any product that is comprised of or contains the Licensed Compound as an active ingredient,
including: (a) any combination product which contains the Licensed Compound as an active ingredient; (b) the Existing Licensed Product;
and (c) all formulations, dosages and forms of release for any of the foregoing products.

 

1.116.
“Licensed Product Agreement” means, with respect to a Licensed Product, any agreement entered into by and between
a Party or any of its Affiliates, on the one hand, and one (1) or more Third Parties, on the other hand, that is necessary or reasonably
useful for the Exploitation of such Licensed Product in the Field, including: (a) supply agreements pursuant to which a Party or its
Affiliates obtain or will obtain quantities of such Licensed Product; (b) clinical trial agreements; (c) contract research organization
agreements; and (d) service agreements.

 

1.117.
“Licensee” has the meaning set forth in the preamble hereto.

 

1.118.
“Licensee Covenant Patent” means any Patent that (a) the Licensee or any of its Affiliates Controls that is not
part of the Licensee Technology and (b) would be infringed by the exercise by Eisai of any of the rights granted to Eisai under Section
2.2.

 

1.119.
“Licensee Developed Technology” means all Intellectual Property Rights owned by Licensee pursuant to Section 6.1.2.

 

1.120.
“Licensee Funded Technology” has the meaning set forth in Section 6.1.3.

 

1.121.
“Licensee Indemnitees” has the meaning set forth in Section 9.2.

 

1.122.
“Licensee Know-how” means all rights in Know-how comprised within the Licensee Technology.

 

1.123.
“Licensee Patents” means all Patents owned by the Licensee or any of its Affiliates that are filed after the Original
Effective Date and that contain, disclose or claim any Licensee Know-how.

 

1.124.
“Licensee Proprietary Product” means any pharmaceutical product that is owned, licensed or otherwise controlled
by Licensee or any of its Affiliates.

 

    12

    

    

 

1.125.
 “Licensee Regulatory Documentation” means (a) all Regulatory Documentation transferred to the Licensee under
this Agreement, including Eisai Existing Regulatory Documentation for the Licensee Territory and (b) all Regulatory Documentation Controlled
by the Licensee or any of its Affiliates created after the Original Effective Date which relates to the Licensed Compound or Licensed
Products.

 

1.126.
“Licensee Technology” means the Licensee Developed Technology and the Licensee Funded Technology.

 

1.127.
“Licensee Territory” means all countries in the world, excluding those countries in the Eisai Territory; provided
that following any exercise of the India Option by the Licensee in accordance with Section 2.7 the “Licensee Territory”
shall include India.

 

1.128.
“Licensee Territory Commercialization Plan” has the meaning set forth in Section 3.3.3(a).

 

1.129.
“Licensee Territory Development Plan” has the meaning set forth in Section 3.1.6.

 

1.130.
“Licensee Trademarks” means any Trademark other than an Eisai Trademark or any Corporate Name used by or on behalf
of the Licensee or any of its Affiliates on or in connection with the Exploitation of any Licensed Product in the Licensee Territory
in accordance with Section 6.7.1(b), but excluding, for clarity, any trade dress.

 

1.131.
“Losses” has the meaning set forth in Section 9.1.

 

1.132.
“Manufacture” and “Manufacturing” mean, in respect of a biologic product, all activities related
to the production, manufacture, processing, filling, finishing, packaging, labeling, shipping and holding of such product or any intermediate
thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture
and analytic development, product characterization, stability testing, quality assurance and quality control.

 

1.133.
“Manufacturing Process” has the meaning set forth in Section 3.5.2.

 

1.134.
“Manufacturing Transfer Services” has the meaning set forth in Section 3.5.2.

 

1.135.
“Material Anti-Corruption Law Violation” means a violation of an Anti-Corruption Law relating to the subject matter
of this Agreement that would, if it were publicly known, be reasonably likely to have a material adverse effect on a Party or on the
reputation of the Party because of its relationship with the other Party.

 

1.136.
“Net Sales” means, with respect to a Licensed Product in a particular country in the Licensee Territory and a
particular period of time, the gross sales recorded by the Licensee or any of its Affiliates or Sublicensees for such Licensed Product
sold to Third Parties, less the following deductions specifically related to such Licensed Product and actually taken or applied, in
the case of both gross sales and deductions as determined in accordance with GAAP:

 

    13

    

    

 

1.136.1.
 normal trade and cash discounts;

 

1.136.2.
amounts repaid or credited by reasons of defects, rejections, recalls or returns;

 

1.136.3.
fees, rebates and chargebacks to customers and Third Parties (including Medicare, Medicaid, Managed Healthcare, including managed
care or pharmacy benefit management companies, and similar types of rebates), and distribution fees paid to wholesalers and any other
Third Party administrative fees;

 

1.136.4.
amounts provided or credited to customers through coupons and other discount programs;

 

1.136.5.
delayed ship order credits, discounts or payments related to the impact of price increases between purchase and shipping dates and
retroactive price reductions;

 

1.136.6.
costs of outbound freight, insurance, and other transportation charges directly related to the distribution of such Licensed Product
to the purchaser;

 

1.136.7.
compensation paid to non-Affiliate distributors and wholesalers for maintaining agreed inventory level and providing information;
and

 

1.136.8.
other reductions or specifically identifiable amounts deducted for reasons similar to those listed above in accordance with GAAP.

 

Such
deductions shall be booked on an accrual basis by the Licensee and its Affiliates and Sublicensees under GAAP to calculate the recorded
net sale from gross sales. In no event shall any particular amount of deduction identified above be deducted more than once in calculating
Net Sales (i.e., no “double counting” of reductions). With respect to the calculation of Net Sales: (a) Net Sales only include
the value charged or invoiced on an arm’s length sale to a Third Party and sales between or among the Licensee and its Affiliates
and Sublicensees will be disregarded for the purposes of calculating Net Sales unless such Affiliate or Sublicensee is the end-user of
such Licensed Product; and (b) if the Licensed Product is delivered to the Third Party before being invoiced (or is not invoiced), Net
Sales will be calculated at the time all the revenue recognition criteria under GAAP are met, or when payment is received, whichever
is earlier.

 

1.137.
“Non-Breaching Party” has the meaning set forth in Section 10.2.1.

 

1.138.
“Notice Period” has the meaning set forth in Section 10.2.1.

 

1.139.
“Original Agreement” has the meaning set forth in the recitals hereto.

 

1.140.
“Original Effective Date” means March 30, 2016.

 

1.141.
“Party” and “Parties” have the meaning set forth in the preamble hereto.

 

    14

    

    

 

1.142.
“Patents” means: (a) all national, regional and international patents and patent applications, including provisional
patent applications; (b) all patent applications filed either from such patents, patent applications or provisional applications or from
an application claiming priority from either of these, including divisionals, continuations, continuations-in-part, provisionals, converted
provisionals and continued prosecution applications; (c) any and all patents that have issued or in the future issue from the foregoing
patent applications ((a) and (b)), including utility models, petty patents, innovation patents and design patents and certificates of
invention; (d) any and all associated exclusivities, extensions or restorations by existing or future exclusivity, extension or restoration
mechanisms, including post-grant proceedings, revalidations, re-issues, re-examinations and extensions (including any supplementary protection
certificates and the like) of the foregoing patents or patent applications ((a), (b) and (c)); and (e) any similar rights subsisting
anywhere in the world, including so-called pipeline protection or any importation, revalidation, confirmation or introduction patent
or registration patent or patent of additions to any of such foregoing patent applications and patents ((a), (b), (c) and (d)).

 

1.143.
“Payment” has the meaning set forth in Section 5.5.1.

 

1.144.
“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership,
corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other
similar entity or organization, including a government or political subdivision, department or agency of a government.

 

1.145.
“PHSA” means the Public Health Service Act as set forth at 42 U.S.C. Chapter 6A, as may be amended from time to
time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions
and modifications thereto).

 

1.146.
“President Arbitrator” has the meaning set forth in Section 11.5.2(b).

 

1.147.
“Prosecuting Party” has the meaning set forth in Section 6.2.1.

 

1.148.
“Qualifications” has the meaning set forth in Section 11.5.2(b).

 

1.149.
“Quality Agreement” means the Clinical Quality Agreement or Eisai Territory Commercial Quality Agreement, as applicable.

 

1.150.
“Regulatory Approval” means, with respect to a particular Licensed Product and a particular country, any and all
approvals (including approvals of Drug Approval Applications), licenses, registrations or authorizations of any Regulatory Authority
necessary to commercially distribute, sell or market a Licensed Product in such country, including, where applicable: (a) pricing or
reimbursement approval in such country; (b) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing
approval or authorization related thereto); and (c) labeling approval.

 

1.151.
“Regulatory Authority” means any applicable supra-national, federal, national, regional, state, provincial or
local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising
authority with respect to the Exploitation of the Licensed Compound or Licensed Products, including the FDA in the United States and
the EMA in the European Union.

 

    15

    

    

 

1.152.
 “Regulatory Documentation” means all: (a) applications (including all INDs and Drug Approval Applications), registrations,
licenses, authorizations and approvals (including Regulatory Approvals) and (b) correspondence and reports submitted to or received from
Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority)
and all supporting documents with respect thereto, including all adverse event files and complaint files; in each case relating to the
Licensed Compound or a Licensed Product.

 

1.153.
“Representatives” has the meaning set forth in Section 8.4.

 

1.154.
“Senior Officer” means, with respect to Eisai, the chief executive officer or a designee who directly reports
to him or her, and with respect to the Licensee, the chief executive officer or a designee who directly reports to him or her.

 

1.155.
“Sublicensee” means a Person, other than an Affiliate, to which the Licensee grants a sublicense under the grants
in Section 2.1 as provided in Section 2.3.

 

1.156.
“Supply Agreement” means the Clinical Supply Agreement or the Eisai Territory Commercial Supply Agreement, as
applicable.

 

1.157.
“Term” means the Initial Term, plus any Extension Term.

 

1.158.
“Termination Notice” has the meaning set forth in Section 10.2.1.

 

1.159.
“Territory” means: (a) in relation to Eisai, the Eisai Territory; and (b) in relation to the Licensee, the Licensee
Territory.

 

1.160.
“Third Party” means any Person other than Eisai, the Licensee and their respective Affiliates.

 

1.161.
“Third Party Claims” has the meaning set forth in Section 9.1.

 

1.162.
“Third Party Infringement Claim” has the meaning set forth in Section 6.4.1.

 

1.163.
“Third Party Patent Right” has the meaning set forth in Section 6.6.

 

1.164.
“Trademark” means any word, name, logo, tagline, slogan, symbol, device, design, color, shape, designation or
any combination thereof, including any trademark, service mark, trade name, brand name, sub-brand name, trade dress, product configuration
rights, program name, delivery form name, certification mark or collective mark, that functions as an identifier of source, origin or
quality, in each case, whether or not registered, and all statutory and common law rights therein and all registrations and applications
therefor, together with all goodwill associated with, or symbolized by, any of the foregoing.

 

1.165.
“United States” or “U.S.” means the United States of America and its territories and possessions
(including the District of Columbia and Puerto Rico).

 

    16

    

    

 

1.166.
 “United States CTCL Regulatory Costs” means the FTE Costs incurred and the direct out-of-pocket costs recorded
as an expense, in accordance with GAAP, by or on behalf of Eisai or any of its Affiliates with respect to obtaining Regulatory Approval
of the Existing Licensed Product in the United States for the CTCL Indication that are incurred or recorded after the pre-BLA meeting
with the FDA with respect to the Existing Licensed Product in the United States for the CTCL Indication.

 

1.167.
“US CTCL Regulatory Matters” has the meaning set forth in Section 4.2.1(b).

 

1.168.
“Unresolved Joint Subcommittee Matter” has the meaning set forth in Section 4.4.1.

 

1.169.
“Unresolved JSC Matter” has the meaning set forth in Section 4.4.2.

 

1.170.
“VAT” has the meaning set forth in Section 5.5.2.

 

1.171.
“Working Team” has the meaning set forth in Section 4.6.

 

ARTICLE
2

GRANT OF RIGHTS

 

2.1.
Grants to Licensee.

 

2.1.1.
Eisai Technology and Eisai Regulatory Documentation. Subject to Section 2.4.1, as of
the Original Effective Date, Eisai hereby grants, and shall procure that each of its relevant Affiliates shall grant, to the Licensee
an exclusive (including with regard to Eisai and its Affiliates) license (or sublicense) under the Eisai Technology, and an exclusive
(including with regard to Eisai and its Affiliates) license and right of reference under the Eisai Regulatory Documentation, in each
case with the right to grant sublicenses and further rights of reference in accordance with Section 2.3 to: (a) Exploit (other than to
Develop, Manufacture, have Manufactured, make or have made) the Licensed Compound and Licensed Products in the Field in the Licensee
Territory; (b) Develop the Licensed Compound and Licensed Products in the Field anywhere in the world solely for the purposes of obtaining
or maintaining Regulatory Approvals for (i) the Licensed Compound and Licensed Products in the Field in the Licensee Territory or (ii)
any Licensee Proprietary Product for use in concomitant or sequential administration with a Licensed Product anywhere in the world; (c)
Manufacture, have Manufactured, make and have made the Licensed Compound and Licensed Products anywhere in the world solely for the purposes
of Developing, obtaining or maintaining Regulatory Approvals for, or Commercializing the Licensed Compound and Licensed Products in the
Field in the Licensee Territory; (d) Commercialize any Licensee Proprietary Product for use in concomitant or sequential administration
with a Licensed Product anywhere in the world; and (e) perform its obligations under this Agreement, including any agreements entered
into pursuant to this Agreement. For purposes of the use of Regulatory Approval in connection with clause (b)(ii) above, the term “Licensed
Product” in the definition of Regulatory Approval shall be deemed to be a reference to “Licensee Proprietary Product”.

 

    17

    

    

 

2.1.2.
Eisai Trademarks. Subject to Section 2.4.1, as of the Original Effective Date, Eisai hereby grants, and shall procure that each of
its relevant Affiliates shall grant, to the Licensee an exclusive (including with regard to Eisai and its Affiliates) license (or sublicense)
under the Eisai Trademarks, with the right to grant sublicenses in accordance with Section 2.3, to exercise the rights grants to the
Licensee under Section 2.1.1.

 

2.1.3.
Eisai Territory Licensed Product Trademarks. Subject to Section 2.4.1, as of the Original Effective Date, Eisai hereby grants, and
shall procure that each of its relevant Affiliates shall grant, to the Licensee a non-exclusive license (or sublicense) under the Eisai
Territory Product Trademarks, with the right to grant sublicenses solely to any licensee or sublicensee of the Licensee’s rights
with respect to the applicable Licensee Proprietary Product, to Commercialize any Licensee Proprietary Product for use in concomitant
or sequential administration with a Licensed Product in the Eisai Territory.

 

2.2.
Grants to Eisai.

 

2.2.1.
Licensee Technology and Licensee Regulatory Documentation. Subject to Section 2.4.2, as of the Original Effective Date, the Licensee
hereby grants, and shall procure that each of its relevant Affiliates shall grant, to Eisai an exclusive (including with regard to the
Licensee and its Affiliates) license under the Licensee Technology, and an exclusive (including with regard to the Licensee and its Affiliates)
license and right of reference under the Licensee Regulatory Documentation, in each case with the right to grant sublicenses and further
rights of reference in accordance with Section 2.3, to: (a) Exploit (other than to Develop, Manufacture, have Manufactured, make or have
made) the Licensed Compound and Licensed Products in the Field in the Eisai Territory; (b) Develop the Licensed Compound and Licensed
Products in the Field anywhere in the world solely for the purposes of obtaining or maintaining Regulatory Approvals for (i) the Licensed
Compound and Licensed Products in the Field in the Eisai Territory or (ii) any Eisai Proprietary Product for use in concomitant or sequential
administration with a Licensed Product anywhere in the world; (c) Manufacture, have Manufactured, make and have made the Licensed Compound
and Licensed Products anywhere in the world solely for the purposes of Developing, obtaining or maintaining Regulatory Approvals for,
or Commercializing the Licensed Compound and Licensed Products in the Field in the Eisai Territory; (d) Commercialize any Eisai Proprietary
Product for use in concomitant or sequential administration with a Licensed Product anywhere in the world; and (e) perform its obligations
under this Agreement, including any agreements entered into pursuant to this Agreement. For purposes of the use of Regulatory Approval
in connection with clause (b)(ii) above, the term “Licensed Product” in the definition of Regulatory Approval shall be deemed
to be a reference to “Eisai Proprietary Product”.

 

2.2.2.
Licensee Trademarks. Subject to Section 2.4.2, as of the Original Effective Date, the Licensee hereby grants, and shall procure that
each of its relevant Affiliates shall grant, to Eisai a non-exclusive license (or sublicense) under the Licensee Trademarks, with the
right to grant sublicenses solely to any licensee or sublicensee of Eisai’s rights with respect to the applicable Eisai Proprietary
Product, to Commercialize any Eisai Proprietary Product for use in concomitant or sequential administration with a Licensed Product in
the Licensee Territory.

 

    18

    

    

 

2.2.3.
Eisai Technology, Eisai Trademarks and Eisai Regulatory Documentation. Subject to Section 2.4.2, as of the Original Effective Date
until full assignment of Eisai’s rights and delegation of Eisai’s obligations under the Distribution Agreements with respect
to the Distribution Products to Licensee, the Licensee hereby grants, and shall procure that each of its relevant Affiliates shall grant,
to Eisai a non-exclusive license (or sublicense) under the Eisai Technology and Eisai Trademarks, and a non-exclusive license and right
of reference under the Eisai Regulatory Documentation, in each case, with the right to grant sublicenses and further rights of reference
as necessary to maintain Eisai’s compliance with the Distribution Agreements, solely to the extent necessary under the Distribution
Agreements.

 

2.3.
Sublicenses.

 

2.3.1.
Right to Sublicense. Subject to Section 2.3.2, each Party shall have the right to grant sublicenses (or further rights of reference),
through multiple tiers of sublicensees, under the licenses and rights of reference granted in Section 2.1 and Section 2.2 (as applicable)
to:

 

(a)
its Affiliates;

 

(b)
with respect to Eisai, any other Persons; and

 

(c)
with respect to the Licensee, any other Persons; provided that any sublicenses to such other Persons shall be subject to the prior
written consent of Eisai, such consent not to be unreasonably withheld, conditioned or delayed; provided, further, that with respect
to any sublicense to a contract manufacturer or supplier for a Licensed Product that would not involve the disclosure of any Eisai Trade
Secret, Eisai shall provide its response to any request for such consent within [***] ([***]) Business Days after the Licensee’s
request with respect thereto; provided, further, that any sublicense to such other Persons that would involve the disclosure of
any Eisai Trade Secret shall be subject to the prior written consent of Eisai, which may be withheld, conditioned or delayed in its sole
discretion.

 

2.3.2.
Sublicense Terms. Any sublicenses granted pursuant to Section 2.3.1 shall be consistent with, and subject to, the terms and conditions
of this Agreement. Each Party shall cause each of its sublicensees to comply with the applicable terms and conditions of this Agreement,
as if such sublicensee were a Party to this Agreement, and shall be responsible to the other Party for the actions and inactions of its
sublicensees. Each Party hereby waives any requirement that the other Party exhaust any right, power or remedy, or proceed against any
sublicensee of the first Party for any obligation or performance under this Agreement prior to proceeding directly against the sublicensing
Party. Any sublicense granted pursuant to Section 2.3.1 shall terminate immediately if the relevant sublicensee commits or omits to do
any act which would, if committed or omitted by a Party, be a material breach of this Agreement, or would give rise to a right of termination
pursuant to Section 10.2.

 

    19

    

    

 

2.4.
Reservation of Rights.

 

2.4.1.
No Other Rights Granted by Eisai. Notwithstanding anything to the contrary in this Agreement but subject to Section 2.6.2, Eisai
retains, on behalf of itself and its Affiliates, rights in and to the Eisai Technology, the Eisai Regulatory Documentation and the Eisai
Trademarks to: (a) Develop, Manufacture, have Manufactured, make and have made the Licensed Compound and Licensed Products anywhere in
the world solely for the purposes of (i) obtaining or maintaining Regulatory Approvals for, or Commercializing, the Licensed Compound
and Licensed Products in the Field in the Eisai Territory or (ii) obtaining or maintaining Regulatory Approvals for any Eisai Proprietary
Product for use in concomitant or sequential administration with a Licensed Product anywhere in the world; (b) Commercialize any Eisai
Proprietary Product for use in concomitant or sequential administration with a Licensed Product anywhere in the world; and (c) perform
its obligations under this Agreement, including any agreements entered into pursuant to this Agreement. Except as expressly provided
herein, Eisai grants no other right or license, including any rights or licenses to the Eisai Technology, the Eisai Regulatory Documentation,
the Eisai Trademarks, the Eisai Territory Product Trademarks or other Intellectual Property Rights. In no event shall the Licensee or
any of its Affiliates obtain any right or license to any Intellectual Property Rights with respect to any Eisai Proprietary Product under
this Agreement. For purposes of the use of Regulatory Approval in connection with clause (a)(ii) above, the term “Licensed Product”
in the definition of Regulatory Approval shall be deemed to be a reference to “Eisai Proprietary Product”.

 

2.4.2.
No Other Rights Granted by the Licensee. Notwithstanding anything to the contrary in this Agreement but subject to Section 2.6.1,
the Licensee retains, on behalf of itself and its Affiliates, rights in and to the Licensee Technology and the Licensee Regulatory Documentation
to: (a) Develop, Manufacture, have Manufactured, make and have made the Licensed Compound and Licensed Products anywhere in the world
solely for the purposes of (i) obtaining or maintaining Regulatory Approvals for, or Commercializing, the Licensed Compound and Licensed
Products in the Field in the Licensee Territory or (ii) obtaining or maintaining Regulatory Approvals for any Licensee Proprietary Product
for use in concomitant or sequential administration with a Licensed Product anywhere in the world; (b) Commercialize any Licensee Proprietary
Product for use in concomitant or sequential administration with a Licensed Product anywhere in the world; and (c) perform its obligations
under this Agreement, including any agreements entered into pursuant to this Agreement. Except as expressly provided herein, the Licensee
grants no other right or license, including any rights or licenses to the Licensee Technology, the Licensee Regulatory Documentation,
the Licensee Trademarks or any other Intellectual Property Rights. In no event shall Eisai or any of its Affiliates obtain any right
or license to any Intellectual Property Rights with respect to any Licensee Proprietary Product under this Agreement. For purposes of
the use of Regulatory Approval in connection with clause (a)(ii) above, the term “Licensed Product” in the definition of
Regulatory Approval shall be deemed to be a reference to “Licensee Proprietary Product”.

 

2.5.
Covenant Not to Sue.

 

2.5.1.
Covenant Not to Sue the Licensee. Eisai hereby covenants not to assert or cause to be asserted, and will cause its Affiliates not
to assert or cause to be asserted, against the Licensee or any of the Licensee’s Affiliates or Sublicensees, any claim of infringement
under any Eisai Covenant Patent solely with respect to the exercise of the rights granted to the Licensee under Section 2.1.1. If Eisai
or any of its Affiliates licenses, assigns or otherwise transfers any Eisai Covenant Patent to a Third Party, then Eisai or its Affiliate,
as applicable, will require such licensee, assignee or transferee to be bound by a covenant substantially identical to the covenant made
by Eisai in this Section 2.5.1.

 

    20

    

    

 

2.5.2.
Covenant Not to Sue Eisai. The Licensee hereby covenants not to assert or cause to be asserted, and will cause its Affiliates not
to assert or cause to be asserted, against Eisai or any of Eisai’s Affiliates or Sublicensees, any claim of infringement under
any Licensee Covenant Patent solely with respect to the exercise of the rights granted to Eisai under Section 2.2. If the Licensee or
any of its Affiliates licenses, assigns or otherwise transfers any Licensee Covenant Patent to a Third Party, then the Licensee or its
Affiliate, as applicable, will require such licensee, assignee or transferee to be bound by a covenant substantially identical to the
covenant made by the Licensee in this Section 2.5.2.

 

2.6.
Exclusivity and Territorial Restrictions.

 

2.6.1.
Licensee. The Licensee shall not, and shall not permit any of its Affiliates or any of its and their licensees, Sublicensees, or
distributors to, distribute, market, promote, offer for sale, or sell the Licensed Products, directly or indirectly, to any Person for
use outside the Field outside the Licensee Territory. If the Licensee or any of its Affiliates receives or becomes aware of the receipt
by a licensee, Sublicensee or distributor of any orders for any Licensed Products for commercial use outside the Field outside the Licensee
Territory, the Licensee shall notify Eisai thereof and shall cause such recipient to refer such orders to Eisai.

 

2.6.2.
Eisai. Eisai shall not, and shall not permit any of its Affiliates or any of its and their licensees or distributors to, distribute,
market, promote, offer for sale or sell the Licensed Products, directly or indirectly, to any Person for use in the Field in the Licensee
Territory. If Eisai or any of its Affiliates receives or becomes aware of the receipt by a (sub)licensee or distributor of any orders
for any Licensed Product for commercial use in the Field in the Licensee Territory, Eisai shall notify the Licensee thereof and shall
cause such recipient to refer such orders to the Licensee.

 

2.7.
India Option. At any time prior to the filing of a Drug Approval Application for the Exploitation of the Existing Licensed Product
in the United States (the “India Option Period”), the Licensee may, upon [***] ([***]) Business Days’ written
notice to Eisai elect to add India to the Licensee Territory (the “India Option”). If the Licensee timely elects the
India Option during the India Option Period, then thereafter for the purposes of this Agreement, the term “Licensee Territory”
shall include India and the term “Eisai Territory” shall not include India.

 

2.8.
India Restriction. Prior to the filing of a Drug Approval Application for the Exploitation of the Existing Licensed Product in the
United States, Eisai must not Commercialize the Licensed Compound or Licensed Products in India without the prior written consent of
the Licensee.

 

    21

    

    

 

2.9.
Technical Document and Know-How Transfer. Eisai shall, and shall procure that each of its relevant Affiliates shall, provide to the
Licensee the Know-how, Regulatory Documentation (including Eisai Existing Regulatory Documentation for the Licensee Territory) and other
documents relating to the Existing Licensed Product and the Discontinued Product set forth on Schedule 2.9 in the form, and by the delivery
date, set forth on Schedule 2.9. In addition, Eisai will use Commercially Reasonable Efforts to provide the Licensee any other documentation
reasonably requested by the Licensee that embodies any Eisai Technology or Eisai Regulatory Documentation relating to the Licensee Territory.
The Licensee shall reimburse Eisai for the direct out-of-pocket costs recorded as an expense, in accordance with GAAP, by or on behalf
of Eisai or any of its Affiliates related to the provision of any Know-how, Regulatory Documentation or other documents pursuant to this
Section 2.9 within [***] ([***]) days after receipt of an invoice with respect thereto. For clarity, this Section 2.9 contains Eisai’s
obligation to deliver the documents and information set forth on Schedule 2.9 and Eisai’s obligations to provide knowledge transfer
and support are set forth in Section 3.2.2 and Section 3.5.2.

 

2.10.
Distribution Agreements.

 

(a)
Eisai shall use good faith efforts to obtain (or, if requested in writing by Licensee, assist Licensee in obtaining) (i) a written acknowledgement
from [***] of Eisai’s right to partially assign Eisai’s rights and delegate Eisai’s obligations, under the [***] Agreements
with respect to the Distribution Products to Licensee and (ii) written consent from [***] to partially assign Eisai’s rights and
delegate Eisai’s obligations under the [***] Agreement with respect to the Distribution Products to Licensee. If any such acknowledgement
or consent is not obtained within [***] ([***]) days after the Original Effective Date, Eisai shall continue to use its good faith efforts
to obtain such acknowledgement or consent, and Eisai shall cooperate with Licensee in any lawful and economically feasible arrangement
(including subcontracting) to provide that Licensee shall receive the interest of Eisai in any such Distribution Agreement with respect
to the Distribution Products; provided that Licensee shall fulfill any obligations for which Licensee would have been responsible
if such acknowledgement or consent had been obtained, subject to the indemnification obligations of Eisai in Section 9.2. Eisai shall
hold in trust for and pay to Licensee, promptly upon receipt thereof, all income, proceeds and other monies received by Eisai or any
of its Affiliates in connection with the distribution of the Distribution Products under the Distribution Agreements.

 

(b)
Effective upon obtaining such written acknowledgement or consent as described in Section 2.10(a) with respect to the [***] Agreements
or the [***] Agreement, as applicable, Eisai hereby assigns to Licensee all of Eisai’s rights and delegates to Licensee all of
Eisai’s obligations, in each case, under the [***] Agreements or the [***] Agreement, as applicable, with respect to the Distribution
Products and Licensee hereby accepts such assignment and assumes such obligations.

 

    22

    

    

 

ARTICLE
3

DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES

 

3.1.
Development.

 

3.1.1.
In General. Except as provided in Section 3.1.2, Section 3.1.3, and Section 3.2, as between the Parties, (a) subject to clause (c)
and (d), Licensee shall have the sole right and responsibility, at its sole expense, for all aspects of the Development of the Licensed
Compound and Licensed Products for Commercialization in the Field in the Licensee Territory, (b) Eisai shall have the sole right and
responsibility, at its sole expense, for all aspects of the Development of the Licensed Compound and Licensed Products for Commercialization
in the Field in the Eisai Territory, (c) Licensee shall have the sole right and responsibility, at its sole expense, for all aspects
of the Development of any Licensee Proprietary Product for use in concomitant or sequential administration with a Licensed Product anywhere
in the world and (d) Eisai shall have the sole right and responsibility, at its sole expense, for all aspects of the Development of any
Eisai Proprietary Product for use in concomitant or sequential administration with a Licensed Product anywhere in the world. Neither
Party shall perform any Development activities, other than pre-clinical research activities, with respect to the Licensed Compound nor
the Licensed Products except as set forth in the ‘302 Development Plan, CMC Development Plan, Eisai Territory Development Plan
or Licensee Territory Development Plan, as applicable.

 

3.1.2.
‘302 Development Activities.

 

(a)
Eisai shall use Commercially Reasonable Efforts to perform the ‘302 Development Activities in compliance with the ‘302 Development
Plan. Either Party, through its representatives on the JSC, may propose amendments to the ‘302 Development Plan from time to time.
Any and all such amendments to the ‘302 Development Plan shall be subject to approval by the JSC as set forth in Section 4.1.1.
No amendment to the ‘302 Development Plan will be effective unless approved by the JSC in accordance with Section 4.1.1, including
the dispute resolution procedures set forth in Section 4.4. All amendments to the ‘302 Development Plan must be in writing.

 

(b)
After completing the clinical trial described in the ‘302 Development Plan, after internal Eisai review of the first draft of the
Final ‘302 Development Report, Eisai shall provide the Licensee with a copy of each additional draft of the Final ‘302 Development
Report that Eisai distributes within Eisai for review and comment. Eisai shall consider in good faith any comments provided by the Licensee
within the comment period provided for the internal Eisai reviewers; provided that any dispute regarding whether or not to implement
any of the Licensee’s comments with respect to any draft of the Final ‘302 Development Report (each, a “Final ‘302
Development Report Dispute”) shall be submitted to the JSC for resolution. Eisai shall implement any of the Licensee’s
comments with respect to any draft of the Final ‘302 Development Report that has been approved by the JSC (including, if applicable,
in accordance with Section 4.4.2(g)).

 

3.1.3.
CMC Development Activities.

 

(a)
Within [***] ([***]) days after the Original Effective Date, the Parties shall finalize the CMC Development Plan.

 

(b)
Eisai shall use Commercially Reasonable Efforts to perform the CMC Development Activities in compliance with the CMC Development Plan.
Either Party, through its representatives on the JSC, may propose amendments to the CMC Development Plan from time to time. Any and all
such amendments to the CMC Development Plan shall be subject to approval by the JSC as set forth in Section 4.1.1. No amendment to the
CMC Development Plan will be effective unless approved by the JSC in accordance with Section 4.1.1, including the dispute resolution
procedures set forth in Section 4.4. All amendments to the CMC Development Plan must be in writing.

 

    23

    

    

 

(c)
After completing the activities necessary to generate the data and information necessary for the deliverables described in the CMC Development
Plan, after internal Eisai review of the first draft of the Final CMC Development Report, Eisai shall provide the Licensee with a copy
of each additional draft of the Final CMC Development Report that Eisai distributes within Eisai for review and comment. Eisai shall
consider in good faith any comments provided by the Licensee within the comment period provided for the internal Eisai reviewers; provided
that any dispute regarding whether or not to implement any of the Licensee’s comments with respect to any draft of the Final CMC
Development Report (each, a “Final CMC Development Report Dispute”) shall be submitted to the JSC for resolution.
Eisai shall implement any of the Licensee’s comments with respect to any draft of the Final CMC Development Report that has been
approved by the JSC (including, if applicable, in accordance with Section 4.4.2(g)).

 

3.1.4.
‘302 Development Costs. Subject to this Section 3.1.4, Licensee shall reimburse Eisai for its ‘302 Development Costs.

 

(a)
Eisai shall report to Licensee, within [***] ([***]) days after the end of each Calendar Quarter, the ‘302 Development Costs incurred
by Eisai or any of its Affiliates during such Calendar Quarter. Each such report shall (i) specify in reasonable detail all amounts included
in ‘302 Development Costs during such Calendar Quarter (broken down by activity) and the corresponding budgeted expenses for such
Calendar Quarter and (ii) include an invoice for the ‘302 Development Costs incurred by Eisai or any of its Affiliates during such
Calendar Quarter and copies of any invoices or other supporting documentation for any payments to a Third Party that individually exceed
[***] Dollars ($[***]) (or such other amount approved by the JSC). Eisai agrees to provide upon request copies of invoices and details
to Licensee on any invoices not otherwise submitted to Licensee to enable Licensee to comply with its tax, auditing and other obligations.
The Parties shall seek to resolve any questions related to such reports and invoice details within [***] ([***]) days following the Licensee’s
receipt of Eisai’s report hereunder. Subject to clause (b) below, within [***] ([***]) days after the later of (i) the receipt
of any report and (ii) the resolution of any questions with respect to any report, Licensee shall reimburse Eisai for the ‘302
Development Costs set forth in such report; it being understood and agreed that all undisputed amounts shall be payable within [***]
([***]) days after the receipt of the applicable report referred to in clause (i) above.

 

(b)
Unless otherwise agreed by the Parties in writing, in no event shall the Licensee be obligated to reimburse Eisai for more than (i) [***]
Dollars ($[***]) in ‘302 Development Costs , with respect to the ‘302 Development Plan, as it exists as of the Original Effective
Date or as the ‘302 Development Plan may be amended to enable Eisai to provide the Licensee the deliverables set forth in ‘302
Development Plan as of the Original Effective Date in accordance with the timeframe set forth therein, or if FDA requires changes to
the ‘302 Development Plan due to changes in the manufacturing site. For clarity, unless otherwise agreed by the Parties in writing,
Licensee shall reimburse Eisai for its ‘302 Development Costs resulting from any other amendment to the ‘302 Development
Plan.

 

    24

    

    

 

3.1.5.
Eisai Territory Development Plan. As soon as reasonably practicable after the Original Effective Date, and in any event within [***]
([***]) days after the Original Effective Date, Eisai shall provide the JSC with a copy of its plan for the Development of the Licensed
Compound and Licensed Products for Commercialization in the Eisai Territory or any Eisai Proprietary Product for use in concomitant or
sequential administration with a Licensed Product anywhere in the world, other than the ‘302 Development Activities and the CMC
Development Activities (the “Eisai Territory Development Plan”), which Eisai Territory Development Plan shall be subject
to approval by the JSC as set forth in Section 4.1.3. Eisai, through its representatives on the JSC, may propose amendments to the Eisai
Territory Development Plan from time to time. Any and all such amendments to the Eisai Territory Development Plan shall be subject to
approval by the JSC as set forth in Section 4.1.3. Neither the initial Eisai Territory Development Plan nor any amendment to the Eisai
Territory Development Plan will be effective unless approved by the JSC in accordance with Section 4.1.3, including the dispute resolution
procedures set forth in Section 4.4. All amendments to the Eisai Territory Development Plan must be in writing.

 

3.1.6.
Licensee Territory Development Plan. As soon as reasonably practicable after the Original Effective Date, and in any event within
[***] ([***]) days after the Original Effective Date, the Licensee shall provide the JSC with a copy of its plan for the Development
of the Licensed Compound and Licensed Products for Commercialization in the Licensee Territory or any Licensee Proprietary Product for
use in concomitant or sequential administration with a Licensed Product anywhere in the world, other than the ‘302 Development
Activities and the CMC Development Activities (the “Licensee Territory Development Plan”), which Licensee Territory
Development Plan shall be subject to approval by the JSC as set forth in Section 4.1.3. Licensee, through its representatives on the
JSC, may propose amendments to the Licensee Territory Development Plan from time to time. Any and all such amendments to the Licensee
Territory Development Plan shall be subject to approval by the JSC as set forth in Section 4.1.3. Neither the initial Licensee Territory
Development Plan nor any amendment to the Licensee Territory Development Plan will be effective unless approved by the JSC in accordance
with Section 4.1.3, including the dispute resolution procedures set forth in Section 4.4. All amendments to the Licensee Development
Plan must be in writing.

 

3.1.7.
Licensee Development Diligence. Subject to Eisai’s performance of the ‘302 Development Activities and the CMC Development
Activities, Licensee shall use Commercially Reasonable Efforts to Develop a Licensed Product for the United States for the CTCL Indication.

 

3.1.8.
Development Records. Each Party shall, and shall cause its Affiliates to, maintain, in good scientific manner, complete and accurate
books and records pertaining to its Development of the Licensed Compound and the Licensed Products, in sufficient detail to verify compliance
with its obligations under this Agreement. Such books and records shall: (a) be appropriate for patent and regulatory purposes; (b) be
in compliance with Applicable Law; (c) properly reflect all work done and results achieved in the performance of its Development activities
hereunder, including all data and other information obtained in the performance of such activities; and (d) record only such activities
and not include or be commingled with records of activities outside the scope of this Agreement. Eisai shall provide the Licensee electronic
access to such books and records in Eisai or any of its Affiliate’s possession that relate to the CMC Development Activities and
the ‘302 Development Activities via a secure file transfer protocol site or other similar site, which site Eisai shall update at
least once a Calendar Quarter. Except to the extent prohibited by Applicable Law, promptly after Eisai files the BLA for the Existing
Licensed Product for the CTCL Indication in the United States, Eisai shall transfer to the Licensee or its designated Affiliate the original
version (or, where the transfer of the original version is prohibited by Applicable Law, a copy) of all such books and records that relate
to the CMC Development Activities and the ‘302 Development Activities (except that Eisai may retain a copy of the same). Each Party
shall retain a copy of all such books and records for at least [***] ([***]) years after the expiration or termination of this Agreement
or for such longer period as may be required by Applicable Law. Each Party shall have the right, during normal business hours and upon
reasonable notice, to inspect all records of the other Party maintained pursuant to this Section 3.1.8.

 

    25

    

    

 

3.1.9.
FTE Reports. In addition, Eisai shall record and account for (on a monthly and position-by-position basis) its FTE effort with respect
to its FTE Activities performed under this Agreement, in each case, consistent with past practice and in the same manner as used for
other products developed by Eisai, unless otherwise agreed by the Parties in writing.

 

3.1.10.
Development Reports. Without limiting Section 3.1.8, within [***] ([***]) days of the end of the first and third Calendar Quarter
of each Contract Year during which a Party is performing, or causing to be performed, Development activities in relation to the Licensed
Compound or Licensed Product, such Party shall provide the JSC with a reasonably detailed written report of the Development activities
it has performed, or caused to be performed, in respect of the Licensed Compound or Licensed Product since the preceding report (or,
with respect to the first such report, since the Original Effective Date), and the future Development activities it expects to initiate
in respect of the Licensed Compound or Licensed Product during the following twelve (12)-month period. In the case of any report submitted
by Eisai to Licensee, each such report shall contain sufficient detail to enable the Licensee to assess Eisai’s compliance with
the obligations set forth in Section 3.1.2 and Section 3.1.3.

 

3.1.11.
Compliance with Applicable Law. Each Party shall, and shall cause its Affiliates to, comply with all Applicable Law with respect
to the Development of the Licensed Compound and Licensed Products.

 

3.2.
Regulatory Activities.

 

3.2.1.
In General.

 

(a)
Except as otherwise set forth in this Section 3.2, the Licensee shall have the exclusive right, at its own cost, to prepare, submit to
Regulatory Authorities in the Licensee Territory, obtain, and maintain Drug Approval Applications based on the regulatory strategy therefor
approved by the JSC and other submissions (including INDs) for the Licensed Products in the Field in the Licensee Territory, and to conduct
communications with the Regulatory Authorities with respect thereto and all Regulatory Documentation for the Licensed Products in the
Licensee Territory shall be owned by, and shall be the sole property and held in the name of, Licensee or its designated Affiliate. For
clarity, any Eisai Know-how included or referenced in any such Regulatory Documentation shall remain the exclusive property of Eisai
or its applicable Affiliate.

 

    26

    

    

 

(b)
Except as otherwise set forth in this Section 3.2, Eisai shall have the exclusive right, at its own cost, to prepare, submit to Regulatory
Authorities in the Eisai Territory, obtain, and maintain Drug Approval Applications based on the regulatory strategy therefor approved
by the JSC, and other submissions (including INDs) for the Licensed Products in the Field in the Eisai Territory, and to conduct communications
with the Regulatory Authorities with respect thereto and all Regulatory Documentation for the Licensed Products in the Eisai Territory
shall be owned by, and shall be the sole property and held in the name of, Eisai or its designated Affiliate. For clarity, any Licensee
Know-how included or referenced in any such Regulatory Documentation shall remain the exclusive property of the Licensee or its applicable
Affiliate.

 

(c)
Except as otherwise set forth in this Section 3.2, the Licensee shall have the exclusive right to prepare, submit to Regulatory Authorities,
obtain, and maintain all INDs necessary to conduct any Development activities set forth in the Licensee Territory Development Plan, and
to conduct communications with the Regulatory Authorities with respect thereto and all such INDs shall be owned by, and shall be the
sole property and held in the name of, the Licensee or its designated Affiliate.

 

(d)
Eisai shall (i) prepare, submit to Regulatory Authorities, obtain, and maintain all INDs necessary to conduct the ‘302 Development
Activities and the CMC Development Activities, and (ii) have the exclusive right to prepare, submit to Regulatory Authorities, obtain,
and maintain all INDs necessary to conduct any Development activities set forth in the Eisai Territory Development Plan, and in each
case ((i) and (ii)), subject to Section 3.2.2, to conduct communications with the Regulatory Authorities with respect thereto and, subject
to Section 3.2.3, all such INDs shall be owned by, and shall be the sole property and held in the name of, Eisai or its designated Affiliate.

 

3.2.2.
Initial Regulatory Approval in the United States for CTCL Indication.

 

(a)
Eisai shall use Commercially Reasonable Efforts to obtain Regulatory Approval of the Existing Licensed Product in the United States for
the CTCL Indication. For clarity, if any additional non-clinical studies or clinical trials other than the ‘302 Development Activities,
the CMC Development Activities and the non-clinical studies or clinical trials that have been completed by or on behalf of Eisai prior
to the Original Effective Date are required by the FDA to grant Regulatory Approval of the Existing Licensed Product in the United States
for the CTCL Indication, Eisai shall have no obligation to file the BLA for the Existing Licensed Product in the United States for the
CTCL Indication, or engage in communications with the FDA with respect thereto, unless and until such additional non-clinical or clinical
trials have been completed by or on behalf of Licensee.

 

    27

    

    

 

(b)
Subject to Section 3.2.2(d), Eisai shall provide the JDC with copies of the BLA for, and other material or substantive submissions or
communications to the FDA relating to, the Existing Licensed Product for the CTCL Indication in the United States a reasonable amount
of time prior to the anticipated date for the submission or communication to allow the JDC to review and approve such BLA or other submission
or communication. Eisai shall not submit the BLA for, or any other material or substantive submission or communication to the FDA relating
to, the Existing Licensed Product for the CTCL Indication in the United States that has not been approved by the JDC (including, if applicable,
in accordance with Section 4.4.2(g)) or the Expedited Procedures, if applicable; provided, that if Eisai has complied with the
approval procedures set forth in Section 4.4 or the Expedited Procedures, as applicable, and, due to the Licensee’s failure to
comply with the procedures under Section 4.4 of the Expedited Procedures, as applicable, such approval is not provided prior to the applicable
required response date and Eisai is not able to obtain, through reasonable effort, an extension of such response date, Eisai may submit
such BLA or other material or substantive submission or communication to the FDA without such approval.

 

(c)
Subject to Section 3.2.2(d), Eisai shall notify the JDC reasonably in advance of the date of any anticipated meeting with the FDA relating
to the Existing Licensed Product for the CTCL Indication in the United States. The JDC shall agree in advance on the objectives to be
accomplished at, the agenda for, and, if appropriate, the script for, each such meeting. Upon the Licensee’s reasonable request,
Eisai shall, to the extent permitted by the FDA, permit the Licensee to attend meetings between Eisai and the FDA relating to the Existing
Licensed Product for the CTCL Indication in the United States and shall, if requested by Licensee, request that the FDA allow at least
one (1) representative of the Licensee to attend, and, to the extent provided in the applicable agreed agenda or script, participate
in such meetings. Eisai shall use good faith efforts to provide the Licensee with an opportunity to be present at, as an observer, to
the extent practical, any unscheduled or ad-hoc meetings with the FDA relating to the Existing Licensed Product for the CTCL Indication
in the United States, provided that if an applicable agenda or script is agreed to by both Parties prior to any unscheduled or
ad hoc meetings, Licensee may participate in such meetings to the extent provided therein.

 

(d)
Within [***] ([***]) after the Original Effective Date, senior regulatory representatives from each Party shall agree in good faith on
written expedited procedures for the approval of material or substantive submissions or communications to the FDA relating to the Existing
Licensed Product for the CTCL Indication in the United States or, with respect to any meeting with the FDA relating to the Existing Licensed
Product for the CTCL Indication in the United States, the objectives to be accomplished at, and the agenda for, and, if appropriate,
the script for, each such meeting, to the extent that an expedited review is necessary to enable Eisai to comply with Applicable Law
or requirements of the FDA (such matters “Expedited Matters” and such procedures, “Expedited Procedures”).
The allocation of final-decision making authority between the Parties with respect to the Expedited Matters shall be the same as the
allocation set forth in Section 4.4.2(g) with respect to US CTCL Regulatory Matters. Each Party shall comply with the applicable Expedited
Procedures with respect to each Expedited Matter.

 

    28

    

    

 

(e)
Licensee shall reimburse Eisai for its United States CTCL Regulatory Costs. Eisai shall report to Licensee, within [***] ([***]) days
after the end of each Calendar Quarter, the United States CTCL Regulatory Costs incurred by Eisai or any of its Affiliates during such
Calendar Quarter. Each such report shall (i) specify in reasonable detail all amounts included in such United States CTCL Regulatory
Costs during such Calendar Quarter (broken down by activity) and the corresponding budgeted expenses for such Calendar Quarter and (ii)
include an invoice for United States CTCL Regulatory Costs incurred by Eisai or any of its Affiliates during such Calendar Quarter and
copies of any invoices or other supporting documentation for any payments to a Third Party (including filings fees) that individually
exceed [***] Dollars ($[***]) (or such other amount approved by the JSC). Eisai agrees to provide upon request copies of invoices and
details to Licensee on any invoices not otherwise submitted to Licensee to enable Licensee to comply with its tax, auditing and other
obligations. The Parties shall seek to resolve any questions related to such reports within [***] ([***]) days following the Licensee’s
receipt of Eisai’s report hereunder. Within [***] ([***]) days after the later of (A) the receipt of any report and (B) the resolution
of any questions with respect to any report, Licensee shall reimburse Eisai for the United States CTCL Regulatory Costs set forth in
such report; it being understood and agreed that all undisputed amounts shall be payable within [***] ([***]) days after the receipt
of the applicable report referred to in clause (A) above.

 

3.2.3.
Transfer of BLA and INDs. Promptly after the earlier of (a) Regulatory Approval of the Existing Licensed Product in the United States
for the CTCL Indication and (b) Eisai’s receipt of a complete response letter from the FDA with respect to the BLA filed by Eisai
with the FDA for the Existing Licensed Product for the CTCL Indication, Eisai shall assign, and shall cause its Affiliates to assign,
to the Licensee all of Eisai’s and its Affiliates’ right, title and interest in and to such BLA and any INDs with respect
to the Existing Licensed Product in the Licensee Territory and all related Regulatory Documentation with respect thereto; provided,
that with respect to a complete response letter that only identifies minor deficiencies with respect to the BLA for the Existing Licensed
Product in the United States for the CTCL Indication, then, at the Licensee’s option, Eisai shall either (x) assign, and shall
cause its Affiliates to assign, to the Licensee all of Eisai’s and its Affiliates’ right, title and interest in and to such
BLA and any INDs with respect to the Existing Licensed Product in the Licensee Territory and all related Regulatory Documentation with
respect thereto or (y) retain such BLA and any INDs and use Commercially Reasonable Efforts to resubmit such BLA to correct such deficiency.
Where Licensee elects to have Eisai retain such BLA and INDs and use Commercially Reasonable Efforts to resubmit such BLA to correct
minor deficiencies, the first sentence of this Section 3.2.3 shall apply with respect to additional FDA action. During the [***] ([***])
months after any such assignment, at the Licensee’s reasonable request, Eisai shall provide the Licensee reasonable knowledge transfer
and support as necessary for the Licensee to Develop Licensed Products in the Field in the Licensee Territory or prepare, obtain and
maintain any Regulatory Approvals for the Licensed Products in the Field in the Licensee Territory; provided, that in no event
shall Eisai be required to provide the Licensee more than [***] ([***]) hours of such knowledge transfer and support. For clarity, Eisai’s
support obligations with respect to the transfer of the Manufacturing Process shall be as set forth in Section 3.5.2. The Licensee shall
reimburse Eisai for the FTE Costs incurred and the direct out-of-pocket costs recorded as an expense, in accordance with GAAP, by or
on behalf of Eisai or any of its Affiliates pursuant to this Section 3.2.3 within [***] ([***]) days after receipt of an invoice with
respect thereto. Save as otherwise agreed by the Parties, the JSC shall be responsible for discussing, planning and coordinating any
technical transfer services pursuant to this Section 3.2.3 and any responses to a complete response letter from the FDA with respect
to the BLA filed by Eisai.

 

    29

    

    

 

3.2.4.
Access to Regulatory Documentation. Except to the extent prohibited by Applicable Law, and without limiting Section 3.1.10, each
Party shall, promptly following receipt of a request from the other Party, deliver to the other Party a copy of all Regulatory Documentation
Controlled by the first Party or any of its Affiliates which relates to the Licensed Compound or Licensed Products in the Field in the
other Party’s Territory and which the requesting Party requires to, or which are necessary or reasonably useful for the requesting
Party to, exercise the rights granted to it under Section 2.1.1 or Section 2.2, as applicable.

 

3.2.5.
[Intentionally left blank.]

 

3.2.6.
Communications and Filings with Regulatory Authorities. The provisions of this Section 3.2.6 shall not apply with respect to Eisai’s
activities under Section 3.2.2(a), which shall be governed by Section 3.2.2(b), Section 3.2.2(c) or Section 3.2.2(d), as applicable.
Each Party shall, subject to Applicable Law and except to the extent a need for exigent action prevents it from doing so, provide the
other Party with copies of each Drug Approval Application or other submission or communication to a Regulatory Authority relating to
the Licensed Compound or a Licensed Product in its own Territory a reasonable amount of time prior to the anticipated date for the submission
or communication to allow the other Party to review and comment on such Drug Approval Application, submission or communication, and the
first Party shall consider all reasonable comments and proposed revisions from the other Party in good faith in connection with effecting
such submission or communication. The first Party shall consult with the other Party regarding, and keep the other Party reasonably informed
of, the status of the preparation of all Drug Approval Applications it submits relating to a Licensed Product, Regulatory Authority review
of any such Drug Approval Application, and all approvals of Drug Approval Applications or other Regulatory Approvals and other submissions
(including INDs) that it obtains with respect to a Licensed Product in its Territory. Upon the other Party’s reasonable request,
and subject to Applicable Law, the first Party shall provide to the other Party full, complete and correct copies of all final Drug Approval
Applications it submits in its Territory. The first Party shall consult with the other Party reasonably in advance of the date of any
anticipated meeting with a Regulatory Authority relating to the Licensed Compound or a Licensed Product and shall consider any timely
and reasonable recommendations made by the other Party in preparation for such meeting. Upon the other Party’s reasonable request,
the first Party shall, to the extent permitted by the relevant Regulatory Authority, permit the other Party to attend particular meetings
between the first Party and any Regulatory Authority in the first Party’s Territory relating to the Licensed Compound or a Licensed
Product if such meeting is anticipated to address a matter that does, or may be reasonably expected to, impact the Exploitation of the
Licensed Compound or a Licensed Product in the other Party’s Territory and shall, where necessary, request that the applicable
Regulatory Authority allow at least one (1) representative of the other Party to attend, solely as an observer, such meetings; provided
that the foregoing shall not apply to informal meetings or unscheduled teleconferences or meetings or teleconferences otherwise intended
by the Regulatory Authority to be between it and the first Party’s representatives only. The other Party shall strictly follow
the first Party’s instructions with respect to any such meeting that it attends pursuant to this Section 3.2.6 and shall not discuss
the contents of any such meeting with any Regulatory Authority in the first Party’s Territory except as required by Applicable
Law or authorized by the first Party in writing.

 

    30

    

    

 

3.2.7.
Recalls, Suspensions or Withdrawals. Each Party shall notify the other Party promptly following its determination that any event,
incident or circumstance has occurred that may result in the need for a recall, market suspension, or market withdrawal of a Licensed
Product in the Field in the first Party’s Territory and shall include in such notice the reasoning behind such determination and
any supporting facts. As between the Parties, the first Party shall have the right to make the final determination whether to voluntarily
implement any such recall, market suspension, or market withdrawal in the Field in its Territory; provided that prior to any implementation
of such a recall, market suspension, or market withdrawal, the first Party shall consult with the other Party and shall consider the
other Party’s reasonable comments in good faith. If a recall, market suspension, or market withdrawal of a Licensed Product in
the Field in a Party’s Territory is mandated by a Regulatory Authority in such Territory, then, as between the Parties, such Party
shall initiate such a recall, market suspension, or market withdrawal in compliance with Applicable Law. For all recalls, market suspensions,
or market withdrawals undertaken pursuant to this Section 3.2.7, each Party shall, as between the Parties, be solely responsible for
the execution and costs thereof in its own Territory.

 

3.2.8.
Pharmacovigilance Agreement; Global Safety Database. No later than the earlier of (a) the date that is [***] ([***]) months before
the date Licensee files an IND for a clinical study with respect to any Licensed Product and (b) the date that Eisai files the BLA for
the Existing Licensed Product for the CTCL Indication in the United States, the Parties shall enter into a separate written pharmacovigilance
agreement providing details related to managing and reporting adverse events in respect of the Licensed Compound or any Licensed Product
that occur during clinical studies and other safety and reporting practices and procedures in compliance with all Applicable Laws. Each
Party shall, at its sole cost, establish, hold and maintain the safety database for Licensed Products in its respective Territory. Each
Party shall provide the other Party with information in the possession and Control of the first Party as necessary for the other Party
to comply with its pharmacovigilance responsibilities in respect of the Licensed Compound and the Licensed Products in its Territory,
including, as applicable, any adverse drug experiences (including those events or experiences that are required to be reported to the
FDA under 21 C.F.R. section 312.32 or 600.80 or to foreign Regulatory Authorities under corresponding Applicable Law outside the United
States) from pre-clinical or clinical laboratory, animal toxicology and pharmacology studies, clinical studies, and commercial experiences
with a Licensed Product, in each case, in the form reasonably requested by the other Party.

 

3.3.
Commercialization.

 

3.3.1.
Responsibility. The Licensee shall, as between the Parties, be solely responsible for the Commercialization of the Licensed Products
in the Field throughout the Licensee Territory at the Licensee’s own cost and Eisai shall, as between the Parties, be solely responsible
for the Commercialization of the Licensed Products throughout the Eisai Territory at Eisai’s own cost. The Licensee shall use Commercially
Reasonable Efforts to Commercialize a Licensed Product in the United States for the CTCL Indication.

 

3.3.2.
Booking of Sales; Distribution. Each Party shall be responsible for invoicing and booking sales, establishing all terms of sale (including
pricing and discounts), and warehousing and distributing the Licensed Products (including Licensed Products that are used in concomitant
or sequential administration with a Licensee Proprietary Product or an Eisai Proprietary Product, as the case may be) in the Field in
its Territory and performing or causing to be performed all related services. Subject to Section 3.2.7, each Party shall handle all returns,
recalls or withdrawals, order processing, invoicing, collection, distribution, and inventory management with respect to the Licensed
Products in the Field in its Territory.

 

    31

    

    

 

3.3.3.
Commercialization Plans.

 

(a)
At least [***] ([***]) days prior to the anticipated first commercial sale of a Licensed Product in the Licensee Territory, the Licensee
shall provide the JCC with a copy of its plan for the Commercialization of the Licensed Products in the Licensee Territory (the “Licensee
Territory Commercialization Plan”). At least once each Contract Year, the Licensee shall provide the JCC with an updated Licensee
Territory Commercialization Plan that reflects all amendments and updates to the previously provided Licensee Territory Commercialization
Plan.

 

(b)
At least [***] ([***]) days prior to the anticipated first commercial sale of a Licensed Product in the Eisai Territory, Eisai shall
provide the JCC with a copy of its plan for the Commercialization of the Licensed Products in the Eisai Territory (the “Eisai
Territory Commercialization Plan”). At least once each Contract Year, Eisai shall provide the JCC with an updated Eisai Territory
Commercialization Plan that reflects all amendments and updates to the previously provided Eisai Territory Commercialization Plan.

 

3.3.4.
Commercialization Reports. Within [***] ([***]) days of the end of the first and third Calendar Quarter of each Contract Year during
which the Licensee is conducting Commercialization activities hereunder, the Licensee shall provide the JSC with reasonably detailed
written reports of the Commercialization activities it has performed, or caused to be performed, in respect of the Licensed Product since
the preceding report (or, with respect to the first such report, since the Original Effective Date), and the future Commercialization
activities it expects to initiate in respect of the Licensed Product during the following twelve (12)-month period.

 

3.4.
Compliance with Applicable Law. Each Party shall, and shall cause its Affiliates to, comply with all Applicable Law with respect
to the Exploitation of Licensed Products.

 

3.5.
Supply of Licensed Compound and Licensed Products.

 

3.5.1.
In General. As between the Parties, each Party shall, at its own cost, be solely responsible for the Manufacture and supply of the
Licensed Compound and Licensed Products for all of its Development and Commercialization activities under this Agreement. Subject to
Section 3.5.3 and Section 3.5.4, neither Party shall have any obligation to supply the other Party with any quantities of Licensed Compound
or Licensed Product. Promptly after the Original Effective Date, the Parties shall discuss in good faith the Manufacture and supply plan
for the Licensed Compound and the Existing Licensed Product for Commercialization in the Licensee Territory, which shall take into account
the Manufacturing Process transfer as set forth in Section 3.5.2 and as well as timing of approval of additional permitted Manufacturing
sites that Licensee may designate.

 

    32

    

    

 

3.5.2.
Manufacturing Process Transfer. Eisai shall, when and as reasonably requested by the Licensee in writing, transfer, at the Licensee’s
sole expense, to the Licensee or its permitted designee (which designee may be an Affiliate, Sublicensee or a permitted Third Party manufacturer)
the Know-how related to the then-current process for the Manufacture of the Licensed Compound and the Existing Licensed Product (the
“Manufacturing Process”) and, subject to Section 3.1.8, Regulatory Documentation. In addition, Eisai shall, as reasonably
requested by the Licensee and subject to this Section 3.5.2, provide such support, at the Licensee’s sole expense, as may be necessary
or reasonably useful to the Licensee or its designee to use and practice the Manufacturing Process (the “Manufacturing Transfer
Services”). The Licensee shall reimburse Eisai for the FTE Costs incurred and the direct out-of-pocket costs recorded as an
expense, in accordance with GAAP, by or on behalf of Eisai or any of its Affiliates related to the transfer of the Manufacturing Process
or provision of Manufacturing Transfer Services within [***] ([***]) days after receipt of an invoice with respect thereto. Save as otherwise
agreed by the Parties, the JMC shall be responsible for discussing, planning and coordinating any technical transfer services pursuant
to this Section 3.5.2.

 

3.5.3.
Clinical Supply Agreement. Eisai shall have the right at any time upon written notice to the Licensee to elect to have the Licensee
supply Eisai with some or all of its requirements of Licensed Products for its Development activities under this Agreement. If Eisai
provides such notice to the Licensee, then the Parties shall, through the JMC, use diligent efforts to negotiate and execute a manufacturing
and supply agreement pursuant to which the Licensee, or its designated subcontractor, Sublicensee or Affiliate, would supply Licensed
Products to Eisai for its Development activities under this Agreement (the “Clinical Supply Agreement”), and a related
quality agreement (the “Clinical Quality Agreement”) within [***] ([***]) days after Eisai provides such notice. The
Clinical Supply Agreement and Clinical Quality Agreement shall contain terms and conditions that are usual and customary for a clinical
supply agreement or related quality agreement, as applicable, between companies in the pharmaceutical/biological industry of comparable
size and expertise to the respective Parties; provided, that purchase price payable by Eisai to the Licensee for Licensed Products
under the Clinical Supply Agreement shall be equal to the Licensee’s Cost of Goods for such Licensed Products.

 

3.5.4.
Eisai Territory Commercial Supply Agreement. Eisai shall have the right at any time upon written notice to the Licensee to elect
to have the Licensee supply Eisai with some or all of its requirements of Licensed Compound or Licensed Products for Commercialization
in the Eisai Territory. If Eisai provides such notice to the Licensee, then the Parties shall, through the JMC, use diligent efforts
to negotiate and execute a manufacturing and supply agreement pursuant to which the Licensee, or its designated subcontractor, Sublicensee
or Affiliate, would supply Licensed Compound or Licensed Products to Eisai for Commercialization in the Eisai Territory (the “Eisai
Territory Commercial Supply Agreement”), and a related quality agreement (the “Eisai Territory Commercial Quality
Agreement”) within [***] ([***]) days after Eisai provides such notice. The Eisai Territory Commercial Supply Agreement and
Eisai Territory Commercial Quality Agreement shall contain terms and conditions that are usual and customary for a commercial supply
agreement or related quality agreement, as applicable, between companies in the pharmaceutical/biological industry of comparable size
as expertise to the respective Parties.

 

    33

    

    

 

3.5.5.
Failure to Agree on Supply Agreement or Quality Agreement. If a Supply Agreement (or related Quality Agreement) has not been agreed
and executed within the applicable period set forth in Section 3.5.3 or Section 3.5.4, as applicable, then the determination of the final
terms and conditions of such Supply Agreement (or related Quality Agreement) shall be subject to the applicable dispute resolution procedures
in Section 4.4.2(g).

 

3.6.
Subcontracting. Eisai may subcontract with a Third Party to perform any or all of its rights or obligations hereunder. The Licensee
may subcontract with a Third Party to perform any or all of its rights or obligations hereunder (including by appointing one (1) or more
distributors); provided that any subcontracting by the Licensee that would involve the disclosure of any Eisai Trade Secret shall
be subject to the prior written consent of Eisai, which may be withheld, conditioned or delayed in its sole discretion.

 

3.7.
Assumption of Activities upon a Change of Control of Eisai. If Eisai undergoes a Change of Control prior to the completion of the
‘302 Development Activities or the CMC Development Activities or the assignment of the BLA and INDs to the Licensee pursuant to
Section 3.2.3, then not later than [***] ([***]) Business Days following the public announcement of such Change of Control of Eisai,
Eisai shall provide written notice to the Licensee of such transaction. In the event of any such Change of Control, the Licensee shall
have the right, in its sole discretion, to (a) assume control of (i) the ‘302 Development Activities and the CMC Development Activities
and (ii) obtaining Regulatory Approval of the Existing Licensed Products in the United States for the CTCL Indication and (b) have the
BLA and INDs assigned to the Licensee, by notifying Eisai of such election within [***] ([***]) days after receipt of such notice. If
the Licensee makes such election, then:

 

(a)
Eisai shall use Commercially Reasonable Efforts to effect a smooth and orderly transition of the ‘302 Development Activities and
the CMC Development Activities to the Licensee and the Licensee shall thereafter use Commercially Reasonable Efforts to perform such
activities;

 

(b)
the Licensee shall use Commercially Reasonable Efforts to obtain Regulatory Approval of the Existing Licensed Product in the United States
for the CTCL Indication, and the provision of Section 3.2.2 shall apply mutatis mutandis;

 

(c)
the Parties shall enter into good faith negotiations with regard to compensating the Licensee for any expenses the Licensee may incur
due to the Licensee’s assumption of the control of the ‘302 Development Activities or the CMC Development Activities;

 

(d)
Eisai shall no longer have any obligations under Section 3.1.2, Section 3.1.3 or Section 3.2.2;

 

    34

    

    

 

(e)
Eisai shall assign the BLA (or any in-process draft BLA, if applicable) and INDs to the Licensee pursuant to Section 3.2.3;

 

(f)
  notwithstanding Section 4.4.2(a), the Licensee shall have the right to make the final decision with respect to the Development
Plans, unless such amendment would decrease the scope of the activities to be performed under the Development Plans, in which case the
proposed amendment shall be deemed rejected; and

 

(g)
notwithstanding Section 4.4.2(g), the Licensee shall have the right to make the final decision on any US CTCL Regulatory Matter.

 

ARTICLE
4

GOVERNANCE

 

4.1.
Joint Steering Committee. Within [***] ([***]) days after the Original Effective Date, the Parties shall establish a joint committee
(the “Joint Steering Committee” or “JSC”), which shall consist of at least two (2) executive-level
representatives from each of the Parties, each with the requisite experience and seniority to enable such person to make decisions on
behalf of the Party it represents with respect to the issues falling within the jurisdiction of the JSC; provided, that no Senior
Officer may be a representative to the JSC. Simultaneously with establishing the JSC, the Parties shall identify their initial representatives.
From time to time, each Party may substitute one (1) or more of its representatives to the JSC with a suitably qualified substitute on
written notice to the other Party. The JSC shall have the responsibilities and authority allocated to it in this Section 4.1 and shall
operate by the procedures set forth in Section 4.3. Neither the JSC nor any Joint Subcommittee shall have any decision-making authority
other than as explicitly set forth in this Section 4.1 or Section 4.2, as applicable, and all such decision-making authority shall be
subject to the dispute resolution procedures in Section 4.4. The JSC shall:

 

4.1.1.
review and approve any and all amendments to the ‘302 Development Plan or the CMC Development Plan(for the avoidance of doubt,
the JSC will not be responsible for managing or controlling ‘302 Development Activities or CMC Development Activities);

 

4.1.2.
review and approve the regulatory strategy for Licensed Products in the Licensee Territory;

 

4.1.3.
review and approve the initial Licensee Territory Development Plan, the initial Eisai Territory Development Plan and any and all
updates or amendments to either of the foregoing;

 

4.1.4.
discuss whether any proposed Development activities under the Licensee Territory Development Plan or the Eisai Territory Development
Plan should be jointly funded by the Parties;

 

4.1.5.
review and approve the regulatory strategy for Licensed Products in the Eisai Territory;

 

    35

    

    

 

4.1.6.
 review and discuss the proposed labeling of each Licensed Product in each country in either Territory;

 

4.1.7.
monitor the performance of the Development of the Licensed Compound and Licensed Products in the Field in the Licensee Territory
and Eisai Territory, including by reviewing the conduct of the Development activities and reviewing Development reports as provided in
Section 3.1.10;

 

4.1.8.
monitor the performance of the Commercialization of Licensed Products in the Field in the Licensee Territory and Eisai Territory,
including by reviewing the conduct of the Commercialization activities and reviewing Commercialization reports as provided in Section
3.3.3;

 

4.1.9.
serve as a forum for discussing matters, and attempting to resolve disputes, disagreements or other issues arising under this Agreement
and referred by the Parties that the Joint Subcommittees or Alliance Managers are unable to resolve;

 

4.1.10.
coordinate the Parties’ activities under this Agreement;

 

4.1.11.
discuss, plan and coordinate any technical transfer services pursuant to Section 3.2.3 or Section 3.5.2 not otherwise planned or
coordinated by the JDC or JMC;

 

4.1.12.
if Licensee elects the India Option pursuant to Section 2.7, discuss feasibility of Eisai or its Affiliates co-promoting or co-marketing
the Licensed Products in India;

 

4.1.13.
resolving Final ‘302 Development Report Disputes and Final CMC Development Report Disputes; and

 

4.1.14.
perform such other functions as are set forth herein or as the Parties may mutually agree in writing, except where in conflict with
any provision of this Agreement.

 

4.2.
Joint Subcommittees. Within fifteen (15) days after the Original Effective Date, the Parties shall establish (a) a joint development
committee (“Joint Development Committee” or “JDC”), (b) a joint manufacturing committee (“Joint
Manufacturing Committee” or “JMC”), and (c) a joint intellectual property committee (“Joint IP
Committee” or “JIPC”). The JSC may, at its option establish a joint commercialization committee (“Joint
Commercialization Committee” or “JCC,” and together with the JDC, JMC and JIPC, the “Joint Subcommittees”).
Each Joint Subcommittee shall consist of (i) with respect to the JDC and JMC, at least two (2) representatives from each of the Parties,
and (ii) with respect to the JIPC and JCC, at least one (1) representative from each of the Parties, in each case ((i) and (ii)), each
with the requisite experience to enable such person to make decisions on behalf of the Parties with respect to the issues falling within
the jurisdiction of the relevant Joint Subcommittee; provided, that no Senior Officer may be a representative to a Joint Subcommittee.
Simultaneously with establishing each such Joint Subcommittee, the Parties shall identify their initial representatives to such Joint
Subcommittee. Each Subcommittee shall have the responsibilities and authority allocated to it in this Section 4.2 and shall operate by
the procedures set forth in Section 4.3. If any Joint Subcommittee is not established, then the JSC shall have the responsibilities allocated
to such Joint Subcommittee and any reference to such Joint Subcommittee in this Agreement shall be deemed to be a reference to the JSC.
No Joint Subcommittee shall have authority that exceeds the authority granted to the JSC.

 

    36

    

    

 

4.2.1.
Joint Development Committee. The JDC shall have the following responsibilities:

 

(a)
develop the overall strategic objectives and plans, including objectives and plans with respect to Regulatory Approval(s), for the Development
of the Licensed Products in the Field in the Licensee Territory and Eisai Territory and submit the same to the JSC for review and approval,
if applicable;

 

(b)
except with respect to Expedited Matters, which shall be reviewed and approved in accordance with the applicable Expedited Procedures,
review and approve (i) the BLA for, and any other material or substantive submissions or communications to the FDA relating to the Existing
Licensed Product for the CTCL Indication in the United States and (ii) with respect to any meeting with the FDA relating to, the Existing
Licensed Product for the CTCL Indication in the United States, the objectives to be accomplished at, the agenda for, and, if appropriate,
the script for, each such meeting (such review and approval responsibilities, “US CTCL Regulatory Matters”);

 

(c)
oversee and coordinate the transfer of Know-how, Regulatory Documentation and other documents pursuant to Section 2.9 that are not related
to the Manufacturing Process;

 

(d)
review and approve clinical protocols for any clinical trial to be conducted by or on behalf of either Party under this Agreement;

 

(e)
review Eisai Territory Development Plan with respect to activities that may impact the Licensee Territory;

 

(f)
  review Licensee Territory Development Plan with respect to activities that may impact the Eisai Territory; and

 

(g)
after the execution of the pharmacovigilance agreement pursuant to Section 3.2.8, oversee global safety data exchange and pharmacovigilance-related
matters for the Licensed Products in accordance with such agreement.

 

4.2.2.
Joint Manufacturing Committee. The JMC shall have the following responsibilities (for the avoidance of doubt, the JMC will not be
responsible for managing or controlling CMC Development Activities):

 

(a)
oversee any manufacturing technical transfer services pursuant to Section 3.5.2;

 

    37

    

    

 

(b)
oversee and coordinate the transfer of Know-how, Regulatory Documentation and other documents pursuant to Section 2.9 that are related
to the Manufacturing Process;

 

(c)
manage the supply chain for the Licensed Compound and Licensed Products;

 

(d)
negotiate and determine the final terms and conditions of any Supply Agreement (or related Quality Agreement) elected by Eisai in accordance
with Section 3.5.3 or Section 3.5.4, as applicable; and

 

(e)
serve as a forum for discussing any quality-related issues with respect to the Licensed Compound or Licensed Products.

 

4.2.3.
Joint Commercialization Committee. The JCC shall have the following responsibilities:

 

(a)
discuss and review the Licensee Territory Commercialization Plan and the Eisai Territory Commercialization Plan;

 

(b)
discuss any new Trademark (other than an Eisai Trademark or any Corporate Name) that the Licensee wishes to use on or in connection with
the Exploitation of any Licensed Product in the Licensee Territory; and

 

(c)
discuss any new Trademark (other than a Licensee Trademark, Eisai Trademark or any Corporate Name) that Eisai wishes to use on or in
connection with the Exploitation of any Licensed Product anywhere in the world.

 

4.2.4.
Joint Intellectual Property Committee. The JIPC shall have the following responsibilities:

 

(a)
determine the worldwide strategy for the prosecution and maintenance of the Eisai Patents and the Licensee Patents to maximize the commercial
potential of the Licensed Products (the “IP Strategy”); and

 

(b)
discuss and agree with respect to ownership of any inventions that are conceived, discovered, developed or otherwise made jointly by
or on behalf of Eisai or its Affiliates or its or their (sub)licensees, as applicable, on the one hand, and Licensee, or its Affiliates
or its or their (sub)licensees, as applicable, in each case, under or in connection with this Agreement and the responsibility for the
prosecution, maintenance, enforcement and defense of any Patents with respect thereto.

 

    38

    

    

 

4.3.
General Provisions Applicable to Committees.

 

4.3.1.
Meetings and Minutes. The JSC and any Joint Subcommittee (each, a “Committee”) shall meet (a) with respect to
the JSC, not less than once every [***] ([***]) months and (b) with respect to any Joint Subcommittee, at least once each Calendar Quarter,
in each case of ((a) and (b)), unless otherwise agreed by the Parties. The location of such meetings shall alternate between locations
designated by the Licensee and locations designated by Eisai. The chairman of the JSC for the Contract Year of the Original Effective
Date and the chairman of each Joint Subcommittee for the Contract Year in which such Joint Subcommittee was created shall be appointed
by Eisai, and thereafter the power to appoint the chairman shall alternate each Contract Year between the Licensee and Eisai. The chairperson
of each Committee shall be responsible for calling meetings on no less than [***] ([***]) Business Days’ notice unless exigent
circumstances require shorter notice. The chairman of a Committee shall call a meeting of such Committee promptly upon the reasonable
request of the other Party. Each Party shall make all proposals for agenda items at least [***] ([***]) Business Days in advance of the
applicable meeting and shall provide all appropriate information with respect to such proposed items at least [***] ([***]) Business
Days in advance of the applicable meeting; provided that under exigent circumstances requiring input by a Committee a Party may
provide its agenda items to the other Party within a shorter period of time in advance of the meeting (or at the meeting) or may propose
that there not be a specific agenda for a particular meeting, so long as the other Party consents to such later addition of such agenda
items or the absence of a specific agenda for such meeting (which consent shall not be unreasonably withheld, conditioned or delayed).
The chairperson of each Committee shall arrange for the preparation and circulation for review and approval of the Parties minutes of
each meeting within [***] ([***]) days of the meeting. The Parties shall agree on the minutes of each meeting promptly, but in any event
prior to the next meeting of such Committee.

 

4.3.2.
Procedural Rules. Each Committee shall have the right to adopt such standing rules as shall be necessary for its work, to the extent
that such rules are not inconsistent with this Agreement. A quorum of a Committee shall exist whenever there is present at a meeting
at least one (1) representative appointed by each Party. Representatives of the Parties on each Committee may attend a meeting either
in person or by telephone, video conference or similar means in which each participant can hear what is said by, and be heard by, the
other participants. Representation by proxy shall be allowed. Subject to Section 4.4.3 and, with respect to the JSC, Section 4.4.1, each
Committee shall take action by unanimous consensus of the representatives present at a meeting at which a quorum exists. Alliance Managers
or other employees or consultants of a Party who are not representatives of the Parties on a Committee may attend meetings of such Committee,
as applicable; provided, however, that such attendees: (a) shall not vote or otherwise participate in the decision-making process
of such Committee; and (b) are bound by obligations of confidentiality and non-disclosure at least as protective of the other Party as
those set forth in Article 7.

 

4.4.
JSC and Joint Subcommittee Dispute Resolution.

 

4.4.1.
Unresolved Joint Subcommittee Matters. If any Joint Subcommittee is unable to reach a consensus with respect to any matter under
the jurisdiction of such Joint Subcommittee within [***] ([***]) Business Days of initially considering such matter (each an “Unresolved
Joint Subcommittee Matter”), then the Unresolved Joint Subcommittee Matter shall be referred to the JSC.

 

4.4.2.
Unresolved JSC Matters. Except as provided otherwise in Section 3.5.5, if the JSC is unable to reach a consensus with respect to
any matter under the jurisdiction of the JSC within [***] ([***]) Business Days of initially considering such matter (each an “Unresolved
JSC Matter”), then

 

    39

    

    

 

(a)
subject to Section 3.7(e), if the Unresolved JSC Matter relates to the approval of any amendment to the Development Plans, or the approval
of any clinical protocol for any clinical trial set forth therein, such Unresolved JSC Matter shall be referred to the Senior Officers
for attempted resolution by good faith negotiations during a period of [***] ([***]) Business Days from the date of such referral, or
such longer period as the Senior Officers may agree in writing. Any final decision mutually agreed to in writing by the Senior Officers
shall be conclusive and binding on the Parties. If such Senior Officers are unable to reach a decision regarding such Unresolved JSC
Matter within such [***] ([***])-Business Day period (or such longer period as the Senior Officers may agree in writing), then the Licensee
shall have the right to make the final decision on such Unresolved JSC Matter unless: (i) such amendment would decrease the scope of
the activities to be performed under the Development Plans, or (ii) with respect to any amendment that is not required by the FDA in
order to obtain or maintain an approved BLA for the Existing Licensed Product for the CTCL Indication in the United States, (A) Eisai
would need to hire additional personnel to implement such amendment without impacting any other programs of Eisai or any of its Affiliates,
(B) such amendment would require that Eisai or any of its Affiliates purchase or acquire access to any additional equipment or Intellectual
Property Rights, or (C) such amendment would reasonably be expected to adversely impact patient safety as demonstrated by written scientific
evidence, in which case ((i) or (ii)), the proposed amendment shall be deemed rejected;

 

(b)
subject to Section 4.4.2(d) and Section 4.4.2(g), if the Unresolved JSC Matter relates to (i) the regulatory strategy for the Licensee
Territory or (ii) the approval of the initial Licensee Territory Development Plan or any amendment thereto, or the approval of any clinical
protocol for any clinical trial set forth therein, in either case ((i) or (ii)),the Licensee shall have the right to make the final decision
on such Unresolved JSC Matter;

 

(c)
subject to Section 4.4.2(e), if the Unresolved JSC Matter relates to (i) the regulatory strategy for the Eisai Territory or (ii) the
approval of the initial Eisai Territory Development Plan or any amendment thereto, or the approval of any clinical protocol for any clinical
trial set forth therein, in either case ((i) or (ii)), Eisai shall have the right to make the final decision on such Unresolved JSC Matter;

 

(d)
if the Unresolved JSC Matter relates to the initiation or continuation of any Development activities under the Licensee Territory Development
Plan that Eisai reasonably believes may result in unreasonable safety risks for patients or subjects, then such activity shall, as applicable,
either not be initiated by or on behalf of the Licensee or shall be terminated by the Licensee as promptly as possible in accordance
with Applicable Law and with due regard to patient safety;

 

(e)
if the Unresolved JSC Matter relates to the initiation or continuation of any Development activities under the Eisai Territory Development
Plan that Licensee reasonably believes may result in unreasonable safety risks for patients or subjects, then such activity shall, as
applicable, either not be initiated by or on behalf of the Eisai or shall be terminated by the Eisai as promptly as possible in accordance
with Applicable Law and with due regard to patient safety;

 

    40

    

    

 

(f) 
if the Unresolved JSC Matter relates to the IP Strategy for a Patent, then the Prosecuting Party with respect to such Patent shall have
the right to make a final decision regarding the strategy for the prosecution and maintenance of such Patent;

 

(g)
subject to Section 3.7(f), if the Unresolved JSC Matter relates to any US CTCL Regulatory Matter, any Final ‘302 Development Report
Dispute or any Final CMC Development Report Dispute, such Unresolved JSC Matter shall be referred to the Senior Officers for attempted
resolution by good faith negotiations during a period of [***] ([***]) Business Days from the date of such referral, or such longer period
as the Senior Officers may agree in writing. Any final decision mutually agreed to in writing by the Senior Officers shall be conclusive
and binding on the Parties. If such Senior Officers are unable to reach a decision regarding such Unresolved JSC Matter within such [***]
([***])-Business Day period (or such longer period as the Senior Officers may agree in writing), then the Licensee shall have the right
to make the final decision on such Unresolved JSC Matter unless Eisai provides written, quantitative evidence that the Licensee’s
approach would reasonably be expected to (i) adversely impact patient safety as demonstrated by written scientific evidence; provided,
that this clause (i) shall not apply with respect to disputes regarding the proposed labeling for the Existing Licensed Product for the
CTCL Indication in the United States, (ii) result in the FDA not approving the BLA for the Existing Licensed Product for the CTCL Indication
in the United States or a substantial delay in such approval or (iii) materially adversely impact the reputation of Eisai or any of its
Affiliates, in which case ((i), (ii) or (iii)), Eisai shall have the right to make the final decision on such Unresolved JSC Matter;
provided that if Eisai undergoes a Change of Control, the exception to the Licensee’s final decision-making authority set forth
in the foregoing clause (ii) shall no longer apply;

 

(h)
if the Unresolved JSC Matter relates to a Supply Agreement or Quality Agreement, such Unresolved JSC Matter shall be referred to the
Senior Officers for attempted resolution by good faith negotiations during a period of [***] ([***]) Business Days from the date of such
referral, or such longer period as the Senior Officers may agree in writing. Any final decision mutually agreed to in writing by the
Senior Officers shall be conclusive and binding on the Parties. If such Senior Officers are unable to reach a decision regarding such
Unresolved JSC Matter within such [***] ([***])-Business Day period (or such longer period as the Senior Officers may agree in writing),
then no action shall be taken on such Unresolved JSC Matter; and

 

(i)
if the Unresolved JSC Matter involves any other matter, such Unresolved JSC Matter shall be referred to the Senior Officers for attempted
resolution by good faith negotiations during a period of [***] ([***]) Business Days from the date of such referral, or such longer period
as the Senior Officers may agree in writing. Any final decision mutually agreed to in writing by the Senior Officers shall be conclusive
and binding on the Parties. If such Senior Officers are unable to reach a decision regarding an Unresolved JSC Matter within such [***]
([***])-Business Day period (or such longer period as the Senior Officers may agree in writing), then the Unresolved JSC Matter shall
be resolved through binding arbitration in accordance with Section 11.5.2.

 

    41

    

    

 

4.4.3.
Limitations on Authority. Without limitation to the foregoing, the Parties hereby agree that matters explicitly reserved to the consent,
approval or other decision-making authority of one (1) or both Parties, as expressly provided in this Agreement, are outside the jurisdiction
and authority of each Committee, including: (a) amendment, modification or waiver of compliance with this Agreement (which may only be
amended or modified as provided in Section 11.8 or compliance with which may only be waived as provided in Section 11.12 ); and (b) such
other matters as are reserved to the consent, approval, agreement or other decision-making authority of either or both Parties in this
Agreement that are not required by this Agreement to be considered by a Committee prior to the exercise of such consent, approval or
other decision-making authority. The JSC’s and each Joint Subcommittee’s role as a forum for reviewing, monitoring or discussing
items set out in Section 4.1 or Section 4.2, as applicable, shall not include any authority to make binding decisions regarding such
items.

 

4.5.
Discontinuation; Disbandment; Annual Reports. Each Committee shall continue to exist until the Parties mutually agree to disband
such Committee. Upon the occurrence of the foregoing: (a) such Committee shall disband, have no further responsibilities or authority
under this Agreement and will be considered dissolved by the Parties; and (b) any requirement of a Party to provide Know-how or other
materials to such Committee shall be deemed a requirement to provide such Know-how or other materials to the other Party and the Party
with final decision-making authority pursuant to Section 4.4.2 shall, after consultation with the other Party and taking the other Party’s
comments, if any, into consideration in good faith, have the right to decide all matters that were subject to the review or approval
by such Committee.

 

4.6.
Working Teams. From time to time, each Committee may establish and delegate duties to other subcommittees or working teams (each,
a “Working Team”) as it deems necessary to achieve the objectives of this Agreement; provided that: (a) each
such Working Team shall have equal representation from each Party; (b) the activities of such Working Team shall be subject to the oversight,
review and approval of, and shall report to, the Committee that established such Working Team; and (c) in no event shall the authority
of any such Working Team exceed that specified for the Committee that established such Working Team under this Agreement.

 

4.7.
Alliance Managers. Each Party shall appoint an individual (each an “Alliance Manager”) who shall oversee contact
between the Parties for all matters between meetings of the JSC and shall have such other responsibilities as the Parties may agree in
writing after the Original Effective Date. A Party may replace the individual serving as its Alliance Manager at any time by notice in
writing to the other Party. The Alliance Managers shall work together to manage and facilitate communication between the Parties under
this Agreement, including the resolution (in accordance with the terms of this Agreement) of issues between the Parties that arise in
connection with this Agreement. The Alliance Managers shall not have final decision-making authority with respect to any matter under
this Agreement.

 

    42

    

    

 

ARTICLE
5

 

PAYMENTS
AND RECORDS

 

5.1.
Upfront Payment. Licensee shall pay to Eisai the following consideration as an upfront payment, which shall be nonrefundable:

 

5.1.1.
US$[***] million shall be due and payable within [***] ([***]) days after September 29, 2017; and

 

5.1.2.
US$[***] million shall be due and payable within [***] ([***]) days after Eisai’s written notice to Licensee of Eisai’s
submission of the application for the Type C meeting with FDA related to CMC.

 

5.2.
Milestones.

 

5.2.1.
Development and Regulatory Milestones. In consideration of the rights granted by Eisai to the Licensee hereunder, the Licensee shall
pay to Eisai the following payments within [***] ([***]) days after the achievement of each of the following milestone events, which
shall be non-refundable, non-creditable and fully earned upon the achievement of the applicable milestone event:

 

	Milestone
    Event	Milestone
    Payment
	First
    approval by the FDA of a Biologics License Application (submitted under subsection (a) of Section 351 of the PHSA) for a Licensed
    Product for the CTCL Indication. 	US$6
    million, save that the payment shall be increased by US$1 million (to US$7 million in total) if, prior to approval by the FDA of
    the BLA for a Licensed Product, the Licensee exercises the India Option pursuant to Section 2.7.
	Achieving
    US$[***] in cumulative Net Sales of Licensed Products in the Licensee Territory. 	US$[***]
    million.
	Achieving
    US$[***] in cumulative Net Sales of Licensed Products in the Licensee Territory. 	US$[***]
    million.
	Achieving
    US$[***] in cumulative Net Sales of Licensed Products in the Licensee Territory.	US$[***]
    million.
	Achieving
    US$[***] in cumulative Net Sales of Licensed Products in the Licensee Territory; provided, that such milestone shall only
    be due and payable if occurring during the Extension Term.	US$[***]
    million.

 

The
milestone payments set out above shall each be payable only once in total, irrespective of the number of Licensed Products which are
the subject of a BLA (and the number of Indications for any single Licensed Product). The Parties acknowledge and agree that the [***]
dollar ($[***]) exclusivity fee paid to Eisai by the Licensee pursuant to that certain letter agreement between the Parties dated November
20, 2015, as amended and extended, shall be set-off against the first milestone payment made hereunder.

 

    43

    

    

 

5.2.2.
Determination That Milestones Have Occurred. The Licensee shall notify Eisai promptly of the achievement of each of the events identified
as a milestone event in Section 5.2.1 and Eisai shall invoice the Licensee for the corresponding milestone payment within [***] ([***])
days after receipt of such notice. In the event that, notwithstanding the fact that the Licensee has not provided Eisai such a notice,
Eisai believes that any such milestone has been achieved, it shall so notify the Licensee in writing and the Parties shall promptly meet
and discuss in good faith whether such milestone has been achieved. Any dispute under this Section 5.2.2 regarding whether or not such
a milestone has been achieved shall be subject to resolution in accordance with Section 11.5.

 

5.3.
Reports and Reconciliation. Following the first commercial sale of a Licensed Product in the Licensee Territory pursuant to this
Agreement until the payment of all milestone payments pursuant to Section 5.2.1, the Licensee shall, within [***] ([***]) days of the
end of each Contract Year, report to Eisai the Net Sales with respect to all Licensed Products in the Licensee Territory during such
Contract Year. Such report shall specify in reasonable detail all deductions in the calculation of Net Sales.

 

5.4.
Mode of Payment; Offsets. All payments to Eisai under this Agreement shall be made by deposit of Dollars in the requisite amount
to such bank account as Eisai may from time to time designate by notice to the Licensee. For the purpose of calculating any sums due
under, or otherwise reimbursable pursuant to, this Agreement (including the calculation of Net Sales), the Licensee shall convert any
amount expressed in a foreign currency into Dollar equivalents using its or its Affiliate’s, as applicable, standard conversion
methodology consistent with GAAP. The Licensee shall have no right to offset, set off or deduct any amounts from or against the amounts
due to Eisai hereunder.

 

5.5.
Taxes.

 

5.5.1.
General. The milestone payments and other amounts payable by the Licensee to Eisai pursuant to this Agreement (each a “Payment”)
shall be paid free and clear of any and all taxes (which, for clarity, shall be the responsibility of the Licensee), except for any withholding
taxes required by Applicable Law. Except as provided in this Section 5.4, Eisai shall be solely responsible for paying any and all taxes
(other than withholding taxes required by Applicable Law to be deducted from the Payments and remitted by the Licensee) levied on account
of, or measured in whole or in part by reference to, any Payments it receives. The Licensee shall deduct or withhold from the Payments
any taxes that it is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if Eisai is entitled under any
applicable tax treaty to a reimbursement of, reduction of rate of, or the elimination of, applicable withholding tax, it may deliver
to the Licensee or the appropriate Governmental Authority (with the assistance of the Licensee to the extent that this is reasonably
required and is requested in writing) the prescribed forms necessary to reimburse the withholding, reduce the applicable rate of withholding
or relieve the Licensee of its obligation to withhold such tax and the Licensee shall seek or issue such reimbursement, as applicable,
apply the reduced rate of withholding or dispense with withholding, as the case may be; provided that, in the case of any reduction
of rate of, or elimination of, applicable withholding tax, the Licensee has received evidence of Eisai’s delivery of all applicable
forms (and, if necessary, its receipt of appropriate governmental authorization) at least [***] ([***]) days prior to the time that the
applicable Payment is due. If, in accordance with the foregoing, the Licensee withholds any amount, it shall pay to Eisai the balance
when due, make timely payment to the proper taxing authority of the withheld amount and send to Eisai proof of such payment within [***]
([***]) days of such payment.

 

    44

    

    

 

5.5.2.
Value Added Tax. Notwithstanding anything contained in Section 5.5.1, this Section 5.5.2 shall apply with respect to value added
tax (“VAT”). All Payments are exclusive of VAT. If any VAT is chargeable in respect of any Payments, the Licensee
shall pay VAT at the applicable rate in respect of any such Payments following the receipt of a VAT invoice in the appropriate form issued
by Eisai in respect of those Payments, such VAT to be payable on the later of the due date of the payment of the Payments to which such
VAT relates and [***] ([***]) days after the receipt by the Licensee of the applicable invoice relating to that VAT payment.

 

5.6.
Interest on Late Payments. If any payment due under this Agreement is not paid when due, then the Licensee shall pay interest thereon
(before and after any judgment) at a rate (but with interest accruing on a daily basis) of [***] percent ([***]%) per annum or the maximum
rate allowable by Applicable Law, whichever is lower, such interest to run from the date on which payment of such sum became due until
payment thereof in full together with such interest.

 

5.7.
Financial Records. The Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, keep complete and accurate
financial books and records pertaining to the Commercialization of Licensed Products hereunder, including books and records of Net Sales,
in sufficient detail to calculate and verify all amounts payable hereunder. The Licensee shall, and shall cause its Affiliates and its
and their Sublicensees to, retain such books and records of Net Sales until the latest of: (a) the end of the Term; (b) [***] ([***])
years after the end of the period to which such books and records pertain; (c) the expiration of the applicable tax statute of limitations
(or any extensions thereof); and (d) such longer period as may be required by Applicable Law. The Licensee shall, and shall cause its
Affiliates and its and their Sublicensees to, retain such books and records (except books and records of Net Sales) until the latest
of: (x) [***] ([***]) years after the end of the period to which such books and records pertain; (y) the expiration of the applicable
tax statute of limitations (or any extensions thereof); and (z) such longer period as may be required by Applicable Law.

 

5.8.
Audit. At the request of Eisai, the Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, permit Eisai
or an independent auditor designated by Eisai and reasonably acceptable to the Licensee, at reasonable times and upon reasonable notice,
to audit the books and records maintained pursuant to Section 5.6 to ensure the accuracy of all reports and payments made hereunder,
provided that this may occur no more than one (1) time per Contract Year unless an audit reveals, with respect to a period, a
variance of more than [***] percent ([***]%) from the reported amounts for such period,
in which case Eisai or an independent auditor designated by Eisai may conduct an additional audit during such Contract Year. Upon its
completion, Eisai shall provide a copy of the final audit report to the Licensee. Except as provided below, the cost of the audit shall
be borne by Eisai, unless the audit reveals, with respect to a period, a variance of more than [***] percent ([***]%) from the reported
amounts for such period, in which case the Licensee shall bear the cost of the audit. For clarity, any second audit during a Contract
Year shall be at Eisai’s expense unless such audit reveals a variance of more than [***] percent ([***]%) from the reported amounts
for such period, in which case the Licensee shall bear the cost of the audit. Unless disputed pursuant to Section 5.9, if such audit
concludes that: (a) additional amounts were owed by the Licensee, the Licensee shall pay the additional amounts, with interest from the
date originally due as provided in Section 5.6; or (b) excess payments were made by the Licensee, Eisai shall reimburse such excess payments,
in either case ((a) or (b)), within [***] ([***]) days of the date on which such audit is completed by Eisai.

 

    45

    

    

 

5.9.
Audit Dispute. In the event of a dispute with respect to any audit under Section 5.8, Eisai and the Licensee shall work in good faith
to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within [***] ([***])
days, the dispute shall be submitted for resolution to a certified public accounting firm jointly selected by each Party’s certified
public accountants or to such other Person as the Parties shall mutually agree (the “Auditor”). The decision of the
Auditor shall be final and the costs of such proceeding as well as the initial audit shall be borne between the Parties in such manner
as the Auditor shall determine. Not later than [***] ([***]) days after such decision and in accordance with such decision, the Licensee
shall pay the additional amounts, with interest from the date originally due as provided in Section 5.6 or Eisai shall reimburse the
excess payments, as applicable.

 

ARTICLE
6

INTELLECTUAL PROPERTY

 

6.1.
Ownership of Intellectual Property.

 

6.1.1.
Ownership of Background Technology. Save as otherwise expressly set out in this Agreement, the Parties acknowledge and agree that
nothing in this Agreement shall transfer or license, or shall operate as an agreement to transfer or license, any right, title, or interest
in or to any Intellectual Property Rights owned by a Party or any of its Affiliates as of the Original Effective Date or otherwise licensed
to a Party, and all such Intellectual Property Rights shall remain the exclusive property of the Party or its applicable Affiliate owning
them (or, where applicable, the Third Party from whom its right to use the Intellectual Property Rights has derived).

 

6.1.2.
Ownership of Developed Technology. Subject to Section 6.1.3, as between the Parties, each Party shall own all right, title and interest
in and to any and all Intellectual Property Rights (including any Intellectual Property Rights subsisting in any Improvements) that are
conceived, discovered, developed or otherwise made solely by or on behalf of such Party or its Affiliates or its or their (sub)licensees,
as applicable, under or in connection with this Agreement.

 

6.1.3.
Ownership of Licensee Funded Developed Technology. As between the Parties, the Licensee shall own all right, title and interest in
and to any and all Intellectual Property Rights (including any Intellectual Property Rights subsisting in any Improvements) conceived,
discovered, developed or otherwise made by or on behalf of a Party or its Affiliates or its or their (sub)licensees, as applicable, arising
out of the ‘302 Development Activities or the CMC Development Activities during the performance of the ‘302 Development Activities
or the CMC Development Activities, as applicable (“Licensee Funded Technology”).

 

    46

    

    

 

6.1.4.
United States Law. The determination of whether Intellectual Property Rights were conceived, discovered, developed or otherwise made
by a Party for the purpose of allocating proprietary rights therein shall, for purposes of this Agreement, be made in accordance with
Applicable Law in the United States as such law exists as of the Effective Date irrespective of where or when such conception, discovery,
development or making occurs.

 

6.1.5.
Assignment. Each Party shall, and shall cause its Affiliates and its and their (sub)licensees to, assign, to the other Party, without
additional compensation, such right, title and interest in and to any Intellectual Property Rights (including Intellectual Property Rights
subsisting in Improvements) as is necessary to fully effect the sole ownership provided for in Section 6.1.2 or Section 6.1.3, as applicable.

 

6.1.6.
Assignment Obligation. Each Party shall cause all Persons who perform Development activities, Manufacturing activities, or regulatory
activities for such Party or its Affiliates under this Agreement, or who conceive, discover, develop or otherwise make any Intellectual
Property Rights on behalf of such Party or its Affiliates or its or their (sub)licensees under or in connection with this Agreement,
to be under an obligation to assign (or, if such Party is unable to cause such Person to agree to such assignment obligation despite
such Party’s using commercially reasonable efforts to negotiate such assignment obligation, then to grant an exclusive license
under (with a scope no less broad than the scope of the license of Intellectual Property Rights granted by such Party under this Agreement)
such Intellectual Property Rights resulting therefrom to such Party).

 

6.1.7.
Ownership of Corporate Names. As between the Parties, each Party shall retain all right, title and interest in and to its Corporate
Names.

 

6.1.8.
Joint Inventions. The Parties shall, through the JIPC, discuss and agree with respect to ownership of any inventions that are conceived,
discovered, developed or otherwise made jointly by or on behalf of Eisai or its Affiliates or its or their (sub)licensees, as applicable,
on the one hand, and Licensee, or its Affiliates or its or their (sub)licensees, as applicable, in each case, under or in connection
with this Agreement and the responsibility for the prosecution, maintenance, enforcement and defense of any Patents with respect thereto;
provided that, notwithstanding the foregoing, any inventions made pursuant to Section 6.1.3 shall be solely owned by Licensee.

 

6.2.
Maintenance and Prosecution of Patents.

 

6.2.1.
In General. Subject to Sections 6.2.2 and 6.2.3, as between the Parties:

 

(a)
Eisai shall have the sole right through counsel of its choice, at its own cost to prepare, file, prosecute and maintain the Eisai Patents,
in accordance with the IP Strategy, including directing any related interference, re-issuance, re-examination and opposition proceedings
with respect thereto; and

 

    47

    

    

 

(b)
the Licensee shall have the sole right through counsel of its choice, at its own cost to prepare, file, prosecute and maintain the Licensee
Patents, in accordance with the IP Strategy, including directing any related interference, re-issuance, re-examination and opposition
proceedings with respect thereto, worldwide, in each case ((a) and (b)), at its sole cost and expense and through counsel of its choice,
and for the purposes of this Section 6.2, the Party prosecuting, maintaining or undertaking other related activities pursuant to the
foregoing sentence with respect to a Patent shall be the “Prosecuting Party”. In no event shall the Licensee disclose
any Eisai Trade Secrets in connection with the preparation, filing, prosecution or maintenance of any Licensee Patent.

 

6.2.2.
Notice. The Prosecuting Party shall give the non-Prosecuting Party and JSC [***] ([***]) Business Days’ written notice prior
to filing any Eisai Patents (in the case of Eisai) or Licensee Patents (in the case of the Licensee), and, following the provision of
such notice shall, consult with the non-Prosecuting Party in good faith regarding the countries in respect of which such Patents will
be filed, and give the non-Prosecuting Party an opportunity to nominate countries in its Territory in respect of which to file the Patents.
The Prosecuting Party shall, at the non-Prosecuting Party’s cost, use Commercially Reasonable Efforts to prepare, file, prosecute
and maintain such Patents, including by directing any related interference, re-issuance, re-examination and opposition proceedings with
respect thereto, in any countries within the Territory of the non-Prosecuting Party nominated by the non-Prosecuting Party.

 

6.2.3.
Abandonment. If the Prosecuting Party decides to abandon the prosecution of any of the Eisai Patents (in the case of Eisai) or the
Licensee Patents (in the case of the Licensee) or any claims thereof, in each case which relate to the Territory of the other Party,
or to discontinue the payment of any maintenance or renewal fees with respect to any such Patents, it shall first offer to assign such
Patents to the other Party by written notice a reasonable amount of time prior to such abandonment such that the other Party has sufficient
time to determine whether to take over the prosecution and maintenance of such Patents. If the other Party elects in writing to take
over the prosecution and maintenance of such Patents, the Prosecuting Party shall assign such Patents to the other Party, and such Patents
shall constitute Licensee Patents (where they have been assigned by Eisai to the Licensee) or Eisai Patents (where they have been assigned
by the Licensee to Eisai). If the other Party does not elect to take over the prosecution and maintenance of the relevant Patents within
[***] ([***]) Business Days of receiving notice of the abandoning Party’s intention to abandon the prosecution of, or discontinue
the payment of any maintenance or renewal fees for, the relevant Patents, the Prosecuting Party may, in its sole discretion, abandon
the prosecution of, or discontinue the payment of any maintenance or renewal fees for, the relevant Patents.

 

6.2.4.
Cooperation. The non-Prosecuting Party shall, and shall cause its Affiliates to, assist and cooperate with the Prosecuting Party,
as the Prosecuting Party may reasonably request from time to time, in the preparation, filing, prosecution and maintenance of the Eisai
Patents or Licensee Patents (as applicable). The Prosecuting Party shall keep the non-Prosecuting Party informed of all steps to be taken
in the preparation and prosecution of all applications for Patents filed by it pursuant to Section 6.2.1 and shall furnish the non-Prosecuting
Party with copies of such applications, amendments thereto and other related correspondence to and from patent offices, and, to the extent
reasonably practicable, permit the non-Prosecuting Party an opportunity to offer its comments thereon before making a submission to a
patent office and the Prosecuting Party shall consider in good faith the non-Prosecuting Party’s comments. Without limiting the
foregoing, the non-Prosecuting Party shall, and shall ensure that its Affiliates shall: (a) offer its comments, if any, promptly; and
(b) provide access to relevant documents and other evidence and make its employees available at reasonable business hours; provided,
however, that neither Party shall be required to provide legally privileged information unless and until procedures reasonably acceptable
to such Party are in place to protect such privilege; and, provided, further, that the Prosecuting Party shall, subject to Section
6.2.2, reimburse the non-Prosecuting Party for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection
therewith.

 

    48

    

    

 

6.2.5.
Patent Term Extension and Supplementary Protection Certificate. Subject to Section 6.2.6, as between the Parties, (a) Eisai shall,
at its own cost, have the sole right to make decisions regarding, and to apply for, patent term extensions, including in the United States
with respect to extensions pursuant to 35 U.S.C. §156 et. seq. and in other jurisdictions pursuant to supplementary protection certificates,
and in all jurisdictions with respect to any other extensions that are now or become available in the future, wherever applicable, for
the Eisai Patents; and (b) Licensee shall, at its own cost, have the sole right to make decisions regarding, and to apply for, patent
term extensions, including in the United States with respect to extensions pursuant to 35 U.S.C. §156 et. seq. and in other jurisdictions
pursuant to supplementary protection certificates, and in all jurisdictions with respect to any other extensions that are now or become
available in the future, wherever applicable, for the Licensee Patents. Each Party shall provide prompt and reasonable assistance, as
requested by and at the cost of (subject to Section 6.2.6) the Party filing the patent term extension, including by taking such reasonable
action as is required of the Regulatory Approval holder under any Applicable Law to obtain such extension or supplementary protection
certificate.

 

6.2.6.
Notice – Patent Term Extension and Supplementary Protection Certificate. Prior to applying for any patent term extension in
respect of the Eisai Patents (in the case of Eisai) or the Licensee Patents (in the case of the Licensee), the relevant Party shall give
the other Party and the JSC [***] ([***]) Business Days’ written notice, and, following the provision of such notice, shall consult
with the other Party in good faith to determine a course of action with respect to such filings, and give the other Party an opportunity
to nominate countries in its Territory in respect of which to file the patent term extensions. The Party applying for any such patent
term extensions in respect of such Patents shall, at the other Party’s cost, use Commercially Reasonable Efforts to prepare, file,
prosecute and maintain such patent term extensions in any countries within the other Party’s Territory nominated by the other Party.

 

6.2.7.
Common Ownership Under Joint Research Agreements. Notwithstanding anything to the contrary in this Article 6, neither Party shall
have the right to make an election under 35 U.S.C. 102(c) when exercising its rights under this Article 6 without the prior written consent
of the other Party. With respect to any such permitted election, the Parties shall coordinate their activities with respect to any submissions,
filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a “joint research agreement”
as defined in 35 U.S.C. 100(h).

 

    49

    

    

 

6.3.
Enforcement of Patents.

 

6.3.1.
Notice. Each Party shall promptly notify the other Party in writing of: (a) any alleged or threatened infringement of the Eisai Patents
or the Licensee Patents in any jurisdiction; or (b) any certification filed under the BPCI Act claiming that any of the Eisai Patents
or Licensee Patents are invalid or unenforceable or claiming that any Eisai Patents or the Licensee Patents would not be infringed by
the making, having made, use, offer for sale, sale or import of a product for which an application under the BPCI Act is filed or any
equivalent or similar certification or notice in any other jurisdiction, in each case ((a) and (b)), of which such Party becomes aware
(an “Infringement”).

 

6.3.2.
Enforcement of Patents. Subject to Section 6.3.3, as between the Parties:

 

(a)
Eisai shall have the first right through counsel of its choice, at its cost, to take whatever action it deems appropriate, for the enforcement
of the Eisai Patents and Licensee Patents against any Infringement, including as a defense or counterclaim in connection with any Third
Party Infringement Claim, that arises in the Eisai Territory. If Eisai fails to take any action in relation to the enforcement of the
Licensee Patents against any Infringement, including as a defense or counterclaim in connection with any Third Party Infringement Claim,
that arises in the Eisai Territory within [***] ([***]) Business Days of being notified of such Infringement, or notifies the Licensee
that it does not wish to take any such action, the Licensee shall have the right through counsel of its choice, at its cost, to take
whatever action it deems appropriate in its sole discretion, for the enforcement of the Licensee Patents against such Infringement in
the Eisai Territory; and

 

(b)
The Licensee shall have the first right through counsel of its choice, at its cost, to take whatever action it deems appropriate, for
the enforcement of the Eisai Patents and Licensee Patents against any Infringement, including as a defense or counterclaim in connection
with any Third Party Infringement Claim, that arises in the Licensee Territory. If the Licensee fails to take any action in relation
to the enforcement of the Eisai Patents against any Infringement, including as a defense or counterclaim in connection with any Third
Party Infringement Claim, that arises in the Licensee Territory within [***] ([***]) Business Days of being notified of such Infringement,
or notifies Eisai that it does not wish to take any such action, Eisai shall have the right through counsel of its choice, at its cost,
to take whatever action it deems appropriate in its sole discretion, for the enforcement of the Eisai Patents against such Infringement
in the Licensee Territory.

 

For
the purposes of this Section 6.3, the Party prosecuting any Infringement pursuant to this Section 6.3.2 with respect to a Patent shall
be the “Enforcing Party”.

 

6.3.3.
Cooperation. The Parties shall cooperate fully in any Infringement action pursuant to this Section 6.3, including by making the inventors,
applicable records, and documents (including laboratory notebooks) with respect to the relevant Patents available to the Enforcing Party
on the Enforcing Party’s request. With respect to an action controlled by the applicable Enforcing Party, the other Party shall,
and shall cause its Affiliates to, assist and cooperate with the Enforcing Party, as the Enforcing Party may reasonably request from
time to time, in connection with its activities set forth in this Section 6.3, including, where necessary, furnishing a power of attorney
solely for such purpose or joining in, or being named as a necessary party to, such action, providing access to relevant documents and
other evidence, and making its employees available at reasonable business hours; provided that the Enforcing Party shall reimburse
such other Party for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith. Unless otherwise
set forth herein, the Enforcing Party shall have the right to settle such claim; provided that neither Party shall have the right to
settle any Infringement action under this Section 6.3 in a manner that has a material adverse effect on the rights or interest of the
other Party or in a manner that imposes any costs or liability on, or involves any admission by, the other Party, without the express
written consent of such other Party (which consent shall not be unreasonably withheld, conditioned or delayed). In connection with any
activities with respect to an Infringement action prosecuted by the applicable Enforcing Party pursuant to this Section 6.3 involving
Patents owned by the other Party or its Affiliates, the Enforcing Party shall: (a) consult with the other Party as to the strategy for
the prosecution of such claim, suit or proceeding; (b) consider in good faith any comments from the other Party with respect thereto
and (c) keep the other Party reasonably informed of any material steps taken, and provide copies of all material documents filed, in
connection with such action.

 

    50

    

    

 

6.3.4.
Counterclaims. If any Third Party alleges that any of the Patents the subject of an Infringement action brought by a Party pursuant
to Section 6.3.2 is invalid or unenforceable as a defense to such Infringement action, the Party that owns such Patents shall have a
right to join such action to defend against such allegation of invalidity or unenforceability in accordance with Section 6.5.

 

6.3.5.
Recovery. Except as otherwise agreed by the Parties in connection with a cost-sharing arrangement, any recovery realized as a result
of such litigation described above in this Section 6.3 (whether by way of settlement or otherwise) shall be first allocated to reimburse
the Parties for their costs and expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover
the totality of such expenses). Any remainder after such reimbursement is made shall be retained by the Enforcing Party; provided,
however, that to the extent that any award or settlement (whether by judgment or otherwise) with respect to an Eisai Patent or Licensee
Patent is attributable to loss of sales or profits with respect to a Licensed Product in the Licensee Territory, the Parties shall negotiate
in good faith an appropriate allocation of such remainder to reflect the economic interests of the Parties under this Agreement with
respect to such Licensed Product.

 

6.3.6.
Biosimilar Applicants. Notwithstanding the other provisions of Section 6.3, if either Party receives a copy of an application for
a Biosimilar Product referencing a Licensed Product, or otherwise becomes aware that such an application has been submitted to a Regulatory
Authority for Regulatory Approval (such as in an instance described in Section 351(l)(9)(C) of the PHSA), then such Party shall promptly
notify the other Party, and the Parties shall discuss in good faith a strategy for responding to such application for a Biosimilar Product.

 

6.4.
Infringement Claims by Third Parties.

 

6.4.1.
If the Exploitation of a Licensed Product results in, or is reasonably expected to result in, any claim, suit or proceeding by a
Third Party alleging infringement of such Third Party’s Intellectual Property Rights (a “Third Party Infringement Claim”),
including as part of any defense or counterclaim in connection with an Infringement action initiated pursuant to Section 6.3.2, the Party
first becoming aware of such Third Party Infringement Claim shall promptly notify the other Party thereof in writing.

 

    51

    

    

 

6.4.2.
As between the Parties, the Licensee shall have the sole right at its discretion to defend against any Third Party Infringement Claim
initiated against the Licensee or any of its Affiliates at its sole cost and expense (subject to the last sentence of this Section 6.4.2),
using counsel of the Licensee’s choice, and Eisai shall have the sole right at its discretion to defend against any Third Party
Infringement Claim initiated against Eisai, at its sole cost and expense, using counsel of Eisai’s choice (in each case, the “Defending
Party”). The non-Defending Party shall, and shall cause its Affiliates to, assist and cooperate with the Defending Party, as
the Defending Party may reasonably request from time to time, in connection with its activities set forth in this Section 6.4, including,
where necessary, furnishing a power of attorney solely for such purpose or joining in, or being named as a necessary party to, such action,
providing access to relevant documents and other evidence, and making its employees available at reasonable business hours; provided
that the Defending Party shall reimburse the non-Defending Party for its reasonable and verifiable out-of-pocket costs and expenses incurred
in connection therewith. The Defending Party shall keep the non-Defending Party reasonably informed of all material developments in connection
with any such claim, suit or proceeding. The Defending Party agrees to provide the non-Defending Party with copies of all material pleadings
filed in such action and to allow the non-Defending Party reasonable opportunity to participate in the defense of the claims. The Parties
shall negotiate in good faith an appropriate allocation of the Licensee’s out-of-pocket expenses, damages, or awards, including
royalties incurred or awarded in connection with any Third Party Infringement Claim defended under this Section 6.4.2, to reflect the
economic interests of the Parties under this Agreement with respect to the Licensed Products.

 

6.5.
Invalidity or Unenforceability Defenses or Actions. Each Party shall promptly notify the other Party in writing of any alleged or
threatened assertion of invalidity or unenforceability of any of the Eisai Patents or the Licensee Patents by a Third Party of which
such Party becomes aware. As between the Parties: (a) Eisai shall have the sole right through counsel of its choice, at its own cost
to defend and control the defense of the validity and enforceability of the Eisai Patents; and (b) the Licensee shall have the sole right
through counsel of its choice, at its own cost to defend and control the defense of the validity and enforceability of the Licensee Patents,
including, in each case ((a) and (b)), when such invalidity or unenforceability is raised as a defense or counterclaim in connection
with an Infringement action initiated pursuant to Section 6.3. For the purposes of this Section 6.5, the Party defending and controlling
the defense of the invalidity or unenforceability action pursuant to the foregoing sentence with respect to a Patent shall be the “Controlling
Party”. In connection with any activities with respect to a defense, claim or counterclaim relating to the Eisai Patents or the
Licensee Patents pursuant to this Section 6.5, the Controlling Party shall: (i) consult with the non-Controlling Party as to the strategy
for such activities; (ii) consider in good faith any comments from the non-Controlling Party; and (iii) keep the non-Controlling Party
reasonably informed of any material steps taken, and provide copies of all material documents filed, in connection with such defense,
claim or counterclaim.

 

    52

    

    

 

6.6.
Third Party Patent Rights. If, in the reasonable opinion of the Licensee, the Exploitation of the Licensed Compound or the Licensed
Products in the Field in the Licensee Territory by the Licensee, any of its Affiliates or any of its or their Sublicensees or distributors
or customers infringes or is reasonably expected to infringe any Patent of a Third Party in any country in the Licensee Territory (such
right, a “Third Party Patent Right”), then, as between the Parties, the Licensee shall have the first right to negotiate
and obtain a license from such Third Party to such Third Party Patent Right as necessary or desirable for the Licensee or its Affiliates
or its or their Sublicensees to Exploit the Licensed Compound and the Licensed Products in the Field in such country; provided that,
as between the Parties, the Licensee shall bear all expenses incurred in connection therewith, including any royalties, milestones or
other payments incurred under any such license.

 

6.7.
Eisai Trademarks.

 

6.7.1.
Use of Eisai Trademarks.

 

(a)
The Licensee hereby acknowledges Eisai’s exclusive right, title and interest in and to the Eisai Trademarks, together with all
goodwill associated therewith and all registrations and registration applications therefor, on a worldwide basis and acknowledges that
nothing herein shall be construed to accord to the Licensee any rights in the Eisai Trademarks except for the license right expressly
granted to the Licensee under Section 2.1.2. The Licensee shall not, and shall cause its Affiliates, Sublicensees and distributors not
to, use in their respective businesses, any Trademark that is confusingly similar to or a colorable imitation of, misleading or deceptive
with respect to or that dilutes any (or any part) of the Eisai Trademarks.

 

(b)
The Licensee shall be free to Commercialize the Licensed Products in the Licensee Territory using the Eisai Trademarks or the Licensee
Trademarks.

 

(c)
The Licensee shall, and shall cause its Affiliates, Sublicensees and distributors to, (i) comply with all Trademark usage guidelines,
quality standards, business practices, methodology, policies and procedures and technical and operational specifications as may be reasonably
specified by Eisai in writing from time to time or as may be imposed by Applicable Law with respect to the nature and quality of the
Licensed Products and the manner of use of the Eisai Trademarks and (ii) promptly make any changes to any Licensed Product labeling,
Licensed Product packaging, Licensed Product inserts or any advertising, marketing, promotional or other materials bearing any of the
Eisai Trademarks as Eisai may reasonably request to achieve compliance with clause (i), and (iii) use Commercially Reasonable Efforts
not to do any act that endangers, destroys or similarly affects, in any material respect, the Eisai Trademarks or the value of the goodwill
associated with the Eisai Trademarks.

 

(d)
Without limiting the Licensee’s obligations under Section 6.7.1(c), the Licensee shall submit to Eisai for review and comment any
new, or any revisions to any existing, Licensed Product label, Licensed Product packaging, Licensed Product insert or advertising, marketing,
promotional or other materials, in each case, bearing an Eisai Trademark that the Licensee wishes to use on or in connection with the
Exploitation of a Licensed Product in the Licensee Territory and shall take any comments from Eisai in good faith that are provided by
Eisai to Licensee within [***] ([***]) days of Licensee’s submission to Eisai.

 

    53

    

    

 

(e)
The Licensee shall not, and shall cause its Affiliates, Sublicensees and distributors not to, (i) directly or indirectly, at any time
challenge Eisai’s or any of its Affiliates’ rights, title or interest in and to the Eisai Trademarks or in any registration
or registration application therefor in any jurisdiction, (ii) do or cause to be done or omit to do anything, the doing, causing or omitting
of which would contest or in any way materially impair the rights of Eisai or any of its Affiliates in and to the Eisai Trademarks or
in any registrations or registration applications therefor in any jurisdiction, (iii) represent to any Third Party that it has, in any
jurisdiction, any ownership rights in or to the Eisai Trademarks or in any registration or registration application therefor or any other
rights in the Eisai Trademarks other than the specific license rights conferred by this Agreement, or (iv) register or attempt to register
the Eisai Trademarks or any confusingly similar Trademark (including any translation or transliteration of any of the Product Trademarks
or any colorable imitation thereof) as a Trademark with any Governmental Authority in its own name or in the name of any of its Affiliate
or any Third Party in any jurisdiction.

 

(f)
  The Licensee acknowledges and agrees that no ownership rights are vested or created in the Eisai Trademarks anywhere in the world
by the licenses and other rights granted in this Agreement (including, for clarity, Section 2.1.2) and that all use of the Eisai Trademarks
by the Licensee, its Affiliates, Sublicensees, and distributors and all goodwill generated in connection therewith, shall inure solely
for and to the benefit of Eisai and its Affiliates.

 

6.7.2.
New Eisai Trademarks. During the Term, the Licensee shall submit to Eisai for review any variation or derivative of an existing Eisai
Trademark, that the Licensee wishes to use on or in connection with the Exploitation of any Licensed Product in the Licensee Territory.
The Licensee shall consider in good faith any comments from Eisai with respect to any proposed Trademarks. With respect to any proposed
Trademark that is a variation or derivation of an existing Eisai Trademark, upon written approval by Eisai in its sole discretion, such
proposed Trademark shall be deemed an Eisai Trademark under this Agreement and subject to the terms hereof.

 

6.7.3.
Clearance, Registration, Prosecution and Maintenance of Eisai Trademarks. All registrations and applications therefor with respect
to the Eisai Trademarks shall be filed, prosecuted, registered and maintained in the name, and for the benefit, of Eisai or its Affiliates.
The Licensee shall have the first right, through counsel reasonably acceptable to Eisai and at Licensee’s cost, to clear, register,
prosecute and maintain the Eisai Trademarks in the Licensee Territory. The Licensee shall (a) provide Eisai from time to time, as reasonably
requested by Eisai, a detailed, written report identifying the current status of all applications and registrations for the Eisai Trademarks
in the Licensee Territory; (b) notify Eisai promptly of, and consult with Eisai with respect to, any material, substantive issue or any
opposition, cancellation, invalidity or other proceeding that may be raised or asserted against any application or registration for any
Eisai Trademark within the Licensee Territory prior to taking any action in response thereto; and (c) from time to time, upon Eisai’s
reasonable request, provide Eisai with copies of any Trademark clearance search reports, registration certificates, renewal applications
and certificates, registration applications, pleadings, or other documentation or information relating to any application or registration
for an Eisai Trademark; provided, however, that the Licensee shall not be required to provide legally privileged information unless
and until procedures reasonably acceptable to the Licensee are in place to protect such privilege. Eisai shall execute such documents
as may be required in the reasonable opinion of the Licensee for the Licensee to be entered as a “registered user” or recorded
licensee of the Eisai Trademarks or to be removed as registered user or licensee thereof. If the Licensee decides to abandon or withdraw
any application for any Eisai Trademark, or permit any registration for any Eisai Trademark to lapse, expire or be cancelled, in either
case, in the Licensee Territory, it shall first notify Eisai. If Eisai elects to continue to register, prosecute and maintain such Eisai
Trademark, it shall have the right to do so using counsel of its choice at is sole expense and such Eisai Trademark shall cease to be
an Eisai Trademark under this Agreement.

 

    54

    

    

 

6.7.4.
Notice. Each Party shall provide to the other Party prompt written notice of any actual or threatened infringement of the Eisai Trademarks
in the Licensee Territory and of any actual or threatened claim that the use of the Eisai Trademarks in the Licensee Territory violates
the rights of any Third Party, in each case, of which such Party becomes aware.

 

6.7.5.
Enforcement of Eisai Trademarks. The Licensee shall have the first right to take such action as the Licensee, after consultation
with Eisai, deems necessary against a Third Party based on any alleged, threatened or actual infringement, dilution, misappropriation,
or other violation of, or unfair trade practices or any other like offense relating to, the Eisai Trademarks by a Third Party in the
Licensee Territory at its sole cost and expense and using counsel of its own choice; provided that Eisai shall have the right
to provide input on the overall strategy for such action and the Licensee shall consider such input in good faith. The Licensee shall
retain any damages or other amounts collected in connection therewith; provided, however, that to the extent that any award or
settlement (whether by judgment or otherwise) with respect to an Eisai Trademark is attributable to loss of sales or profits with respect
to a Licensed Product, the Parties shall negotiate in good faith an appropriate allocation of such remainder to reflect the economic
interests of the Parties under this Agreement with respect to such Licensed Product. If the Licensee fails to take any action in relation
to the enforcement of the Eisai Trademarks against any infringement of the Eisai Trademarks in the Licensee Territory within [***] ([***])
Business Days of being notified of such Infringement, or notifies Eisai that it does not wish to take any such action, Eisai shall have
the right through counsel of its choice, at its cost, to take whatever action it deems appropriate in its sole discretion, for the enforcement
of the Eisai Trademarks against such infringement in the Licensee Territory and Eisai shall retain any damages or other amounts collected
in connection therewith.

 

6.7.6.
Third Party Claims. Eisai shall have the first right to defend against and settle any alleged, threatened or actual claim by a Third
Party that the use or registration of the Eisai Trademarks in the Licensee Territory infringes, dilutes, misappropriates or otherwise
violates any Trademark or other right of that Third Party or constitutes unfair trade practices or any other like offense or any other
claims as may be brought by a Third Party against the Licensee in connection with the use of the Eisai Trademarks with respect to a Licensed
Product in the Licensee Territory, at its sole cost and expense and using counsel of its choice; provided that the Licensee shall
have the right to provide input on the overall strategy for such defense and settlement and Eisai shall consider such input in good faith.
If Eisai fails to take any action in relation to any such claim within [***] ([***]) Business Days of being notified of such claim, or
notifies the Licensee that it does not wish to take any such action, the Licensee shall have the right through counsel of its choice,
at its cost, to take whatever action it deems appropriate in its sole discretion, for the defense of such claim. Any damages or awards,
including royalties incurred or awarded in connection with any such claim defended under this Section 6.7.6, shall be for the account
of the Party defending such claim.

 

    55

    

    

 

6.7.7.
Cooperation. Each Party shall, and shall cause its Affiliates to, assist and cooperate with the other Party, as the other Party may
reasonably request from time to time, in connection with its activities set forth in this Section 6.7, including, where necessary and
applicable, furnishing a power of attorney solely for such purpose or joining in, or being named as a necessary party to, such action,
providing access to relevant documents and other evidence, and making its employees available at reasonable business hours; provided
that the requesting Party shall reimburse the other Party for its and its Affiliates’ reasonable and verifiable out-of-pocket
costs and expenses incurred in connection therewith.

 

6.8.
Eisai Territory Product Trademarks.

 

6.8.1.
The Licensee hereby acknowledges Eisai’s exclusive right, title and interest in and to the Eisai Territory Product Trademarks,
together with all goodwill associated therewith and all registrations and registration applications therefor, with respect to the Eisai
Territory and acknowledges that nothing herein shall be construed to accord to the Licensee any rights in the Eisai Territory Product
Trademarks except for the license right expressly granted to the Licensee under Section 2.1.3. The Licensee shall not, and shall cause
its Affiliates and sublicensees with respect to the Eisai Territory Product Trademarks not to, use in their respective businesses, any
Trademark that is confusingly similar to or a colorable imitation of, misleading or deceptive with respect to or that dilutes any (or
any part) of the Eisai Territory Product Trademarks.

 

6.8.2.
The Licensee shall, and shall cause its Affiliates and sublicensees with respect to the Eisai Territory Product Trademarks to, (a)
comply with all Trademark usage guidelines, quality standards, business practices, methodology, policies and procedures and technical
and operational specifications as may be reasonably specified by Eisai in writing from time to time or as may be imposed by Applicable
Law with respect to the manner of use of the Eisai Territory Product Trademarks and (b) promptly make any changes to any advertising,
marketing, promotional or other materials bearing any of the Eisai Territory Product Trademarks as Eisai may reasonably request to achieve
compliance with clause (i), and (iii) use Commercially Reasonable Efforts not to do any act that endangers, destroys or similarly affects,
in any material respect, the Eisai Territory Product Trademarks or the value of the goodwill associated with the Eisai Territory Product
Trademarks.

 

6.8.3.
Without limiting the Licensee’s obligations under Section 6.8.2, the Licensee shall submit to Eisai for review and comment
any new, or any revisions to any existing, advertising, marketing, promotional or other materials, in each case, bearing an Eisai Territory
Product Trademark that the Licensee wishes to use in connection with Commercializing any Licensee Proprietary Product for use in concomitant
or sequential administration with a Licensed Product in the Eisai Territory, and shall take any comments from Eisai in good faith that
are provided by Eisai to the Licensee within [***] ([***]) days of Licensee’s submission to Eisai.

 

    56

    

    

 

6.8.4.
As between the Parties, Eisai shall have the sole right, at its sole cost and expense, to (a) clear, register, prosecute and maintain
the Eisai Territory Product Trademarks in the Eisai Territory, (b) take such action as Eisai deems necessary against a Third Party based
on any alleged, threatened or actual infringement, dilution, misappropriate or other violation of, or unfair trade practices or any other
like offense relating to, the Eisai Territory Product Trademarks, by a Third Party in the Eisai Territory and retain any damages or other
amounts collected in connection therewith and (c) defend against and settle any alleged, threatened or actual claim by a Third Party
that the use or registration of the Eisai Territory Product Trademarks in the Eisai Territory infringes, dilutes, constitutes, unfair
trade practices or any other like offense or any other claims as may be brought by a Third Party in connection with the use of the Eisai
Territory Product Trademarks with respect to a Licensed Product in the Eisai Territory.

 

6.9.
Licensee Trademarks.

 

6.9.1.
Eisai hereby acknowledges the Licensee’s exclusive right, title and interest in and to the Licensee Trademarks, together with
all goodwill associated therewith and all registrations and registration applications therefor, with respect to the Licensee Territory
and acknowledges that nothing herein shall be construed to accord to Eisai any rights in the Licensee Trademarks except for the license
right expressly granted to Eisai under Section 2.2.2. Eisai shall not, and shall cause its Affiliates and sublicensees with respect to
the Licensee Trademarks not to, use in their respective businesses, any Trademark that is confusingly similar to or a colorable imitation
of, misleading or deceptive with respect to or that dilutes any (or any part) of the Licensee Trademarks in the Licensee Territory.

 

6.9.2.
Eisai shall, and shall cause its Affiliates and sublicensees with respect to the Licensee Trademarks to, (a) comply with all Trademark
usage guidelines, quality standards, business practices, methodology, policies and procedures and technical and operational specifications
as may be reasonably specified by the Licensee in writing from time to time or as may be imposed by Applicable Law with respect to the
manner of use of the Licensee Trademarks and (b) promptly make any changes to any advertising, marketing, promotional or other materials
bearing any of the Licensee Trademarks as the Licensee may reasonably request to achieve compliance with clause (i), and (iii) use Commercially
Reasonable Efforts not to do any act that endangers, destroys or similarly affects, in any material respect, the Licensee Trademarks
or the value of the goodwill associated with the Licensee Trademarks.

 

6.9.3.
Without limiting Eisai’s obligations under Section 6.9.2, Eisai shall submit to the Licensee for review and comment any new,
or any revisions to any existing, advertising, marketing, promotional or other materials, in each case, bearing a Licensee Trademark
that Eisai wishes to use in connection with Commercializing any Eisai Proprietary Product for use in concomitant or sequential administration
with a Licensed Product in the Licensee Territory, and shall take any comments from the Licensee in good faith that are provided by the
Licensee to Eisai within [***] ([***]) days of Eisai’s submission to the Licensee.

 

    57

    

    

 

6.9.4.
As between the Parties, the Licensee shall have the sole right, at its sole cost and expense, to (a) clear, register, prosecute and
maintain the Licensee Trademarks in the Licensee Territory, (b) take such action as the Licensee deems necessary against a Third Party
based on any alleged, threatened or actual infringement, dilution, misappropriate or other violation of, or unfair trade practices or
any other like offense relating to, the Licensee Trademarks, by a Third Party in the Licensee Territory and retain any damages or other
amounts collected in connection therewith and (c) defend against and settle any alleged, threatened or actual claim by a Third Party
that the use or registration of the Licensee Trademarks in the Licensee Territory infringes, dilutes, constitutes, unfair trade practices
or any other like offense or any other claims as may be brought by a Third Party in connection with the use of the License Trademarks
with respect to a Licensed Product in the Licensee Territory.

 

6.10.
Corporate Names. Each Party shall not, and shall procure that each of its Affiliates shall not: (a) use, in their respective businesses,
any Trademark that is confusingly similar to, misleading or deceptive with respect to or that dilutes any (or any part) of the Corporate
Names of the other Party; (b) do any act that endangers, destroys or similarly affects, in any material respect, the value of the goodwill
pertaining to the Corporate Names or the other Party; or (c) attack, dispute or contest the validity of or ownership of the Corporate
Names of the other Party or any registrations issued or issuing with respect thereto or any pending registration thereof. Each Party
shall, and shall procure that each of its Affiliates shall: (i) conform to the customary industry standards for the protection of corporate
names and to such trademark usage guidelines as the other Party may furnish from time to time with respect to the use of its Corporate
Names; and (ii) adhere to and maintain the highest quality standards of the other Party with respect to goods sold and services provided
under the Corporate Names of the other Party.

 

ARTICLE
7

CONFIDENTIALITY AND NON-DISCLOSURE

 

7.1.
Confidentiality Obligations. At all times during the Term and for a period of [***] ([***]) years following termination or expiration
hereof (or, with respect to the Eisai Trade Secrets, for a period of unlimited duration), each Party shall, and shall cause its officers,
directors, employees and agents to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or
indirectly, for any purpose, any Confidential Information furnished or otherwise made known to it, directly or indirectly, by the other
Party, except to the extent such disclosure or use is expressly permitted by the terms of this Agreement. “Confidential Information”
means any technical, business or other information provided by or on behalf of one Party to the other Party in connection with this Agreement,
whether prior to, on or after the Effective Date, including information relating to the terms of this Agreement (subject to Section 7.4),
information relating to the Licensed Compound or any Licensed Product (including the Regulatory Documentation), any Exploitation of the
Licensed Compound or any Licensed Product, any Know-how with respect thereto developed by or on behalf of the disclosing Party or its
Affiliates (including the Licensee Know-how and Eisai Know-how, as applicable) or the scientific, regulatory or business affairs or other
activities of either Party and shall include the Eisai Trade Secrets. Notwithstanding the foregoing, the terms of this Agreement shall
be deemed to be the Confidential Information of both Parties and both Parties shall be deemed to be the receiving Party and the disclosing
Party with respect thereto. Notwithstanding the foregoing, the confidentiality and non-use obligations under this Section 7.1 with respect
to any Confidential Information shall not include any information that:

 

    58

    

    

 

7.1.1.
is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no breach of
this Agreement by the receiving Party;

 

7.1.2.
can be demonstrated by documentation or other competent proof to have been in the receiving Party’s possession prior to disclosure
by the disclosing Party without any obligation of confidentiality with respect to such information;

 

7.1.3.
is subsequently received by the receiving Party from a Third Party who is not bound by any obligation of confidentiality with respect
to such information;

 

7.1.4.
has been published by a Third Party or otherwise enters the public domain through no fault of the receiving Party in breach of this
Agreement; or

 

7.1.5.
can be demonstrated by documentation or other competent evidence to have been independently developed by or for the receiving Party
without reference to the disclosing Party’s Confidential Information.

 

Specific
aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the receiving
Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of
the receiving Party. Further, any combination of Confidential Information shall not be considered in the public domain or in the possession
of the receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession
of the receiving Party, unless the combination and its principles are in the public domain or in the possession of the receiving Party.

 

7.2.
Permitted Disclosures. Each Party may disclose Confidential Information to the extent that such disclosure is:

 

7.2.1.
to Third Parties and Affiliates as necessary, as reasonably determined by the receiving Party, for the performance of the receiving
Party’s obligations under this Agreement; provided, however, that any such Third Party or Affiliate must be subject to obligations
of confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations of confidentiality
and non-use of the receiving Party pursuant to this Article 7;

 

7.2.2.
to the professional advisers (including accountants, counsel, consultants, employees and agents) of a Party; provided, however,
that those advisers must be subject to obligations of confidentiality and non-use with respect to such Confidential Information substantially
similar to the obligations of confidentiality and non-use of the receiving Party pursuant to this Article 7;

 

    59

    

    

 

7.2.3.
 made in response to a valid order of a court of competent jurisdiction or other supra-national, federal, national, regional, state,
provincial and local governmental or regulatory body of competent jurisdiction or, if in the reasonable opinion of the receiving Party’s
legal counsel, such disclosure is otherwise required by Applicable Law or the rules of a stock exchange on which the securities of the
disclosing Party are listed (or to which an application for listing has been submitted); provided, however, that the receiving
Party shall first have given notice to the disclosing Party and given the disclosing Party a reasonable opportunity to quash such order
or to obtain a protective order or confidential treatment requiring that the Confidential Information and documents that are the subject
of such order be held in confidence by such court or agency or, if disclosed, be used only for the purposes for which the order was issued;
and provided, further, that the Confidential Information disclosed in response to such court or governmental order shall be limited
to that information which is legally required to be disclosed in response to such court or governmental order;

 

7.2.4.
made by or on behalf of the receiving Party to the Regulatory Authorities as required in connection with any filing, application
or request for Regulatory Approval; provided, however, that reasonable measures shall be taken to assure confidential treatment
of such information to the extent practicable and consistent with Applicable Law;

 

7.2.5.
made by or on behalf of the receiving Party to a patent authority as may be reasonably necessary or useful for purposes of obtaining
or enforcing a Patent; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information,
to the extent such protection is available;

 

7.2.6.
made by or on behalf of the receiving Party to potential or actual investors or acquirers as may be necessary in connection with
their evaluation of such potential or actual investment or acquisition; provided, however, that such persons shall be subject
to obligations of confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations
of confidentiality and non-use of the receiving Party pursuant to this Article 7 (which confidentiality and non-use obligations shall
subsist for a period that is either: (a) consistent with the period for which the receiving Party’s confidentiality and non-use
obligations subsist under this Article 7; or (b) a minimum of [***] ([***]) months from the date of disclosure; provided, further,
that the disclosure of such Confidential Information to a potential or actual investor or acquirer is subject to a customary return or
destroy provision, which the receiving Party agrees to enforce to protect any disclosed Confidential Information); or

 

7.2.7.
made with the other Party’s prior written approval.

 

Notwithstanding
the foregoing, the Licensee shall not, and shall cause its Affiliates not to, disclose any Eisai Trade Secrets to any Third Party without
the prior written consent of Eisai, such consent not to be unreasonably withheld, conditioned or delayed.

 

7.3.
Use of Name. Except as expressly provided herein, neither Party shall mention or otherwise use the name, logo or Trademark of the
other Party or any of its Affiliates or any of its or their (sub)licensees (or any abbreviation or adaptation thereof) in any publication,
press release, marketing and promotional material or other form of publicity without the prior written approval of such other Party.
The restrictions imposed by this Section 7.3 shall not prohibit: (a) either Party from making any disclosure identifying the other Party
to the extent required in connection with its exercise of its rights or obligations under this Agreement; and (b) either Party from making
any disclosure identifying the other Party that is required by Applicable Law or the rules of a stock exchange on which the securities
of the disclosing Party are listed (or to which an application for listing has been submitted).

 

    60

    

    

 

7.4.
Public Announcements. The Parties have agreed upon the content of one (1) or more press releases which shall be issued substantially
in the form(s) attached hereto as Schedule 7.4, the release of which the Parties shall coordinate in order to accomplish such release
promptly upon execution of this Agreement. Neither Party shall issue any other public announcement, press release or other public disclosure
regarding this Agreement or its subject matter without the other Party’s prior written consent, such consent not to be unreasonably
withheld, conditioned or delayed, except for any such disclosure that is, in the opinion of the disclosing Party’s counsel, required
by Applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed (or to which an application
for listing has been submitted). In the event a Party is, in the opinion of its counsel, required by Applicable Law or the rules of a
stock exchange on which its securities are listed (or to which an application for listing has been submitted) to make such a public disclosure,
such Party shall, to the extent permitted by Applicable Law, submit the proposed disclosure in writing to the other Party as far in advance
as reasonably practicable (and in no event less than [***] ([***]) Business Days prior to the anticipated date of disclosure) so as to
provide a reasonable opportunity to comment thereon. Neither Party shall be required to seek the permission of the other Party to repeat
any information regarding the terms of this Agreement or any amendment hereto that has already been publicly disclosed by such Party
or by the other Party, in accordance with this Section 7.4; provided that such information remains accurate as of such time and provided,
further, that the frequency and form of such disclosure are reasonable.

 

7.5.
Publications. The Parties recognize the desirability of publishing and publicly disclosing the results of, and information regarding,
activities under this Agreement. Accordingly, each Party shall be free to publicly disclose the results of, and information regarding,
activities under this Agreement, subject to prior review by the other Party of any disclosure of that Party’s Confidential Information
for issues of patentability and protection of such Confidential Information, in a manner consistent with Applicable Law and industry
practices, as provided in this Section 7.5. Accordingly, prior to publishing any Confidential Information of the other Party, the publishing
Party shall provide such other Party with drafts of proposed abstracts, manuscripts or summaries of presentations that cover such Confidential
Information. The non-publishing Party shall respond promptly through its designated representative and in any event no later than [***]
([***]) days after receipt of such proposed publication or presentation. The publishing Party agrees to allow a reasonable period (not
to exceed [***] ([***]) days) to permit filings for patent protection and to otherwise address issues of Confidential Information or
related competitive harm to the reasonable satisfaction of the non-publishing Party and, in any event, the publishing Party shall not
publish or publicly disclose any Confidential Information of the other Party over such other Party’s objection. In addition, the
publishing Party shall give due regard to comments furnished by the non-publishing Party and such comments shall not be unreasonably
rejected.

 

    61

    

    

 

7.6.
Return of Confidential Information. Upon the effective date of the expiration or termination of this Agreement for any reason, either
Party may request in writing and the non-requesting Party shall either, with respect to Confidential Information of the requesting Party
to which such non-requesting Party does not retain rights under the surviving provisions of this Agreement, at the requesting Party’s
election: (a) promptly destroy all copies of such Confidential Information in the possession or control of the non-requesting Party and
confirm such destruction in writing to the requesting Party; or (b) promptly deliver to the requesting Party, at the non-requesting Party’s
sole cost and expense, all copies of such Confidential Information in the possession or control of the non-requesting Party. Notwithstanding
the foregoing, the non-requesting Party shall be permitted to retain such Confidential Information: (i) to the extent necessary or useful
for purposes of performing any continuing obligations or exercising any ongoing rights hereunder and, in any event, a single copy of
such Confidential Information for archival purposes; and (ii) any computer records or files containing such Confidential Information
that have been created solely by such non-requesting Party’s automatic archiving and back-up procedures, to the extent created
and retained in a manner consistent with such non-requesting Party’s standard archiving and back-up procedures, but not for any
other uses or purposes. All Confidential Information shall continue to be subject to the terms of this Agreement for the period set forth
in Section 7.1.

 

7.7.
Privileged Communications. In furtherance of this Agreement, it is expected that the Parties may, from time to time, disclose to
one another privileged communications with counsel, including opinions, memoranda, letters and other written, electronic and verbal communications.
Such disclosures are made with the understanding that they shall remain confidential in accordance with this Article 7, that they will
not be deemed to waive any applicable attorney-client or attorney work product or other privilege and that they are made in connection
with the shared community of legal interests existing between Eisai and the Licensee, including the community of legal interests in avoiding
infringement of any valid, enforceable patents of Third Parties and maintaining the validity of the Eisai Patents and the Licensee Patents.
In the event of any litigation (or potential litigation) with a Third Party related to this Agreement or the subject matter hereof, the
Parties shall, upon either Party’s request, enter into a reasonable and customary joint defense agreement. In any event, each Party
shall consult in a timely manner with the other Party before engaging in any conduct (e.g., producing information or documents)
in connection with litigation or other proceedings that could conceivably implicate privileges maintained by the other Party. Notwithstanding
anything contained in this Section 7.7, nothing in this Agreement shall prejudice a Party’s ability to take discovery of the other
Party in disputes between them relating to the Agreement and no information otherwise admissible or discoverable by a Party shall become
inadmissible or immune from discovery solely by this Section 7.7.

 

7.8.
Obligations of the Licensee with Respect to Eisai Trade Secrets. In addition to its obligations in Section 7.1, the Licensee shall
(a) treat the Eisai Trade Secrets as it does its own trade secrets, and (b) implement controls to protect the Eisai Trade Secrets that
are standard in the innovative biopharmaceuticals industry, including using diligent efforts to (i) restrict access to the Eisai Trade
Secrets to individuals with a reasonable need to access such information and restrict use to the Licensed Products, (ii) maintain a list
of such individuals and (iii) inform each such individual regarding the Licensee’s obligations with respect to the Eisai Trade
Secrets under this Agreement and instruct such individuals not to disclose the Eisai Trade Secrets to any individuals that are not on
the list described in the foregoing clause (ii).

 

    62

    

    

 

ARTICLE
8

REPRESENTATIONS AND WARRANTIES

 

8.1.
Mutual Representations and Warranties. Each of Eisai and the Licensee represents and warrants to the other, as of the Original Effective
Date and as of the Execution Date, and covenants, that:

 

8.1.1.
it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has all requisite
power and authority, corporate or otherwise, to execute, deliver and perform this Agreement;

 

8.1.2.
the execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly authorized
by all necessary corporate action and do not violate: (a) such Party’s charter documents, bylaws or other organizational documents;
(b) in any material respect, any agreement, instrument or contractual obligation to which such Party is bound; (c) any requirement of
any Applicable Law; or (d) any order, writ, judgment, injunction, decree, determination or award of any court or governmental agency
presently in effect applicable to such Party;

 

8.1.3.
this Agreement is a legal, valid and binding obligation of such Party enforceable against it in accordance with its terms and conditions,
subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial
principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered
a proceeding at law or equity);

 

8.1.4.
except, with respect to Eisai, under the Distribution Agreements, it is not under any obligation, contractual or otherwise, to any
Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement or that would impede the diligent
and complete fulfillment of its obligations hereunder; and

 

8.1.5.
neither it nor any of its Affiliates has been debarred or is subject to debarment and neither it nor any of its Affiliates will use,
in any capacity, in connection with the services to be performed under this Agreement, any Person who has been debarred pursuant to Section
306 of the FFDCA or who is the subject of a conviction described in such section. It will inform the other Party in writing promptly
if it or any such Person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306
or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of its or its Affiliates’
Knowledge, is threatened, relating to the debarment or conviction of it or any such Person performing services hereunder. Upon request
by either Party (which may be made no more than [***] per Contract Year), the such Party shall (a) screen against the Exclusion Lists
all of its directors, officers, and employees, whose responsibilities, to such Party’s Knowledge, involve the Development or Commercialization
of the Licensed Products as authorized by this Agreement, and (b) certify the results of such screening to the other Party. For purposes
of this Agreement, “Exclusion Lists” shall mean: (i) the HHS/OIG List of Excluded Individuals/Entities (available
through the Internet at http://www.oig.hhs.gov) or any successor list; and (ii) the General Services Administration’s List of Parties
Excluded from Federal Programs (available through the Internet at http://www.epls.gov) or any successor list.

 

    63

    

    

 

8.2.
Additional Representations and Warranties of Eisai. Eisai further represents and warrants to the Licensee, as of the Original Effective
Date, that:

 

8.2.1.
neither Eisai nor any of its Affiliates Controls any Patents that are necessary or desirable for the Exploitation of the Licensed
Compound or a Licensed Product in the Licensee Territory as contemplated herein;

 

8.2.2.
Eisai Controls the Eisai Existing Know-how and Eisai Existing Regulatory Documentation as of the Original Effective Date and has
the right to grant the licenses, rights of reference, sublicenses and further rights of reference specified herein, and, except as set
forth in the Distribution Agreements, has not granted to any Third Parties any conflicting licenses, rights of reference, sublicenses
and further rights of reference;

 

8.2.3.
Eisai owns all right, title and interest in and to the Eisai Trademarks, free and clear of liens, security interests and other encumbrances.
All post-registration requirements with the United States Patent and Trademark Office with respect to the Eisai Trademarks have been
satisfied;

 

8.2.4.
To Eisai’s Knowledge, no Person has infringed, violated or misappropriated, or is infringing, violating or misappropriating,
any of the Eisai Trademarks;

 

8.2.5.
Eisai has not received any written claim or demand alleging that the Exploitation of the Licensed Products as contemplated herein
infringes any Intellectual Property Rights owned by any Third Party;

 

8.2.6.
to Eisai’s Knowledge, the Exploitation of the Licensed Products as contemplated herein does not infringe any Intellectual Property
Rights owned by any Third Party;

 

8.2.7.
to Eisai’s Knowledge, no Person is infringing or threatening to infringe the Eisai Technology and Eisai has not made any such
claim against any Person, nor, to its Knowledge, is there any basis for such a claim;

 

8.2.8.
the Eisai Existing Know-how and the Eisai Existing Regulatory Documentation constitute all of the Intellectual Property Rights that
are owned, licensed or otherwise controlled by Eisai or any of its Affiliates that are necessary or reasonably useful for the Exploitation
of the Licensed Compound and the Licensed Products in the Licensee Territory, as such activities are contemplated on the Original Effective
Date;

 

8.2.9.
all of the Eisai Technology is owned by either Eisai or one of its Affiliates;

 

    64

    

    

 

8.2.10.
 except for those serious adverse events with respect to the Existing Licensed Product that have been reported to the FDA and disclosed
in writing to the Licensee set forth in the email with the subject “E7777 Reportable Adverse Event Disclosure - Rep 8.2.10”
from Eisai to Licensee dated March 25, 2016, neither Eisai nor any of its Affiliates nor, to Eisai’s Knowledge, any Third Parties
involved with Eisai in the Development of the Existing Licensed Product, has any Knowledge of any adverse event, arising prior to the
Original Effective Date, reportable to a Regulatory Authority under Applicable Law with respect to the safety or efficacy of the Existing
Licensed Product;

 

8.2.11.
Eisai or one of its Affiliates is the registered holder of each Regulatory Approval and IND required under Applicable Law for the
Development of the Existing Licensed Product, such Regulatory Approvals and INDs are in full force and effect, no material deficiencies
have been asserted by any applicable Governmental Authority with respect to such Regulatory Approvals and INDs and, to Eisai’s
Knowledge, no facts or circumstances exist that would be likely to lead to such assertions being made;

 

8.2.12.
the Existing Licensed Product has been and is being Developed in all material respects in accordance with applicable Regulatory Approvals
and INDs and in accordance with Applicable Laws. Neither Eisai nor any of its Affiliates nor, to Eisai’s Knowledge, any Third Parties
involved with Eisai in the Development of the Existing Licensed Product, has received any written notices or other correspondence from
any Governmental Authority requiring the termination, suspension or material modification of any studies or tests relating to the Development
of the Existing Licensed Product; and

 

8.2.13.
the information set forth on Schedule 8.2.13 is true, complete and correct.

 

8.3.
DISCLAIMER OF WARRANTIES. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY
WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE AND EACH PARTY SPECIFICALLY DISCLAIMS
ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR
A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS
OF THIRD PARTIES. WITHOUT LIMITING THE FOREGOING, EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, THE EISAI TRADEMARKS ARE LICENSED
“AS IS,” “WITH ALL FAULTS,” AND “WITH ALL DEFECTS,” AND THE LICENSEE EXPRESSLY WAIVES ALL RIGHTS
TO MAKE ANY CLAIM WHATSOEVER AGAINST EISAI FOR MISREPRESENTATION OR FOR BREACH OF PROMISE, GUARANTEE OR WARRANTY OF ANY KIND RELATING
TO ANY EISAI TRADEMARK.

 

8.4. Anti-Bribery
and Anti-Corruption Compliance. Each of the Licensee and Eisai agrees, on behalf of itself, its officers, directors and employees
and on behalf of its Affiliates, agents, representatives, consultants and subcontractors hired in connection with the subject
matter of this Agreement (“Representatives”), that for the performance of its obligations hereunder:
 

8.4.1.
Compliance. Such Party and its Representatives shall comply with the Anti-Corruption Laws and shall not take any action that would,
or would reasonably be expected to, cause the other Party or its Affiliates to be in violation of any such laws or policies. In the course
of the business, each of the Licensee and Eisai and the respective Representatives (a) shall not, directly or indirectly, make payment
or offer or promise to make payment of any bribe (“Corruption”) to a governmental official (including a foreign official,
a person deemed to be a governmental official under the law, and a healthcare professional), a person related to a political party, or
a candidate for public post, (b) shall not engage in Corruption even in terms of private citizens other than government officials through
providing entertainments or gifts deemed inappropriate under business customs, and (c) shall establish and maintain an appropriate compliance
procedure to prevent its management or employees from engaging in Corruption.

 

8.4.2.
Notice. Such Party shall promptly provide the other Party with written notice of the following events: (a) upon becoming aware of
any breach or violation by such Party or its Representative of any representation, warranty or undertaking set forth in Section 8.4.1;
or (b) upon receiving a formal notification that it is the target of a formal investigation by a Governmental Authority for a Material
Anti-Corruption Law Violation or upon receipt of information from any of its Representatives connected with this Agreement that any of
them is the target of a formal investigation by a Governmental Authority for a Material Anti-Corruption Law Violation.

 

    65

    

    

 

ARTICLE
9

INDEMNITY

 

9.1.
Indemnification of Eisai. The Licensee shall indemnify Eisai, its Affiliates and its and their respective directors, officers, employees
and agents (collectively, “Eisai Indemnitees”), and defend and hold each of them harmless, from and against any and
all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) (collectively “Losses”)
incurred by such Persons in connection with any and all suits, investigations, claims or demands of Third Parties (collectively “Third
Party Claims”) arising from or occurring as a result of: (a) the breach by the Licensee of this Agreement, including the enforcement
of Eisai’s rights under this Section 9.1; (b) the gross negligence or willful misconduct on the part of any Licensee Indemnitee
in connection with this Agreement or (c) the Exploitation of any Licensed Product by or on behalf of Licensee, its Sublicensees or any
of its or their respective Affiliates (excluding any Third Party Claims alleging death, personal injury or other product liability to
the extent arising out of or related to the use of any Licensed Compound or Licensed Product sold by or behalf of Eisai in the Eisai
Territory), provided that, in each case ((a), (b) and (c)), with respect to any Third Party Claim for which the Licensee has an
obligation to any Eisai Indemnitee pursuant to this Section 9.1 and Eisai has an obligation to any Licensee Indemnitee pursuant to Section
9.2, each Party shall indemnify each of the Eisai Indemnitees or the Licensee Indemnitees, as applicable, for its Losses to the extent
of its responsibility, relative to the other Party.

 

9.2.
Indemnification of the Licensee. Eisai shall indemnify the Licensee, its Affiliates and its and their respective directors, officers,
employees and agents (collectively, “Licensee Indemnitees”) and defend and hold each of them harmless, from and against
any and all Losses incurred by such Persons in connection with any and all Third Party Claims arising from or occurring as a result of:
(a) the breach by Eisai of this Agreement, including the enforcement of the Licensee’s rights under this Section 9.2; (b) the gross
negligence or willful misconduct on the part of any Eisai Indemnitee in connection with this Agreement; (c) the Exploitation of the Discontinued
Licensed Product by Eisai, its sublicensees or any of its or their respective Affiliates prior to the Original Effective Date; (d) the
Exploitation of any Licensed Product by or on behalf of Eisai, its Sublicensees or any of its or their respective Affiliates (excluding
any Third Party Claims alleging death, personal injury or other product liability to the extent arising out of or related to the use
of any Licensed Compound or Licensed Product sold by or behalf of the Licensee in the Licensee Territory) or (e) the partial assignment
and delegation with respect to the Distribution Agreements pursuant to Section 2.10(a) or Eisai’s breach of any of its obligations
under the Distribution Agreements, except to the extent Licensee is obligated to fulfill such obligation pursuant to Section 2.10(a)
or such breach arises out of any act or omission by Licensee, provided that, in each case ((a) (b), (c), (d) and (e)), with respect
to any Third Party Claim for which Eisai has an obligation to any Licensee Indemnitee pursuant to this Section 9.2 and the Licensee has
an obligation to any Eisai Indemnitee pursuant to Section 9.1, each Party shall indemnify each of the Eisai Indemnitees or the Licensee
Indemnitees, as applicable, for its Losses to the extent of its responsibility, relative to the other Party.

 

9.3.
Indemnification Procedures.

 

9.3.1.
Notice of Claim. All indemnification claims in respect of an Eisai Indemnitee or a Licensee Indemnitee, as applicable, shall be made
solely by such Party to this Agreement (the “Indemnified Party”). The Indemnified Party shall give the indemnifying
Party prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of fact upon which such
Indemnified Party intends to base a request for indemnification under this Article 9, but in no event shall the indemnifying Party be
liable for any Losses that result from any delay in providing such notice to the extent materially prejudiced thereby. Each Indemnification
Claim Notice must contain a reasonably detailed description of the claim and the nature and amount of such Loss (to the extent that the
nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the indemnifying Party copies
of all papers and official documents received in respect of any Losses and Third Party Claims.

 

9.3.2.
Control of Defense. The indemnifying Party shall have the right to assume the defense of any Third Party Claim by giving written
notice to the Indemnified Party within [***] ([***]) days of the indemnifying Party’s receipt of an Indemnification Claim Notice.
The assumption of the defense of a Third Party Claim by the indemnifying Party shall not be construed as an acknowledgment that the indemnifying
Party is liable to indemnify any Eisai Indemnitee or Licensee Indemnitee, as applicable, in respect of the Third Party Claim, nor shall
it constitute a waiver by the indemnifying Party of any defenses it may assert against an Eisai Indemnitee’s or a Licensee Indemnitee’s,
as applicable, claim for indemnification. Upon assuming the defense of a Third Party Claim, the indemnifying Party may appoint as lead
counsel in the defense of the Third Party Claim any legal counsel selected by the indemnifying Party. In the event the indemnifying Party
assumes the defense of a Third Party Claim, the Indemnified Party shall promptly deliver to the
indemnifying Party all original notices and documents (including court papers) received by any Eisai Indemnitee or Licensee Indemnitee,
as applicable, in connection with the Third Party Claim. Should the indemnifying Party assume the defense of a Third Party Claim, except
as provided in Section 9.3.3, the indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently
incurred by such Indemnified Party or any Eisai Indemnitee or Licensee Indemnitee, as applicable, in connection with the analysis, defense
or settlement of the Third Party Claim, unless the incurrence of such legal expenses by the Indemnified Party or Eisai Indemnitee or
Licensee Indemnitee, as applicable, is specifically requested in writing by the indemnifying Party; provided that the indemnifying
Party is diligently pursuing the defense or settlement of such Third Party Claim. In the event that it is ultimately determined that
the Indemnifying Party is not obligated to indemnify, defend or hold harmless an Eisai Indemnitee or Licensee Indemnitee, as applicable,
from and against a Third Party Claim, the Indemnified Party shall reimburse the indemnifying Party for any and all costs and expenses
(including attorneys’ fees and costs of suit) incurred by the indemnifying Party in its defense of such Third Party Claim.

 

    66

    

    

 

9.3.3.
Right to Participate in Defense. Without limiting Section 9.3.2, any Indemnified Party shall be entitled to participate in the defense
of a Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be
at the Indemnified Party’s sole cost and expense, unless: (a) the employment thereof has been specifically authorized by the indemnifying
Party in writing (in which case, the defense shall be controlled as provided in Section 9.3.2); (b) the indemnifying Party has failed
to assume the defense and employ counsel in accordance with Section 9.3.2 or otherwise is not diligently pursuing the defense and settlement
of such claim (in which case the Indemnified Party shall control the defense at the indemnifying Party’s sole expense); or (c)
the interests of any Eisai Indemnitee or Licensee Indemnitee, as applicable, on the one hand, and the indemnifying Party, on the other
hand, with respect to such Third Party Claim are sufficiently adverse to prohibit the representation by the same counsel of all such
Persons under Applicable Law, ethical rules or equitable principles (in which case, the Indemnified Party shall control its defense at
the indemnifying Party’s sole expense).

 

9.3.4.
Settlement. With respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim and
that shall not result in any Eisai Indemnitee or Licensee Indemnitee, as applicable, becoming subject to injunctive or other relief or
otherwise adversely affecting the business of any Eisai Indemnitee or Licensee Indemnitee, as applicable, in any manner hereunder, and
as to which the indemnifying Party shall have acknowledged in writing the obligation to indemnify such Eisai Indemnitee or Licensee Indemnitee,
as applicable, the indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or
otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole discretion, shall deem appropriate so long as the
terms of any such settlement contain a complete and unconditional release of such Eisai Indemnitees or Licensee Indemnitees, as applicable,
with respect to such Third Party Claim. With respect to all other Losses in connection with Third Party Claims, where the indemnifying
Party has assumed the defense of the Third Party Claim in accordance with Section 9.3.2, the indemnifying Party shall have authority
to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss; provided that it obtains
the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed,
and a consent shall not be considered unreasonably withheld, conditioned or delayed if the terms of such settlement do not contain a
complete and unconditional release of such Eisai Indemnitees or Licensee Indemnitees, as applicable, with respect to such Third Party
Claim). If the indemnifying Party does not assume and conduct the defense of a Third Party Claim as provided above, the Indemnified Party
may defend against such Third Party Claim at the indemnifying Party’s sole cost and expense; provided that the Indemnified
Party shall not settle any Third Party Claim without the prior written consent of the indemnifying Party (which consent shall not be
unreasonably withheld, conditioned or delayed).

 

9.3.5.
Cooperation. Regardless of whether the indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party
shall, and shall cause each Eisai Indemnitee or Licensee Indemnitee, as applicable, to, cooperate in the defense or prosecution thereof
and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings,
hearings, trials and appeals and access to records and information and other employees and agents, as may be reasonably requested in
connection therewith. Such cooperation shall include access during normal business hours afforded to the indemnifying Party to, and reasonable
retention by the Indemnified Party and any Eisai Indemnitee or Licensee Indemnitee, as applicable, of, records and information that are
reasonably relevant to such Third Party Claim, and making all Eisai Indemnitees or Licensee Indemnitees, as applicable, and other employees
and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder;
provided that neither Party shall be required to disclose legally privileged information unless and until procedures reasonably acceptable
to such Party are in place to protect such privilege. The indemnifying Party shall reimburse the Indemnified Party for all reasonable
and verifiable out-of-pocket expenses of any Eisai Indemnitee or Licensee Indemnitee, as applicable, in connection therewith.

 

9.3.6.
Expenses. Except as provided above, the costs and expenses, including fees and disbursements of counsel, incurred by any Eisai Indemnitee
or Licensee Indemnitee, as applicable, in connection with any Third Party Claim shall be reimbursed on a Calendar Quarter basis by the
indemnifying Party, without prejudice to the indemnifying Party’s right to contest such Eisai Indemnitee’s or Licensee Indemnitee’s,
as applicable, right to indemnification and subject to refund in the event the indemnifying Party is ultimately held not to be obligated
to indemnify the Eisai Indemnitee or Licensee Indemnitee, as applicable.

 

    67

    

    

 

9.4.
Special, Indirect and Other Losses. EXCEPT (a) IN THE EVENT OF WILLFUL MISCONDUCT OR FRAUD OF A PARTY OR OF A PARTY’S BREACH
OF ITS OBLIGATIONS UNDER Article 7 OR SECTION 2.6 OR (b) TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART
OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS Article 9, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE IN
CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY INDIRECT, CONSEQUENTIAL, EXEMPLARY, SPECIAL OR PUNITIVE DAMAGES
OR FOR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY.

 

ARTICLE
10 

TERM AND TERMINATION

 

10.1.
Term and Expiration. This Agreement shall commence on the Effective Date and, unless earlier terminated in accordance herewith, shall
continue in full force and effect until (a) if there has not been a first commercial sale of a Licensed Product in the Licensee Territory
before the tenth (10th) anniversary of the Original Effective Date, the tenth (10th) anniversary of the Original Effective Date, or (b)
if there has been a first commercial sale of a Licensed Product in the Licensee Territory before the tenth (10th) anniversary of the
Original Effective Date, the tenth (10th) anniversary of the first commercial sale of a Licensed Product in the Licensee Territory (such
period, the “Initial Term”); provided, that if the Licensee does not extend the Initial Term pursuant to the
following sentence, then with respect to each country in the Territory in which there has been a first commercial sale of a Licensed
Product prior to the tenth (10th) anniversary of the Original Effective Date, then the Initial Term shall continue in each
such country until the tenth (10th) anniversary of the first commercial sale of a Licensed Product in such country. The Licensee
may extend the Term for additional ten (10)-year periods (each, an “Extension Term”) for all countries in the Licensee
Territory by notifying Eisai in writing of such extension and paying Eisai an extension fee equal to $10 Million at least [***] ([***])
days prior to the expiration of the then current Term.

 

10.2.
Termination.

 

10.2.1.
Material Breach. In the event that either Party (the “Breaching Party”) shall be in material breach of any of
its obligations under this Agreement, in addition to any other right and remedy the other Party (the “Non-Breaching Party”)
may have, the Non-Breaching Party may terminate this Agreement in its entirety by providing [***] ([***]) days’ (or, with respect
to payment breaches, [***] ([***]) days’) (the “Notice Period”) prior written notice (the “Termination
Notice”) to the Breaching Party specifying the breach and its claim of right to terminate; provided that:

 

(a)
prior to issuing the Termination Notice, the Non-Breaching Party shall refer the issue to the Senior Officers for attempted resolution
by good faith negotiations during a period of [***] ([***]) Business Days from the date of such referral, or such longer period as the
Senior Officers may agree in writing;

 

(b)
if any alleged material breach hereunder is disputed in accordance with Section 11.5, the Notice Period shall be suspended for the duration
of, and until resolution of, such dispute resolution process; and

 

(c)
the termination shall not become effective at the end of the Notice Period if the Breaching Party cures the breach specified in the Termination
Notice during the Notice Period (or, if such default cannot be cured within the Notice Period, if the Breaching Party commences actions
to cure such breach within the Notice Period and thereafter diligently continues such actions, provided, that such breach is cured within
[***] ([***]) [***] after the receipt of the Termination Notice).

 

10.2.2.
Termination for Anti-Bribery and Anti-Corruption Breach. Notwithstanding Section 10.2.1, in the event that either Party materially
breaches of any of its obligations under Section 8.4 in a way that constitutes a Material Anti-Corruption Law Violation, in addition
to any other right and remedy the other Party may have, such other Party may terminate this Agreement in its entirety immediately upon
written notice to such first Party; provided that if any such alleged breach is disputed in accordance with Section 11.5, the termination
shall not become effective for the duration of such dispute resolution process, and unless and until such dispute is resolved in favor
of the terminating Party.

 

10.2.3.
Termination for Eisai Trade Secret Breach. Notwithstanding Section 10.2.1, in the event that the Licensee breaches any of its obligations
under the last sentence of Section 7.2, in addition to any other right and remedy Eisai may have, Eisai may terminate this Agreement
in its entirety immediately upon written notice to the Licensee; provided that if any such alleged breach is disputed in accordance with
Section 11.5, the termination shall not become effective for the duration of such dispute resolution process, and unless and until such
dispute is resolved in favor of Eisai.

 

10.2.4.
Termination for Insolvency. In the event that either Party (a) files for protection under bankruptcy or insolvency laws, (b) makes
an assignment for the benefit of creditors, (c) appoints or suffers appointment of a receiver or trustee over substantially all of its
property that is not discharged within [***] ([***]) days of such filing, (d) proposes a written agreement of composition or extension
of its debts, (e) proposes or is a voluntary party to any dissolution or liquidation, (f) files a petition under any bankruptcy or insolvency
act or (g) admits in writing its inability generally to meet its obligations as they fall due in the general course, then the other Party
shall have the right to terminate this Agreement in its entirety, immediately upon written notice to such Party.

 

    68

    

    

 

10.2.5.
Termination for Challenge.

 

(a)
If the Licensee or any of its Affiliates (i) Challenges an Eisai Patent in any country or (ii) challenges the validity of any Eisai Trade
Secret in any country, then, in either case ((i) or (ii)), Eisai may terminate this Agreement immediately upon written notice of termination
to the Licensee.

 

(b)
If Eisai or any of its Affiliates Challenges a Licensee Patent in any country, then Licensee may terminate this Agreement immediately
upon written notice of termination to Eisai.

 

10.2.6.
Termination for Change of Control.

 

(a)
Not later than [***] ([***])) days following the effective date of a Change of Control of the Licensee, the Licensee shall provide written
notice to Eisai of such transaction and Eisai shall have the right to request a determination of the fair market value pursuant to Section
10.6.5 on written notice to the Licensee given at any time during the period commencing on the date described above and ending [***]
([***]) days after receipt of such notice.

 

(b)
Eisai shall have the right to terminate this Agreement immediately on written notice to the Licensee given at any time during the period
commencing on the date the Licensee notifies Eisai of the Change of Control of the Licensee and ending [***] ([***]) days after the determination
of the fair market value pursuant to Section 10.6.5.

 

(c)
If at any time during the period beginning upon the Change of Control of the Licensee and ending upon the expiration of the [***] ([***])-day
period in Section 10.2.6(b), the Licensee is in material breach of any of its obligations under this Agreement, the time periods set
forth in this Section 10.2.6 and Section 10.6.5 shall be suspended for the duration of, and until resolution of, any dispute regarding
such material breach (including pursuant to Section 10.2.1(a)), and if it is determined that the Licensee is in material breach of any
of its obligations under this Agreement, then Eisai shall have the right to terminate this Agreement pursuant to Section 10.2.1 and the
provisions of Section 10.6 shall not apply.

 

10.2.7.
Termination for Withdrawal. If Regulatory Authorities cause the withdrawal on a permanent basis of any Licensed Product from any
national or supra-national market in the Licensee Territory, Eisai may terminate this Agreement with respect to such market (each such
market, on a country-by-country basis, a “Terminated Territory”) immediately upon notice to the Licensee, except that
such right of termination shall apply only to withdrawal of the entire marketing authorization for such Licensed Product and shall not
apply in circumstances where such withdrawal is limited to particular Manufacturing batches or lots as a result of a correctable Manufacturing
defect.

 

10.3.
Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by the Licensee or Eisai are, and shall
otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country
or jurisdiction, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The
Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights
and elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction. The Parties further agree
that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous
provisions in any other country or jurisdiction, the Party that is not a Party to such proceeding shall be entitled to a complete duplicate
of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if
not already in the non-subject Party’s possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy
proceeding upon the non-subject Party’s written request therefor, unless the Party subject to such proceeding elects to continue
to perform all of its obligations under this Agreement, or (b) if not delivered under clause (a) above, following the rejection of this
Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party.

 

10.4.
Consequences of Termination of this Agreement in its Entirety. In the event of a termination of this Agreement in its entirety:

 

10.4.1.
all rights and licenses granted by either Party under Section 2.1 or Section 2.2, as applicable, and any sublicenses granted by either
Party pursuant to Section 2.3 shall immediately terminate;

 

    69

    

    

 

10.4.2.
 the Licensee hereby grants, and shall cause its Affiliates to grant, Eisai and its Affiliates an exclusive, perpetual, royalty-free
license, with the right to grant multiple tiers of sublicenses, in and to the Licensee Technology owned or Controlled by the Licensee
or any of its Affiliates as of the effective date of the applicable termination of this Agreement to Exploit the Licensed Products in
the Field anywhere in the world;

 

10.4.3.
to the extent requested in writing by Eisai:

 

(a)
the Licensee shall, and shall cause its Affiliates to, assign to Eisai all of its right, title and interest in and to all Licensee Regulatory
Documentation then owned or Controlled by the Licensee or any of its Affiliates and notify the applicable Regulatory Authorities of,
and take any other action reasonably necessary to effect, such assignment; provided that, if any such Regulatory Documentation
is not immediately transferable in a country, the Licensee shall provide Eisai with all benefit of such Regulatory Documentation, and
such assistance and cooperation as necessary or reasonably requested by Eisai to timely transfer such Regulatory Documentation to Eisai
or its designee or, at Eisai’s option, to enable Eisai to obtain a substitute for such Regulatory Documentation;

 

(b)
the Licensee shall, and shall cause its Affiliates to, grant Eisai an exclusive, perpetual, royalty-free right of reference, with the
right to grant multiple tiers of further rights of reference, in and to all Licensee Regulatory Documentation then owned or Controlled
by the Licensee or any of its Affiliates that is not assigned to Eisai pursuant to clause (a) above to the extent necessary to Exploit
the Licensed Products in the Field anywhere in the world, as such Regulatory Documentation exists as of the effective date of such termination
of this Agreement and the Licensee shall continue to maintain such Regulatory Documentation (including any Regulatory Approvals) at Eisai’s
sole cost and expense unless and until Eisai notifies the Licensee in writing that such maintenance is no longer required;

 

(c)
unless expressly prohibited by any Regulatory Authority, the Licensee shall, and shall cause its Affiliates to, transfer control to Eisai
or its designee of all clinical studies of each Licensed Product being conducted by or on behalf of the Licensee as of the effective
date of termination and continue to conduct such clinical studies, at Eisai’s sole cost and expense, for up to [***] ([***]) months
to enable such transfer to be completed without interruption of any such clinical study; provided that (i) Eisai shall not have any obligation
to continue any clinical study unless required by Applicable Law and (ii) with respect to each clinical study (A) for which such transfer
is expressly prohibited by the applicable Regulatory Authority or (B) that is required for Regulatory Approval that Eisai does not request
that the Licensee transfer control of such clinical study to Eisai, if any, the Licensee shall continue to conduct such clinical study
to completion, at Eisai’s sole cost and expense;

 

(d)
the Licensee shall, and shall cause its Affiliates to, assign to Eisai or its designee all Licensed Product Agreements relating to the
Exploitation of the Licensed Products in the Field in the Licensee Territory, unless, with respect to any such Licensed Product Agreement,
such Licensed Product Agreement: (i) expressly prohibits such assignment (in which case, the Licensee or its Affiliate, as applicable,
shall cooperate with Eisai in all reasonable respects to secure the consent of the applicable Third Party to such assignment); and (ii)
does not relate solely to the Exploitation of the Licensed Products in the Field in the Licensee Territory (in
which case, at Eisai’s request, the Licensee or its Affiliate, as applicable, shall cooperate with Eisai in all reasonable respects
to secure the written agreement of the applicable Third Party to a partial assignment of the applicable part of the Licensed Product
Agreement that relates to the Exploitation of the Licensed Products in the Eisai Territory) and if the Licensee is unable to secure such
consent to assign or partially assign any such Licensed Product Agreement, then the Licensee shall use Commercially Reasonable Efforts
to obtain for Eisai substantially all of the practical benefit and burden under such Licensed Product Agreement, including by (A) entering
into appropriate and reasonable alternative arrangements on terms mutually agreeable to Eisai and the Licensee and (B) subject to the
consent and control of Eisai, enforcing, at Eisai’s sole cost and expense and for the account of Eisai, any and all rights of the
Licensee against the other party thereto arising out of the breach or cancellation thereof by such other party or otherwise;

 

    70

    

    

 

(e)
the Licensee shall, and shall cause its Affiliates to, provide Eisai with copies of all reports and data generated or obtained by the
Licensee or any of its Affiliates that relate to any Licensed Product that have not previously been provided to Eisai; and

 

(f)
  the Licensee shall, and shall cause its Affiliates to, assign to Eisai all of Licensee’s and its Affiliates’ right,
title and interest in and to the Licensee Trademarks and any trade dress with respect to the Licensed Products;

 

10.4.4.
all Confidential Information of the Licensee relating to the Exploitation of the Licensed Products in the Field in the Licensee Territory
shall become the Confidential Information of Eisai; and

 

10.4.5.
without limiting Eisai’s rights under other provisions of this Article 10, the Licensee shall, at the request and sole expense
of Eisai, provide Eisai with such assistance as is reasonably necessary to effectuate a smooth and orderly transition of any Development,
Manufacture and Commercialization activities to Eisai or its designee so as to minimize any disruption of such activities.

 

10.5.
Consequences of Termination of this Agreement for a Terminated Territory. In the event of a termination of this Agreement with respect
to a Terminated Territory:

 

10.5.1.
to the extent requested in writing by Eisai:

 

(a)
the Licensee shall, and shall cause its Affiliates to, assign to Eisai all of its right, title and interest in and to all Licensee Regulatory
Documentation in the Terminated Territory then owned or Controlled by the Licensee or any of its Affiliates and notify the applicable
Regulatory Authorities in the Terminated Territory of, and take any other action reasonably necessary to effect, such assignment; provided
that, if any such Regulatory Documentation is not immediately transferable in the Terminated Territory or also relates to countries
that are not in the Terminated Territory, the Licensee shall provide Eisai with all benefit of such Regulatory Documentation, and such
assistance and cooperation as reasonably necessary or reasonably requested by Eisai to timely transfer such Regulatory Documentation
to Eisai or its designee or, at Eisai’s option, to enable Eisai to obtain a substitute for
such Regulatory Documentation;

 

(b)
the Licensee shall, and shall cause its Affiliates to, assign to Eisai or its designee all Licensed Product Agreements relating to the
Exploitation of the Licensed Products in the Field in the Terminated Territory, unless, with respect to any such Licensed Product Agreement,
such Licensed Product Agreement: (i) expressly prohibits such assignment (in which case, the Licensee or its Affiliate, as applicable,
shall cooperate with Eisai in all reasonable respects to secure the consent of the applicable Third Party to such assignment); and (ii)
does not relate solely to the Exploitation of the Licensed Products in the Field in the Terminated Territory (in which case, at Eisai’s
request, the Licensee or its Affiliate, as applicable, shall cooperate with Eisai in all reasonable respects to secure the written agreement
of the applicable Third Party to a partial assignment of the applicable part of the Licensed Product Agreement that relates to Exploitation
of the Licensed Products in the Terminated Territory) and if the Licensee is unable to secure such consent to assign or partially assign
any such Licensed Product Agreement, then the Licensee shall use Commercially Reasonable Efforts to obtain for Eisai substantially all
of the practical benefit and burden under such Licensed Product Agreement, including by (A) entering into appropriate and reasonable
alternative arrangements on terms mutually agreeable to Eisai and the Licensee and (B) subject to the consent and control of Eisai, enforcing,
at Eisai’s sole cost and expense and for the account of Eisai, any and all rights of the Licensee against the other party thereto
arising out of the breach or cancellation thereof by such other party or otherwise;

 

    71

    

    

 

(c)
the Licensee shall, and shall cause its Affiliates to, assign to Eisai all of the Licensee’s and its Affiliates’ right, title
and interest in and to the Licensee Trademarks and any trade dress with respect to the Licensed Products, in the Terminated Territory;

 

(d)
the Licensee shall, and shall cause its Affiliates to, provide Eisai with copies of all reports and data generated or obtained by the
Licensee or any of its Affiliates that relate to any Licensed Product in the Terminated Territory that have not previously been provided
to Eisai; and

 

(e)
all Confidential Information of the Licensee relating solely to the Exploitation of the Licensed Products in the Field in the Terminated
Territory shall become the Confidential Information of Eisai.

 

10.6.
Additional Consequences for Change of Control Termination. If Eisai exercises its termination right pursuant to Section 10.2.6, then:

 

10.6.1.
if Eisai exercises such termination right on or prior to the date the FDA approves the BLA for the Existing Licensed Product for
the CTCL Indication in the United States, Eisai shall pay the Licensee an amount equal to the sum of (a) the ‘302 Development Costs
for which Licensee had paid Eisai hereunder, plus (b) the FTE Costs incurred and the direct out-of-pocket costs recorded as an expense
(including pre-marketing expenses and research and development costs), in accordance with GAAP, by or on behalf of Licensee or any of
its Affiliates in connection with the Development of a Licensed Product prior to the effective date of such termination, which amount
shall be payable within [***] ([***]) days after the end of Calendar Quarter in which the later of the following occurs (x) Eisai’s
receipt of a report with respect to the costs described in the foregoing clause (b) and (y) the effective date of such termination. Section
3.1.4(a) and Section 3.1.8 shall apply mutatis mutandis for purposes of this Section 10.6.1; and

 

10.6.2.
if Eisai exercises such termination right within [***] ([***]) years from the first commercial sale of the Existing Licensed Product
for the CTCL Indication in the United States (“US First Commercial Sale”), Eisai shall pay the Licensee an amount
equal to [***] percent ([***]%) of the fair market value of the Licensee Technology and Licensee Trademarks owned or Controlled by Licensee
or any of its Affiliates as of the effective date of such termination;

 

10.6.3.
if Eisai exercises such termination right at any time after [***] ([***]) years from US First Commercial Sale up to and including
seven (7) years from US First Commercial Sale, Eisai shall pay the Licensee an amount equal to [***] percent ([***]%) of the fair market
value of the Licensee Technology and Licensee Trademarks owned or Controlled by Licensee or any of its Affiliates as of the effective
date of such termination; and

 

10.6.4.
if Eisai exercises such termination right at any time after [***] ([***]) years from US First Commercial Sale, Eisai shall pay Licensee
an amount equal to [***] percent ([***]%) of the fair market value of the Licensee Technology and Licensee Trademarks owned or Controlled
by Licensee or any of its Affiliates as of the effective date of such termination.

 

10.6.5.
For purposes of this Section 10.6, “fair market value” shall mean, as of any date of determination, the current fair
market value of the fully paid-up license to the Licensee Technology and assignment of the Licensee Trademarks, taking into account the
prior investment in the Exploitation of the Licensed Products, any milestone payments, future royalties, lifecycle extensions, and additional
Indications which may not have been approved, determined as follows:

 

(a)
Within [***] ([***]) days following Eisai’s exercise of its right under Section 10.2.6(a) to request a determination of the fair
market value, the Parties shall appoint a valuation expert from the Expert List (the “Expert”).

 

(b)
Within [***] ([***]) days after the appointment of the Expert, each Party shall submit to the Expert a written statement of its position
regarding the fair market value, which may include any scientific, financial, technical or other relevant information in support of such
fair market value. No later than [***] ([***]) days after the earlier of (i) receipt of such written statement from each of the Parties
and (ii) the [***] ([***]) day after appointment of the Expert, the Expert shall make a determination of the fair market value, which
determination shall not be less than the lower of the fair market values submitted by the Parties or greater than the higher of the fair
market values submitted by the Parties. Eisai shall bear the fees and costs of the Expert.

 

    72

    

    

 

10.6.6.
 Within [***] ([***]) days after the BLA transfer pursuant to Section 3.2.3 and thereafter at least once per Contract Year, the Senior
Officers will mutually agree in writing on a list of at least three (3) valuation experts with relevant expertise with respect to the
valuation of Intellectual Property Rights and Trademarks in the biopharmaceutical industry (the “Expert List”). In
connection with each such agreement on the Expert List, each Party must disclose any prior business relationship it that it has had with
any proposed valuation experts within the past [***] ([***]) months.

 

10.7.
Remedies. Except as otherwise expressly provided herein, termination of this Agreement in accordance with the provisions hereof shall
not limit remedies that may otherwise be available in law or equity.

 

10.8.
Accrued Rights; Surviving Obligations. Termination or expiration of this Agreement for any reason shall be without prejudice to any
rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall
not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement. Without
limiting the foregoing, Section [***] and [***] of this Agreement shall survive the termination or expiration of this Agreement for any
reason.

 

ARTICLE
11

MISCELLANEOUS

 

11.1.
Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or breached
this Agreement for failure or delay in fulfilling or performing any term of this Agreement (other than an obligation to make payments)
when such failure or delay is caused by or results from events beyond the reasonable control of the non-performing Party, including fires,
floods, earthquakes, hurricanes, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorist
acts, insurrections, riots, civil commotion, strikes, lockouts or other labor disturbances (whether involving the workforce of the non-performing
Party or of any other Person), changes in laws, regulations, orders and embargoes, acts of God or acts, omissions or delays in acting
by any Governmental Authority (except to the extent such delay results from the breach by the non-performing Party or any of its Affiliates
of any term or condition of this Agreement). The non-performing Party shall notify the other Party of such force majeure within [***]
([***]) days of such occurrence by giving written notice to the other Party stating the nature of the event, its anticipated duration
and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer
duration than is necessary, and the non-performing Party shall use commercially reasonable efforts to remedy its inability to perform.
Without limitation to the foregoing, in the event that the suspension of performance continues for [***] ([***]) days after the date
of the occurrence and such suspension of performance would constitute a material breach of this Agreement in the absence of this Section
11.1, the other Party shall have the right to terminate this Agreement in its entirety, in its sole discretion, upon written notice to
the non-performing Party.

 

11.2.
Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information from
the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it will not export,
directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical
information to a location or in a manner that, at the time of export, requires an export license or other governmental approval, without
first obtaining the written consent to do so from the appropriate agency or other governmental entity in accordance with Applicable Law.

 

11.3.
Assignment.

 

11.3.1.
Assignment. Neither Party may assign its rights or, except as provided in Section 3.6, delegate its obligations under this Agreement,
whether by operation of law or otherwise, in whole or in part, without the prior written consent of the other Party, which consent shall
not be unreasonably withheld, conditioned or delayed, except that (a) Eisai may, without such consent, (i) prior to the transfer of the
BLA and INDs pursuant to Section 3.2.3, assign this Agreement and its rights and obligations hereunder to its successor entity or acquirer
in the event of a merger, consolidation or Change of Control of Eisai; provided that such successor has at least substantially
similar pharmaceutical research and development capabilities to those of Eisai at the time of such merger, consolidation or Change of
Control and (ii) after the transfer of the BLA and INDs pursuant to Section 3.2.3, assign this Agreement and its rights and obligations
hereunder to the purchaser of the Eisai Technology or to its successor entity or acquirer in the event of a merger, consolidation or
Change of Control of Eisai; (b) the Licensee may, without such consent, assign this Agreement and its rights and obligations hereunder
to its successor entity or acquirer in the event of a merger, consolidation or Change of Control of the Licensee and (c) either Party
may, without such consent, assign any or all of its rights and delegate any or all of its obligations hereunder to any of its Affiliates.
Any permitted successor of a Party or any permitted assignee of all of a Party’s rights under this Agreement that has also assumed
all of such Party’s obligations hereunder in writing shall, upon any such succession or assignment and assumption, be deemed to
be a party to this Agreement as though named herein in substitution for the assigning Party, whereupon the assigning Party shall cease
to be a party to this Agreement and shall cease to have any rights or obligations under this Agreement. All validly assigned rights of
a Party shall inure to the benefit of and be enforceable by, and all validly delegated obligations of such Party shall be binding on
and be enforceable against, the permitted successors and assigns of such Party. Any attempted assignment or delegation in violation of
this Section 11.3.1 shall be void and of no effect.

 

    73

    

    

 

11.3.2.
Treatment of Assignee’s Intellectual Property Rights. The Intellectual Property Rights: (a) owned, licensed or otherwise controlled
by a Third Party permitted assignee of a Party that were owned, licensed or otherwise controlled by such Third Party permitted assignee
(and not such Party) immediately prior to such assignment (other than as a result of a license or other grant of rights, covenant or
assignment by such Party or its Affiliates to, or for the benefit of, such Third Party permitted assignee); or (b) owned, licensed or
otherwise controlled by an Affiliate of a Party that becomes an Affiliate through any Change of Control of such Party that were owned,
licensed or otherwise controlled by such Affiliate (and not such Party) immediately prior to such Change of Control (other than as a
result of a license or other grant of rights, covenant or assignment by such Party or its other Affiliates to, or for the benefit of,
such Affiliate), in each case ((a) and (b)), shall be automatically excluded from the rights licensed or granted to the other Party under
this Agreement.

 

11.4.
Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable for any reason, and if the rights
or obligations of either Party under this Agreement will not be materially and adversely affected thereby: (a) such provision shall be
fully severable; (b) this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never
comprised a part hereof; (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected
by the illegal, invalid or unenforceable provision or by its severance herefrom; and (d) such provision shall be deemed modified to the
minimum degree necessary to make such provision valid and enforceable under Applicable Law and reasonably acceptable to the Parties,
and such modified provision shall thereafter be enforced to the fullest extent possible. To the fullest extent permitted by Applicable
Law, each Party hereby waives any provision of law that would render any provision hereof illegal, invalid or unenforceable in any respect.

 

11.5.
Dispute Resolution.

 

11.5.1.
Referral to Senior Officers. Except as provided in Section 4.4, Section 5.9 or Section 11.9, if a dispute arises between the Parties
in connection with or relating to this Agreement, including a dispute as to the interpretation, validity or performance of this Agreement
or this Section 11.5.1, or any document or instrument delivered in connection herewith, or any payment dispute, excluding any Unresolved
JSC Matter, excluding any dispute regarding Eisai withholding its consent under the third proviso in Section 2.3.1 or the proviso in
Section 3.6 (a “Dispute”), then either Party shall have the right to refer such Dispute to the Senior Officers for
attempted resolution by good faith negotiations during a period of [***] ([***]) Business Days. Any final decision mutually agreed to
by the Senior Officers in writing shall be conclusive and binding on the Parties.

 

11.5.2.
Arbitration.

 

(a)
If such Senior Officers are unable to resolve any such Dispute within such [***] ([***])-Business Day period, either Party shall be free
to submit such Dispute to the International Chamber of Commerce (the “ICC”) for resolution by arbitration before three
(3) arbitrators (such arbitrators, collectively, the “Arbitral Tribunal”) under the Arbitration Rules of the ICC (the
“Arbitration Rules”), as modified by this Section 11.5.2. Except as expressly limited by Section 11.5.2(h), the Arbitral
Tribunal shall have the authority to grant any equitable relief or any other remedies that would be available in any judicial proceeding
instituted to resolve a disputed matter under the substantive laws of New York.

 

(b)
The number of arbitrators shall be three (3), who shall be selected as follows: each of Eisai, on the one hand, and the Licensee on the
other hand, shall nominate one (1) arbitrator. The initiating Party shall nominate its arbitrator in the Request for Arbitration (as
described in the Arbitration Rules), and the other Party shall nominate its arbitrator in its Answer (as described in the Arbitration
Rules) to the Request for Arbitration (provided, that if the other Party receives an extension of time to submit its Answer, it shall
nonetheless nominate its arbitrator on the date its Answer otherwise would have been due under Article 5(1) of the Arbitration Rules),
and those Party-nominated arbitrators shall unanimously nominate the third arbitrator, who will act as president of the Arbitral Tribunal
(the “President Arbitrator”), within [***] ([***]) days of the appointment of the last Party-nominated arbitrator.
Each of the three arbitrators shall be an attorney in good standing licensed to practice for at least [***] ([***]) years and with substantial
experience representing pharmaceutical companies in disputes or contract negotiations (the “Qualifications”); provided
that if the Party-nominated arbitrators do not jointly nominate such a President Arbitrator within the [***] ([***])-day period, then
the ICC Court (as described in the Arbitration Rules) shall within [***] ([***]) days after the expiration of that [***] ([***])-day
period prepare and submit to each of the Party-nominated arbitrators (with copies sent to the Parties) a list of fifteen (15) candidates
for nomination as President Arbitrator, each of which candidates shall have the Qualifications. The list shall be accompanied by copies
of the candidates’ curriculum vitae. Each Party-nominated arbitrator may object to any unacceptable candidates on the list, and
shall rank each acceptable candidate in numerical order, with the candidate ranked number 1 being that Party-nominated arbitrator’s
most preferred candidate, and with any other acceptable candidates listed with ascending numerical ranking thereafter through the last
acceptable candidate remaining on the list. The Party-nominated arbitrators may discuss the candidates on the list. Each Party-nominated
arbitrator shall return the list to the ICC Court within [***] ([***]) days after receiving it, reflecting the objected-to candidates
and the numerical ranking of the acceptable candidates. The Party-nominated arbitrators shall not exchange their returned lists with
each other. The candidate ranked as acceptable on both returned lists with the lowest combined numerical ranking shall be deemed by the
ICC Court to be nominated as the President Arbitrator by both Party-nominated arbitrators.

 

    74

    

    

 

(c)
If the two lists returned to the ICC Court by the Party-nominated arbitrators do not contain any candidates ranked as acceptable by both
Party-nominated arbitrators, then the ICC Court shall within [***] ([***]) days thereafter submit to each of the Party-nominated arbitrators
(with copies sent to the Parties) a second list of fifteen (15) candidates for nomination as President Arbitrator, each of which candidates
shall have the Qualifications. The list shall be accompanied by copies of the candidates’ curriculum vitae. Each Party-nominated
arbitrator may object to any unacceptable candidates on the list, but not to all candidates on the list, and shall rank each acceptable
candidate in numerical order, with the candidate ranked number 1 being that Party-nominated arbitrator’s most preferred candidate,
and with any other acceptable candidates listed in ascending numerical ranking thereafter through the last acceptable candidate remaining
on the list. The Party-nominated arbitrators may discuss the candidates on the list. Each Party-nominated arbitrator shall return the
list to the ICC Court within [***] ([***]) days after receiving it, reflecting the objected-to candidates and the numerical ranking of
the acceptable candidates. The Party-nominated arbitrators shall not exchange their returned lists with each other. The candidate ranked
as acceptable on both returned lists with the lowest combined numerical ranking shall be deemed by the ICC Court to be nominated as the
President Arbitrator by both Party-nominated arbitrators.

 

(d)
If the two lists returned to the ICC Court by the Party-nominated arbitrators again do not contain any candidates ranked as acceptable
by both Party-nominated arbitrators, then the ICC Court shall within [***] ([***]) days thereafter so advise both Party-nominated arbitrators
and the Parties, and shall give the Party-nominated arbitrators a final period of [***] ([***]) days within which to determine if they
can agree upon a nominee for President Arbitrator, whether from either list submitted to them by the ICC Court, or otherwise. The two
Party-nominated arbitrators will, at or before the expiration of that [***]-day period, jointly advise the ICC Court either of the name
of an agreed-upon nominee for President Arbitrator, or that they have been unable to agree. If they
are unable to agree, then the ICC Court shall appoint the President Arbitrator pursuant to the Arbitration Rules, provided that the appointee
must have the Qualifications.

 

(e)
The place of arbitration shall be New York, New York. All proceedings involving attendance by the Parties shall be conducted in New York,
New York (unless another location is otherwise agreed to by the parties on one or more occasions), at a suitable venue to be agreed by
the Parties and arbitrators. The proceedings shall be conducted in the English language.

 

(f)
  The decision and award of the Arbitral Tribunal shall be made by majority decision and shall be conclusive and binding on the
Parties and their successors and assigns. The arbitral award shall be accompanied by a reasoned opinion.

 

(g)
The arbitral award may include both pre-and post-award interest, at the rate of [***] percent ([***]%) per annum or the maximum rate
allowable by Applicable Law, whichever is lower.

 

(h)
Without limiting the authority of the Arbitral Tribunal with respect to non-monetary relief, the Arbitral Tribunal shall only have the
power to award monetary relief consistent with Section 9.4.

 

(i)
The Arbitral Tribunal’s final award shall be rendered within the [***] ([***])-month period specified in Article 30(1) of the Arbitration
Rules, and any extension thereof pursuant to Article 30(2) of the Arbitration Rules. Notwithstanding any provision of the Arbitration
Rules: (i) each Party shall be permitted to (A) serve up to ten (10), interrogatories on the other Party, (B) take up to five (5), depositions,
(C) obtain production of documents from the other Party pursuant to Article 3 of the International Bar Association Rules on the Taking
of Evidence in International Arbitration as current on the Effective Date, (D) appoint one (1) or more experts to testify at the hearing,
each of whom the appointing Party shall identify to the other Party (by name, address and employer/professional affiliation) and for
whom the appointing Party shall provide to the other Party a general statement of the subject matter and opinions to which such expert
is expected to testify, and each of whom shall provide a written, dated and signed report, setting forth a complete statement of all
opinions the expert will express and the bases and reasons for them, the facts or data considered by the expert in forming the opinions,
and including any exhibits that will be used to summarize or support the opinions and a copy of such expert’s then-current curriculum
vitae, which report shall constitute the direct testimony of such expert at the hearing (it being agreed by the Parties that any such
expert shall be made available for examination at the hearing by the other Party and the Arbitral Tribunal), and (E) exchange exhibits
and information as provided for in the Arbitration Rules, all of the foregoing on dates and locations to be mutually agreed upon (or,
failing such agreement, as the President Arbitrator shall select after hearing from the Parties); and (ii) neither Party shall be required
to provide legally privileged information. The Parties shall make their respective employees available for depositions (subject to the
above limitations) and hearing testimony as reasonably requested by the other Party. Judgment on any arbitral award issued by the Arbitral
Tribunal may be entered in any court having competent jurisdiction.

 

    75

    

    

 

(j)
Except as required by Applicable Law or the rules of a stock exchange on which its securities are listed (or to which an application
for listing has been submitted), or as necessary for recognition and enforcement of the arbitral decision and award, neither a Party
nor an arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of the
Parties. Any documents submitted to or issued by the Arbitral Tribunal shall be kept confidential and shall not be disclosed, except
that any such documents may be disclosed (i) as reasonably necessary in connection with any action to enforce or collect the award or
(ii) to the extent discoverable or admissible in any action arising out of or in connection with this Agreement.

 

(k)
The (i) fees of the Arbitral Tribunal and (ii) costs and expenses of the arbitration will be shared equally by the Parties. The Parties
will otherwise bear their respective expenses (including their respective legal, expert and other fees, expenses and costs) of the arbitration.

 

11.6.
Governing Law, Jurisdiction and Service.

 

11.6.1.
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York excluding any
conflicts or choice of law, rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive
law of another jurisdiction. The Parties agree to exclude the application to this Agreement of the United Nations Convention on Contracts
for the International Sale of Goods.

 

11.6.2.
Jurisdiction. Subject to Section 11.5 and Section 11.9, the Parties hereby irrevocably and unconditionally consent to the exclusive
jurisdiction of the federal and state courts of the state of New York for any action, suit or proceeding (other than appeals therefrom)
arising out of or relating to this Agreement, and agree not to commence any action, suit or proceeding (other than appeals therefrom)
related thereto except in such courts, not to assert, as a defense in any action, suit or proceeding for the interpretation or enforcement
hereof, that it is not subject thereto or that such action, suit or proceeding may not be brought or is not maintainable in said courts
or that this Agreement may not be enforced in or by said courts. The Parties hereby consent to and grant any such court jurisdiction
over the person of such Parties and over the subject matter of any such dispute.

 

11.6.3.
Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY
HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT: (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY
HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER;
(B) EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER; (C) EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY;
AND (D) EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN
THIS SECTION 11.6.3.

 

11.6.4.
Venue. The Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any action, suit
or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the federal and state courts of the state
of New York and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such
action, suit or proceeding brought in any such court has been brought in an inconvenient forum.

 

11.6.5.
Service. Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set
forth in Section 11.7.2 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement
in any such court.

 

    76

    

    

 

11.7.
Notices.

 

11.7.1.
Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication permitted or required under this
Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent
by facsimile transmission (with transmission confirmed) or by internationally recognized overnight delivery service that maintains records
of delivery, addressed to the Parties at their respective addresses specified in Section 11.7.2 or to such other address as the Party
to whom notice is to be given may have provided to the other Party in accordance with this Section 11.7.1. Such notice shall be deemed
to have been given as of the date delivered by hand or transmitted by facsimile (with transmission confirmed) or on the second Business
Day (at the place of delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by facsimile
shall be confirmed by a hard copy delivered as soon as practicable thereafter. This Section 11.7.1 is not intended to govern the day-to-day
business communications necessary between the Parties in performing their obligations under the terms of this Agreement.

 

11.7.2.
Address for Notice.

 

If
to the Licensee, to:

 

Dr.
Reddy’s Laboratories S.A.

Elisabethenanlage
11

4051
Basel, Switzerland

Attention:
Executive Vice President, Proprietary Products

Facsimile:[***]

 

with
a copy (which shall not constitute notice) to:

 

Dr.
Reddy’s Laboratories, S.A.

Attention:
Legal Affairs

Facsimile:
[***]

 

If
to Eisai:

 

Eisai
Co., Ltd.

Koishikawa 4-6-10

Bunkyo-Ku

Tokyo 112-8088

Japan

Attention: President, Oncology Business Group

Facsimile: [***]

 

with
copies to:

 

Eisai
Co., Ltd.

Koishikawa 4-6-10

Bunkyo-Ku

Tokyo 112-8088

Japan

Attention: General Counsel

Facsimile: [***]

 

and

 

Eisai
Inc.

100 Tice Blvd.

Woodcliff Lake, NJ 07677

Attention: President

General Counsel

Facsimile: [***]

 

    77

    

    

 

11.8.
Entire Agreement; Amendments; Termination of Binding Term Sheet.

 

11.8.1.
This Agreement, together with the Schedules attached hereto, sets forth and constitutes the entire agreement and understanding between
the Parties with respect to the subject matter hereof, and all prior agreements, understandings, promises and representations, whether
written or oral, with respect thereto are superseded hereby (including the Binding Term Sheet). Each Party confirms that it is not relying
on any representations or warranties of the other Party except as specifically set forth in this Agreement. No amendment, modification,
release or discharge shall be binding on the Parties unless in writing and duly executed by authorized representatives of both Parties.
In the event of any inconsistencies between this Agreement and any schedules or other attachments hereto, the terms of this Agreement
shall control. For the avoidance of doubt, the all performances and activities (including payments) under the Original Agreement and
the Binding Term Sheet until the Effective Date shall be valid.

 

11.8.2.
 The Parties mutually agree that the Binding Term Sheet is hereby terminated as of the Execution Date.

 

11.9.
English Language. This Agreement shall be written and executed in, and all other communications under or in connection with this
Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof and, in
the event of any conflict in interpretation between the English version and such translation, the English version shall control.

 

11.10.
Equitable Relief. Each Party acknowledges and agrees that the restrictions and obligations set forth in Section 2.6 and Article 6
and Article 7 are reasonable and necessary to protect the legitimate interests of the other Party and that such other Party would not
have entered into this Agreement in the absence of such restrictions and that any breach or threatened breach of any provision of such
Section or Articles may result in irreparable injury to such other Party for which there will be no adequate remedy at law. In the event
of a breach or threatened breach of any provision of such Section or Articles, the non-breaching Party shall be authorized and entitled
to obtain from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, specific performance and an equitable
accounting of all earnings, profits and other benefits arising from such breach, which rights shall be cumulative and in addition to
any other rights or remedies to which such non-breaching Party may be entitled in law or equity. Both Parties agree to waive any requirement
that the other (a) post a bond or other security as a condition for obtaining any such relief and (b) show irreparable harm, balancing
of harms, consideration of the public interest or inadequacy of monetary damages as a remedy. Nothing in this Section 11.10 is intended
or should be construed, to limit either Party’s right to equitable relief or any other remedy for a breach of any other provision
of this Agreement.

 

11.11.
Change of Control. In the event of a Change of Control of the Licensee, if Eisai elects not to terminate pursuant to Section 10.2.6,
Eisai shall have the right, in its sole discretion, by written notice delivered to the Licensee (or its successor), to provide that the
Licensee no longer has the right to make the final decision on Unresolved JSC Matters that relate to the approval of any amendment to
the ‘302 Development Plan that is not required by the FDA in order to obtain or maintain an approved BLA for the Existing Licensed
Product for the CTCL Indication in the United States, in which case any such proposed amendment to the ‘302 Development Plan would
be deemed rejected if the Senior Officers are unable to reach a decision regarding such amendment within the applicable time period set
forth in Section 4.4.1.

 

11.12.
Waiver and Non-Exclusion of Remedies. Any term or condition of this Agreement may be waived at any time by the Party that is entitled
to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf
of the Party waiving such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach
by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether
of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy
provided by Applicable Law or otherwise available except as expressly set forth herein.

 

    78

    

    

 

11.13.
No Benefit to Third Parties. Except as provided in Article 9, covenants and agreements set forth in this Agreement are for the sole
benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other
Persons.

 

11.14.
Further Assurance. Each Party shall duly execute and deliver or cause to be duly executed and delivered, such further instruments,
and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments,
as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the
provisions and purposes hereof or to better assure and confirm unto such other Party its rights and remedies under this Agreement.

 

11.15.
Relationship of the Parties. It is expressly agreed that Eisai, on the one hand, and the Licensee, on the other hand, shall be independent
contractors and that the relationship between the two (2) Parties shall not constitute a partnership, joint venture or agency. Neither
Eisai, on the one hand, nor the Licensee, on the other hand, shall have the authority to make any statements, representations or commitments
of any kind or to take any action that will be binding on the other Party without the prior written consent of the other Party to do
so. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred
by reason of any such employment shall be for the account and expense of such first Party.

 

11.16.
References. Unless otherwise specified: (a) references in this Agreement to any Article, Section or Schedule shall mean references
to such Article, Section or Schedule of this Agreement; (b) references in any Section to any clause are references to such clause of
such Section; and (c) references to any agreement, instrument or other document in this Agreement refer to such agreement, instrument
or other document as originally executed or, if subsequently amended, replaced or supplemented from time to time, as so amended, replaced
or supplemented and in effect at the relevant time of reference thereto.

 

11.17.
Construction. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular,
the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). Whenever
this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement
are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent
of any provision contained in this Agreement. The terms “including”, “include”, or “includes” as
used herein shall mean including without limiting the generality of any description preceding such term. The language of this Agreement
shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either
Party.

 

11.18.
Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile, PDF format via email, or
other electronically transmitted signatures, and such signatures shall be deemed to bind each Party as if they were original signatures.

 

[SIGNATURE
PAGE FOLLOWS.]

 

    79

    

    

 

THIS
AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first written above.

 

	Eisai Co, Ltd.	 	Dr. Reddy’s Laboratories S.A.
	 	 	 
	By:	/s/
    [***]	 	By:	/s/ Sameeer Natu
	Name:	[***]	 	Name:	Sameer Natu
	Title	Corporate Officer, Chief Planning	 	Title	Sr. Director
	 	 	 	Date:	20/3/18
	Date: 	March 9, 2018	 	 	 

 

	 	By:	/s/ Mukundan Baprothan
	 	Name:	Mukundan Baprothan
	 	Title	Director
	 	Date: 	 

 

    80

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]